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ABSTRACT 
People at Clinical High Risk for psychosis (CHR-P) present with a clinical syndrome 
that includes attenuated positive psychotic symptoms and impairments of 
social/emotional functioning. The CHR-P state is associated with a 20% risk of 
developing psychosis over a two-year period. However, treatment options remain 
limited—no licensed pharmacological therapies are currently available, and the 
comparative efficacy of the available treatments remains unknown. The purpose of this 
PhD was to address aspects of these outstanding issues in two distinct but 
complementary ways.  
 
Part 1 of this thesis provides an evidence synthesis of the CHR-P treatment literature. 
Following a qualitative introductory review, I used systematic review and network 
meta-analyses to compare and summarise the relative efficacy and acceptability of 
current treatments for (a) preventing transition to psychosis from a CHR-P state [Paper 
1], and (b) reducing attenuated positive psychotic symptoms [Paper 2]. The results of 
Papers 1 and 2 indicated that, to date, there is a lack of evidence that any specific 
intervention is particularly effective over any others in preventing transition to psychosis 
from a CHR-P state or in reducing attenuated positive psychotic symptoms. These 
results also suggest a need to identify potential novel therapeutics that may better target 
the pathophysiological mechanisms underlying psychosis onset and that may thereby 
alter the course of the disorder. 
 
Part 2 of this thesis sought to examine the neurophysiological basis for the effects of a 
potential novel treatment strategy, the neuropeptide oxytocin, in an intranasal oxytocin 
vs placebo acute challenge study using magnetic resonance imaging. Part 2 starts with 
the rationale for selecting oxytocin from the numerous candidate compounds indicated 
for those at CHR-P, followed by a discussion of the oxytocinergic system and its links 
to psychosis and the CHR-P state. I then present two experiments that tested whether 
oxytocin modulated (a) resting cerebral perfusion using arterial spin labelling, with a 
particular focus on the hippocampus [Paper 3], and (b) neurochemical metabolite levels 
(particularly glutamate, and glutamate plus glutamine, Glx) in the hippocampus, 
thalamus, and anterior cingulate cortex, as measured using proton magnetic resonance 
spectroscopy [Paper 4]. The results of the two neuroimaging experiments suggested 
that oxytocin can modulate hippocampal perfusion in CHR-P individuals [Paper 3]—
which is a key pathophysiological mechanism strongly implicated in psychosis onset—
 [5] 
but does not appear to have effects on glutamate or Glx concentrations in the 
hippocampus, thalamus, or anterior cingulate cortex [Paper 4]. However, based on the 
hippocampal perfusion findings alone, oxytocin merits further investigation as a 
candidate novel treatment for this group. 
 
Part 3 of this thesis extends the discussion of the findings from Part 1 and Part 2. Here, 
I use the results of the evidence syntheses and wider literature to highlight a number of 
critical challenges, and proposed solutions, for future CHR-P treatment research. I then 
place the experimental oxytocin findings in the context of CHR-P pathophysiology, 
before bringing together the two distinct methodological approaches (evidence synthesis 
and experimental medicine) to show how both—combined—could facilitate a new era 
of improved interventional research in the CHR-P field. 
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PREFACE 
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• Chapter 3, Paper 2 – Network Meta-Analysis for Attenuated Psychotic  
          Symptoms (published) (Davies et al, 2018b) 
 
• Chapter 5, Paper 3 – Oxytocin, Arterial Spin Labelling Study  
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In addition, the general discussion section [Part 3 of this thesis] contains text from the 
following paper which was co-authored by me and largely based on my work in Papers 
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PART 1 – TREATMENTS FOR THE CHR-P 
STATE: EVIDENCE SYNTHESIS 
1
1. INTRODUCTION
1.1. THE CHR-P STATE
The Clinical High Risk for Psychosis (hereafter CHR-P) construct was introduced in 
1995 to enable the prospective identification of individuals at incipient risk for psychotic 
disorders (Yung et al, 1996, 2005), which opened up new possibilities for research into 
preventative treatments. As such, preventative intervention within this putative 
prodrome became not only feasible but a clinical priority. Individuals at CHR-P present 
with attenuated positive psychotic symptoms, cognitive (basic) symptoms, impaired 
social and emotional function, neurophysiological alterations (at group level) and help-
seeking behaviour (Fusar-Poli et al, 2013a). Whether a patient meets CHR-P criteria is 
established using validated semi-structured interviews such as the Comprehensive 
Assessment of At-Risk Mental States (CAARMS) (Yung et al, 2005) and Structured 
Interview for Prodromal Syndromes (SIPS) (Miller et al, 2003). Over recent years, the 
risk of developing psychosis in CHR-P samples has declined from approximately 30%
(Fusar-Poli et al, 2012a) to 20% (Fusar-Poli et al, 2016b) at two years, although there 
are some exceptions (Fusar-Poli et al, 2018c). Preventing transition (or “progression”) 
to psychosis from a CHR-P state has been a key goal of this paradigm and has been the 
primary outcome in the majority of treatment research studies to date (Fusar-Poli et al, 
2013a). This follows the conceptualisation of the CHR-P state as a putative prodrome, 
in which there is an (unique) opportunity to arrest early pathophysiological processes 
before more severe or enduring neural changes take place (Millan et al, 2016). Further 
goals include reduction of attenuated positive and negative symptoms, improved social 
and occupational functioning and quality of life.
With accumulating knowledge has come increased focus on clinical services for CHR-P 
individuals, with specialist CHR-P clinics now available in many countries 
worldwide. In the UK, the specialist assessment, treatment and monitoring of CHR-
P individuals is recognised as a key component of secondary mental health services 
by the National Institute for Health and Care Excellence (NICE, 2014) guidelines 
(Guideline CG178). However, as with medicine more broadly, if the CHR-P construct
—which is essentially prognosis (Fusar-Poli et al, 2018b)—is to be useful and 
provide tangible benefits for patients, we need effective interventions. While results 
of previous treatment studies have been invariably mixed and often conflicting, 
the current NICE guidelines recommend that individual Cognitive Behavioural 
Therapy (CBT) be offered, with or without family interventions, while 
antipsychotics are prohibited (NICE, 2014).
[17] 
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Currently, there are no licensed pharmacological treatments for this patient group, which 
remains an unmet clinical need. 
1.2. CHR-P TREATMENT RESEARCH 
Over the past two decades, numerous psychological and pharmacological interventions 
have been tested in randomised controlled trials (RCTs), with varying levels of success. 
This qualitative introduction aims to provide an overarching perspective of this 
literature, with a particular focus on two key outcomes: preventing transition to first-
episode psychosis from a CHR-P state and reducing attenuated positive psychotic 
symptoms. 
1.3. PHARMACOLOGICAL AND COMBINED TREATMENTS 
1.3.1. ANTIPSYCHOTICS 
Risperidone and CBT  
The first randomised, double-blind, placebo-controlled interventional trial in the CHR-
P field took a “best bet” approach, combining risperidone (mean dose = 1.3mg/day) and 
individual CBT and comparing this package to a needs-based intervention (total N=59) 
(McGorry et al, 2002). After 6 months of treatment, 10 of the 28 individuals receiving 
needs-based interventions had transitioned vs 3 of 31 receiving risperidone and CBT 
(P=.03). However, by 12 months and using intention-to-treat analysis, there was no 
significant difference between treatment arms. One limitation of this trial was that the 
relative contributions of risperidone and CBT could not be separated. In a later, larger 
(N=115) multi-arm RCT, risperidone plus CBT was compared to placebo plus CBT, and 
placebo plus supportive therapy (McGorry et al, 2013; Yung et al, 2011). Here, after 12 
months of treatment, no significant differences in transition risk emerged between the 
three treatment arms (with transition risk at approximately 10% in each group, which is 
relatively low). 
Olanzapine 
One of the earliest interventional RCTs used 5-15mg/day olanzapine in a fixed-flexible 
dosing schedule (Woods et al, 2003), finding a significant reduction in attenuated 
psychotic symptoms in the olanzapine vs placebo group after 8 weeks of treatment, 
although this was accompanied by significantly greater weight gain. However, the 
longer-term follow up of the study found no significant difference in transition to 
psychosis, or in overall severity of attenuated psychotic symptoms (McGlashan et al, 
2006), although the olanzapine group did show significantly lower levels of symptoms 
 [19] 
between weeks 8–28 of the treatment year.  
 
Aripiprazole 
Aripiprazole has been tested in two studies. The first used a fixed-flexible dosing 
schedule (5-30mg/day) for eight weeks in a small (N=15), uncontrolled, open-label pilot 
study (Woods et al, 2007). No participants transitioned to psychosis (albeit at 8 weeks, 
the study duration was short) and a significant reduction in attenuated psychotic 
symptoms was observed after one week of treatment and at all further timepoints. A 
large, multi-arm, double-blind RCT comparing aripiprazole, placebo, and CBT has 
since been conducted; the initial results appear to show no significant difference in the 
number of transitions between treatment arms (Bechdolf et al, 2016) but the full 
scientific report is yet to be published.  
 
Ziprasidone 
More recently, ziprasidone (20-160mg/day) was compared to placebo in a randomised, 
double-blind design (N=51) (Woods, 2016). There was no significant difference in the 
number of individuals transitioning to psychosis (likely owing to a lack of power for 
assessing this outcome), but a significant difference favouring ziprasidone was observed 
in levels of attenuated psychotic symptoms (Woods et al, 2017). There were no group 
differences in weight gain or QTc prolongation, potentially suggesting a more 
favourable side-effect profile relative to other antipsychotics, such as olanzapine. 
 
Amisulpride 
A randomised, open-label study (N=124) of amisulpride (50-800mg/day) vs placebo 
(both combined with needs-based intervention) found that amisulpride produced 
superior effects on attenuated and full-blown psychotic symptoms, global functioning 
and depressive, negative and basic symptoms (Ruhrmann et al, 2007). Transition was 
not assessed.  
 
Perospirone 
Finally, one very small (N=11), uncontrolled, open-label study of perospirone reported 
significant improvements in total and attenuated positive symptom scores (measured 
using the Scale of Prodromal Symptoms, SOPS) from baseline to 26 week follow up 




A naturalistic study of interventions delivered in real-world clinical routine 
demonstrated that antidepressants plus CBT were associated with lower transition risk 
over time relative to antipsychotics plus CBT (Hazard Ratio (HR)= 0.129, 95% CI 0.03–
0.57, P=.007), which did not appear to be secondary to different baseline levels of 
psychopathology (Fusar-Poli et al, 2015b). Another naturalistic study found 
significantly higher transition risk in antipsychotic vs antidepressant treated patients, 
although nearly all transitions were associated with antipsychotic nonadherence 
(Cornblatt et al, 2007). While these and other studies (Cannon et al, 2008; Kim et al, 
2012) may suggest a therapeutic effect of antidepressants on transition, there are 
numerous limiting factors associated with these studies. The naturalistic design means 
that a causal link between antidepressant prescription and psychosis prevention cannot 
be made. For example, there appeared to be a preponderance of patients belonging to 
the Brief Limited Intermittent Psychotic Symptoms (BLIPs) subgroup—who have the 
highest transition risk of all subgroups (Fusar-Poli et al, 2016b)—in the antipsychotic-
treated group, and a trend-level greater number of affective comorbidities in the 
antidepressant-treated group (Fusar-Poli et al, 2015b). This may indicate that 
differences in baseline psychopathology and clinical presentation were subtly 
influencing clinicians’ treatment decisions, meaning that those with the highest levels 
of risk (such as the BLIPs) were prescribed antipsychotics, and those with lowest risk 
(e.g. those false-positives who will later go on to develop non-psychotic disorders or 
remit) were prescribed antidepressants. 
 
1.3.3. EXPERIMENTAL TREATMENTS 
Omega-3 
Following positive results in patients with schizophrenia (Irving et al, 2006) and given 
the known, potentially serious adverse effects associated with antipsychotic medication, 
there was great optimism that long-chain omega-3 polyunsaturated fatty acid 
supplementation might also prove efficacious in CHR-P populations. In the first study 
of its kind, 81 individuals were randomised to receive either 1.2g/day omega-3 or 
placebo over 12 weeks followed by a monitoring period (Amminger et al, 2010). 
Omega-3 was found to significantly reduce the risk of transition, with 5% of the omega-
3 group and 28% of the placebo group having transitioned to psychosis by 12 months 
(P=.007). Relative to placebo, omega-3 also significantly reduced positive and negative 
symptoms and improved functioning. These beneficial effects on transition risk and 
functioning appeared to have been maintained long-term, until approximately 6.7 years 
 [21] 
of follow up (Amminger et al, 2015). However, in the largest of all RCTs in this field 
to date (N=304), omega-3 (1.4g/day) was compared to placebo, both combined with 
cognitive-behavioural case management over 6 months (McGorry et al, 2017). Here, no 
significant differences in transition risk or symptoms were observed at 6 or 12 months, 
with the medium-term follow up (mean 3.4 years) recently reaching a similar conclusion 
(Nelson et al, 2018a). The authors suggest that the high quality psychosocial 
intervention delivered in (both arms of) this trial may have produced a ceiling effect, 
beyond which omega-3 had little opportunity to demonstrate a significant benefit 
(McGorry et al, 2017). These sobering findings were echoed again in an independent 
study of 127 patients from the NAPLS consortium, where omega-3 failed to provide any 
benefit on risk of transition relative to placebo (Cadenhead et al, 2017). As is the case 
in the majority of studies in CHR-P individuals, both groups significantly improved in 
terms of symptoms and functioning over time but there were no between-group 
differences. This also demonstrates why uncontrolled studies in this patient population 
are problematic and must be interpreted with caution—even in the absence (or 
regardless) of treatment, these patients often improve from baseline over time (Fusar-
Poli et al, 2015b).  
 
Glycine site compounds  
Three studies have tested glycine site allosteric modulators (co-agonists) of the N-
methyl-D-aspartate (NMDA) receptor, namely D-serine and glycine. In a pair of related, 
small-scale pilot studies, oral glycine was first titrated (open-label) in 10 CHR-P 
individuals for 8 weeks (Woods et al, 2013). Significant within-group improvements in 
total, positive, negative and depressive symptoms were observed. However, the authors 
then conducted a randomised, double-blind, glycine vs placebo study in 8 patients for 
12 weeks (Woods et al, 2013), finding a significant reduction in depressive symptoms 
only. Transition was not explicitly investigated due to the short study duration. The 
extremely small sample sizes in these studies was a clear and major limitation, but they 
did provide initial proof-of-concept evidence. Shortly after, in a randomised, double-
blind, placebo-controlled study, 44 CHR-P individuals received ~4.2g/day of D-serine 
or placebo for 16 weeks (Kantrowitz et al, 2015). D-serine led to a significant (36%, 
SD=18) reduction in negative symptoms (P=.03), which was the study’s primary 
outcome. There were no effects on attenuated positive or total symptoms as measured 




Based on its antioxidant and neuroprotective profile of effects, n-acetylcysteine, a 
glutathione precursor, was tested in a very small uncontrolled case series of 5 CHR-P 
individuals for 12 weeks (Miyake et al, 2016). There were no significant within-group 
effects on total SOPS scores, but n-acetylcysteine appeared to be well tolerated and 
potential beneficial effects on cognitive functioning were observed at 24-week follow 
up. However, the small case series design means that these results are unlikely to be 
robust. A large, multi-centre RCT of n-acetylcysteine is now underway (Schmidt et al, 
2019). 
1.4. PSYCHOLOGICAL TREATMENTS 
1.4.1. COGNITIVE BEHAVIOURAL THERAPY (CBT) 
Individual CBT is the most studied intervention for CHR-P individuals. While the exact 
protocols differ between studies, broadly speaking, 6 RCTs have been conducted to date. 
The first study, from 2004, compared 6 months of CBT to treatment as usual (usually 
defined as “needs-based interventions”) in 58 CHR-P individuals (Morrison et al, 2004). 
CBT significantly reduced transition to psychosis over a 12-month period (odds ratio 
(OR)=0.04, 95% CI 0.01–0.71, P=.028) as well as the severity of attenuated psychotic 
symptoms. However, blinding was not maintained and when an intention-to-treat 
approach was applied, there were no significant results. The second RCT compared 6 
months of CBT to supportive therapy in 51 CHR-P patients, and found no significant 
differences in transition, attenuated positive and negative symptoms, depression, 
anxiety or social functioning as assessed at 6, 12 and 18-month follow ups (Addington 
et al, 2011). These results were echoed by a subsequent, larger study (N=288), where 
CBT plus monitoring was compared to monitoring only (Morrison et al, 2012). Here, 
no effects on transition or symptom-related distress were observed, but the severity of 
attenuated psychotic symptoms was significantly reduced at 12 months in the CBT 
group. The low transition risk (7% in CBT group, 9% in monitoring group) may have 
led to underpowered analyses for the transition outcome (Morrison et al, 2012). Using 
an enhanced CBT protocol that specifically targeted cognitive biases and 
psychoeducation on dopamine system super-sensitivity, one study randomised 201 
patients to CBT or treatment as usual for 6 months, with an 18-month follow up (van 
der Gaag et al, 2012). This CBT protocol significantly reduced transition to psychosis 
(OR=0.52, 95% CI 0.19–0.95) as well as the distress associated with attenuated 
psychotic symptoms at 6 months. The overall transition risk of 16.3% is notably higher 
than the aforementioned studies that found no treatment effects. However, it should be 
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noted that using an intention-to-treat approach abolished the significant results, and for 
the distress outcome, data were based on non-transitions only (van der Gaag et al, 2012). 
Contrasting results were found in a more recent RCT of 57 CHR-P individuals, which 
compared CBT to a more “active” control condition (non-directive reflective listening), 
both in addition to standard care (Stain et al, 2016). There were too few transitions to 
perform statistical analyses on this outcome (5% transition; 3 transitions in the CBT 
group and 0 in the control group), but the control treatment significantly reduced the 
distress associated with attenuated psychotic symptoms relative to CBT. Compared to 
the other trials, the sample in this study was younger, higher functioning and had lower 
levels of attenuated psychotic symptoms. Such characteristics may account for the better 
treatment effects of the control intervention and would be in line with the clinical staging 
model (Stain et al, 2016). As previously mentioned, initial results from a large (N=280), 
multi-arm, single-blind RCT comparing aripiprazole, placebo, and CBT appeared to 
show no difference between any treatment arms in preventing transition, although the 
full report has yet to be published (Bechdolf et al, 2016).  
 
1.4.2. INTEGRATED PSYCHOLOGICAL INTERVENTIONS (IPI) 
Individual CBT has also been tested as part of a multi-component package of therapies, 
which included group skills training, cognitive remediation and multifamily 
psychoeducation, termed “integrated psychological interventions”, which was 
compared to supportive counselling, both delivered for 12 months, in 128 individuals 
(Bechdolf et al, 2012). The results showed that integrated psychological interventions 
significantly reduced the number of transitions at 12 (3.2% vs 16.9%, P=.008) and 24-
month (6.3% vs 20.0%, P=.019) follow ups.  
 
1.4.3. FAMILY-FOCUSED THERAPY (FFT) 
Family therapy is suggested as a treatment option for CHR-P patients in the current 
NICE guidelines (NICE, 2014). However, only one RCT (N=129) has investigated 
family-focused therapy vs an “enhanced care” control condition in these individuals 
(Miklowitz et al, 2014). Here, the family intervention was associated with greater 
improvement in attenuated psychotic symptoms over 6 months relative to control. There 
were fewer transitions in the family-focused group (2% vs 11%), although this was not 
statistically tested. The overall risk of transition was 6%. A different group-and-family-
based CBT intervention has also been tested in one small (N=6), open, uncontrolled 
study, but the methodological shortcomings from the poor design limit its interpretation 
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(Landa et al, 2016).   
 
1.4.4. OTHER STUDIES 
One study took a risk-based allocation approach, assigning those with the highest risk 
of psychosis to a family-aided assertive community treatment, while those with lower 
risk were assigned to community care (McFarlane et al, 2015). The family-aided 
treatment demonstrated some benefits over community care, but no difference was 
observed in transition to psychosis and the quasi-experimental design severely hampers 
interpretation of the results. A separate study, that has often been included in reviews 
and meta-analyses of CHR-P patients, focused on patients with schizotypal disorder, 
finding that an integrated treatment (including social skills training and multi-family 
group psychoeducation) significantly reduced risk of transition relative to standard care 
(Nordentoft et al, 2006). However, strictly speaking, schizotypal disorder is not per se 
comparable to the CHR-P state (genetic risk and deterioration syndrome includes 
schizotypal disorder plus functional decline in help-seeking patients) as defined by 
consensus criteria (Fusar-Poli et al, 2013a). Finally, a number of studies of cognitive 
remediation have been conducted but they have not focused on preventing transition to 
psychosis (Hooker et al, 2014; Loewy et al, 2016; Piskulic et al, 2015; Urben et al, 
2012). However, a large RCT in CHR-P individuals that will assess effects on symptoms 
is currently underway (Glenthøj et al, 2015).  
 
From this qualitative review, it becomes clear that many trials provide conflicting results 
regarding the efficacy of their tested treatments. In an attempt to overcome such 
discrepancies, a number of research groups have performed meta-analyses. In the 
following section, a review of these meta-analyses, their results and associated 
methodological concerns and limitations are discussed. 
1.5. PREVIOUS SYSTEMATIC REVIEWS AND META-ANALYSES 
One of the first comprehensive meta-analyses was conducted by Stafford et al in 2013, 
who performed a series of pairwise meta-analyses of different treatments and stratified 
results by time (Stafford et al, 2013a, 2013b), which is important given the time-varying 
outcomes in this patient group (Fusar-Poli et al, 2016b; Kempton et al, 2015). At 6 
months, CBT did not reduce transition to psychosis relative to supportive counselling 
(risk ratio (RR)=0.62, 95% CI 0.29–1.31; 4 studies), but in those completing treatment, 
CBT was associated with a significant reduction in transition at 12 months (RR=0.54, 
95% CI 0.34–0.86; 5 studies) and beyond 12 months (RR=0.63, 95% CI 0.40–0.99; 4 
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studies). While there was no significant meta-analytic benefit of CBT on attenuated 
positive symptoms at 6–12 months, the multiple errors in reporting these results (see 
figure 4 and the erratum in (Stafford et al, 2013a, 2013b)) prevents citation of the exact 
statistics. The only other treatment comparisons with more than one study available for 
meta-analysis was CBT plus risperidone vs supportive counselling, with CBT plus 
risperidone associated with significantly reduced transition at 6 months (RR=0.35, 95% 
CI 0.13–0.95; 2 studies) but not at 12 months (RR=0.63, 95% CI 0.33–1.21; 2 studies). 
Overall, the authors found mostly low to very low quality evidence, but their suggestion 
for treatment strategies combining family and individual CBT appear to have had a 
major influence on the current NICE guidelines, which recommend these interventions 
(NICE, 2014). 
 
Another meta-analysis, from the same year, did not stratify their analyses by specific 
treatments at all, instead pooling all of the different interventions (including olanzapine, 
omega-3, CBT, integrated psychological interventions, risperidone plus CBT) together 
and comparing them to the various control conditions (van der Gaag et al, 2013). At 12 
months, they found that the treatment conditions generally designated as the “active” 
intervention of interest, when pooled into a heterogeneous group (including olanzapine, 
omega-3, CBT, integrated psychological interventions, risperidone plus CBT), were 
significantly more efficacious in reducing transition relative to those treatment 
conditions generally labelled “control” (RR=0.46, 95% CI 0.33–0.64). This convoluted 
finding serves to highlight why such an approach is not a useful or clinically meaningful 
evidence synthesis approach; these results do not tell us how effective any of the 
aforementioned treatments are (at the meta-analytic level) beyond the results of the 
individual studies themselves, thereby defeating the purpose of the meta-analysis. In 
addition, one study that they included was a study of schizotypy rather than CHR-P 
individuals (Nordentoft et al, 2006). The authors then go on to present an analysis by 
“type of intervention”, which raises further problems. They find that combining 
heterogeneous treatments that include any antipsychotic significantly reduced transition 
(RR=0.55, P=.029), but two of the three studies were of antipsychotics plus CBT. 
Furthermore, what the authors do not make explicitly clear is that their meta-analysis of 
CBT-based interventions at 12 months showed no significant benefit of CBT over 
control (RR=0.52, 95% CI 0–79). This point is obfuscated within the abstract and article 
text and these data are not presented in any of the forest plots, which the incorrect 
labelling of their figure 2 (which labels the plot as ‘CBT’ vs ‘treatment as usual’, when 
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it is in fact ‘all different treatments’ vs ‘all different controls’), misleadingly claims to 
do (van der Gaag et al, 2013). 
 
A more recent meta-analysis, conducted for the European Psychiatric Association 
(EPA) guidelines, similarly asked (a) whether there is evidence that “focused early 
interventions” (as a whole, combining—as previously discussed—all different 
treatment types) are effective compared to controls, and (b) whether there are 
differences between two broad classes of interventions: any pharmacological and any 
psychological (Schmidt et al, 2015). Although they find a significant benefit of the more 
“focused” treatments in reducing transition at all time points (with only fixed effect 
results reported, when random effects would be more appropriate), because the authors 
did not stratify the comparisons by treatment, the EPA meta-analysis could not provide 
evidence on the likely effectiveness of any specific treatments, and again the problem 
of a broad-brush dichotomous approach (pharmacological vs psychological) is not 
specific enough to inform evidence-based clinical guidelines (Schmidt et al, 2015).  
 
A 2014 meta-analysis focusing specifically on CBT (Hutton and Taylor, 2014) found 
no significant benefit of CBT on transition at 6 months (RR=0.52, 95% CI 0.27–1.02, 6 
studies) but a significant effect emerged at 12 months (RR=0.45, 95% CI 0.28–0.73, 6 
studies) and 18–24 months, albeit within this analysis they included the study of 
integrated psychological interventions which combines numerous approaches beyond 
CBT (Bechdolf et al, 2012). Similarly, there was no effect on (overall) symptoms at 6 
months (Hedges’ g = -0.11, 95% CI -0.29 to 0.07, P=.23, 4 studies) but a significant 
benefit of CBT over control was found at 12 months (Hedges’ g = -0.25, 95% CI -0.46 
to -0.03, P=.024, 5 studies) (Hutton and Taylor, 2014).  
 
A number of additional (earlier) meta-analyses have been conducted but the limited 
number of included studies (Marshall and Rathbone, 2011; Preti and Cella, 2010) or 
very poor meta-analytic approach (Deas et al, 2016; Kelly et al, 2010) means that they 
provide little further insight to the results discussed above. 
1.6. SUMMARY & STUDY RATIONALE 
In summary, studies to date have investigated a variety of psychological and 
pharmacological interventions for those at CHR-P, including CBT, cognitive 
remediation, family-focused therapy, integrated psychological interventions, 
antipsychotics, antidepressants, omega-3, glycine-site compounds, and combined 
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interventions. However, many of these have been small, uncontrolled studies (Tsujino 
et al, 2013; Woods et al, 2007), some of low quality (Landa et al, 2016), while others 
were observational (Fusar-Poli et al., 2015). Across the randomised controlled trials, 
results have been markedly inconsistent. The three largest interventional studies in 
CHR-P individuals have all yielded negative findings (Fusar-Poli, 2017a; McFarlane et 
al, 2015; McGorry et al, 2017; Morrison et al, 2012).  
 
Several pairwise meta-analyses of this topic have been conducted previously (van der 
Gaag et al, 2013; Hutton and Taylor, 2014; Preti and Cella, 2010; Schmidt et al, 2015; 
Stafford et al, 2013a), with the most consistent finding being of an approximate 50% 
reduction in transition risk associated with CBT compared to control interventions at 12 
months but not at 6 months (and sometimes in later time points) (Hutton and Taylor, 
2014; Stafford et al, 2013a, 2013b). Despite this, the evidence base for CBT’s 
effectiveness appears far from robust. The largest CBT trial ever conducted in these 
patients showed no benefit of CBT over monitoring of mental state only (Morrison et 
al, 2012). In addition, previous meta-analytic results have often been estimated after 
pooling heterogeneous treatments together in pairwise comparisons (e.g. including 
integrated psychological interventions with studies of CBT alone (Hutton and Taylor, 
2014)). The most recent meta-analysis without methodological shortcomings was 
conducted in 2013 (Stafford et al, 2013a, 2013b), and 7 new trials have since been 
conducted. Importantly, previous meta-analyses do not tell us which interventions are 
likely to be the most effective nor how each treatment fares against each other currently 
available treatment option. This leaves the possibility that a treatment other than CBT 
may be more effective. 
 
In the following chapters (Papers 1 and 2), I address these issues by conducting an 
updated systematic review of the CHR-P treatment literature and performing a novel 
and sophisticated evidence synthesis approach: network meta-analysis. This method 
allows comparison of each treatment vs every other treatment on any available given 
outcome, is more statistically powerful than pairwise approaches, and allows the ranking 
of treatments from best to worst (Cipriani et al, 2013; Kanters et al, 2016). Specifically, 
in Paper 1, I present a published paper focusing on the efficacy and acceptability of 
treatments for preventing transition to psychosis. In Paper 2, I use the same methods 
but focus instead on the efficacy and acceptability of treatments for reducing attenuated 
(positive) psychotic symptoms. This is followed by an interim summary to conclude 
Part 1 of this thesis. 
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Aims and objectives 
Papers 1 and 2 aim to: 
- Quantify the consistency and magnitude of the efficacy of each specific 
intervention for preventing transition to psychosis in those at CHR-P using 
network meta-analysis (Paper 1).  
 
- Quantify the consistency and magnitude of the efficacy of each specific 
intervention for reducing attenuated positive psychotic symptoms in those at 
CHR-P using network meta-analysis (Paper 2).
 [29] 
2. NETWORK META-ANALYSIS – TRANSITION 
2.1. PAPER 1 – NETWORK META-ANALYSIS – TRANSITION 
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Lack of evidence to favor specific preventive interventions
in psychosis: a network meta-analysis
Cathy Davies1, Andrea Cipriani2, John P.A. Ioannidis3-7, Joaquim Radua1,8,9, Daniel Stahl10, Umberto Provenzani1,11, Philip McGuire12,13,
Paolo Fusar-Poli1,11,13,14
1Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London,
London, UK; 2Department of Psychiatry, University of Oxford, and Oxford Health NHS Foundation Trust, Oxford, UK; 3Department of Medicine, Stanford Prevention
Research Center, Stanford, CA, USA; 4Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA; 5Department of Biomedical
Data Science, Stanford University School of Medicine, Stanford, CA, USA; 6Meta-Research Innovation Center at Stanford, Stanford University, Stanford, CA, USA; 7Department
of Statistics, Stanford University School of Humanities and Sciences, Stanford, CA, USA; 8FIDMAG Germanes Hospital!aries, CIBERSAM, Sant Boi de Llobregat, Spain; 9Depart-
ment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden; 10Biostatistics Department, Institute of Psychiatry, Psychology & Neu-
roscience, King’s College London, London, UK; 11Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 12Department of Psychosis Studies, Institute of
Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 13National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre, London,
UK; 14OASIS Service, South London and Maudsley NHS Foundation Trust, London, UK
Preventing psychosis in patients at clinical high risk may be a promising avenue for pre-emptively ameliorating outcomes of the most severe
psychiatric disorder. However, information on how each preventive intervention fares against other currently available treatment options
remains unavailable. The aim of the current study was to quantify the consistency and magnitude of effects of specific preventive interventions
for psychosis, comparing different treatments in a network meta-analysis. PsycINFO, Web of Science, Cochrane Central Register of Controlled
Trials, and unpublished/grey literature were searched up to July 18, 2017, to identify randomized controlled trials conducted in individuals at
clinical high risk for psychosis, comparing different types of intervention and reporting transition to psychosis. Two reviewers independently
extracted data. Data were synthesized using network meta-analyses. The primary outcome was transition to psychosis at different time points
and the secondary outcome was treatment acceptability (dropout due to any cause). Effect sizes were reported as odds ratios and 95% confi-
dence intervals (CIs). Sixteen studies (2,035 patients, 57% male, mean age 20.1 years) reported on risk of transition. The treatments tested were
needs-based interventions (NBI); omega-31NBI; ziprasidone1NBI; olanzapine1NBI; aripiprazole1NBI; integrated psychological interven-
tions; family therapy1NBI; D-serine1NBI; cognitive behavioural therapy, French & Morrison protocol (CBT-F)1NBI; CBT-F1 risperi-
done1NBI; and cognitive behavioural therapy, van der Gaag protocol (CBT-V)1CBT-F1NBI. The network meta-analysis showed no evi-
dence of significantly superior efficacy of any one intervention over the others at 6 and 12 months (insufficient data were available after 12
months). Similarly, there was no evidence for intervention differences in acceptability at either time point. Tests for inconsistency were non-
significant and sensitivity analyses controlling for different clustering of interventions and biases did not materially affect the interpretation of
the results. In summary, this study indicates that, to date, there is no evidence that any specific intervention is particularly effective over the
others in preventing transition to psychosis. Further experimental research is needed.
Key words: Psychosis, risk, prevention, needs-based interventions, cognitive behavioural therapy, antipsychotics, omega-3, integrated psy-
chological interventions, family therapy, network meta-analysis, guidelines
(World Psychiatry 2018;17:196–209)
Individuals at clinical high risk for psychosis (CHR-P)1 pre-
sent with attenuated psychotic symptoms, impairments of
social, emotional and cognitive functioning2, and help-seeking
behaviour3. They have around 20% risk of developing psycho-
sis (but not any other non-psychotic disorder4,5) over a two-
year period6.
Primary indicated prevention in CHR-P individuals has the
unique potential to alter the course of the disorder7 and im-
prove clinical outcomes8. Current international guidelines –
such as those of the National Institute for Health and Care
Excellence (NICE) and the European Psychiatric Association
(EPA) – recommend that CHR-P individuals be primarily offer-
ed cognitive behavioural therapy (CBT) with or without family
interventions9,10. However, while prophylactic treatment with
antipsychotics is altogether prohibited by NICE guidelines9,
the EPA allows its use in the case of severe and progressive
symptomatology10.
The evidence supporting these partially conflicting recom-
mendations is relatively unclear11, despite several pairwise
meta-analyses having been published to date10,12-18. For ex-
ample, earlier meta-analyses concluded that no reliable rec-
ommendations with respect to specific interventions could be
made, because studies were too heterogeneous12, with compa-
rable efficacy across different treatments16 or no effects at all17.
The most recent meta-analysis concluded that both CBT and
antipsychotics are effective13. The other meta-analyses were
affected by mistakes19 or methodological limitations, such as
the use of overall effect sizes computed across heterogeneous
interventions of questionable clinical interpretability10,12,18,
inclusion of patients not assessed with standard CHR-P instru-
ments (e.g., with schizotypal disorders20)12,13,15,18, inclusion of
non-randomized and uncontrolled trials10, pooling of time-de-
pendent outcomes21 in the same group (e.g., 6 and 12 months18)
or no time stratification at all13, or poor meta-analytical ap-
proaches13. Meta-analyses have acquired a major influence on
clinical practice and guidelines22, so they can be particularly
harmful if they are of suboptimal quality.
Another problem is that the included trials involved a vari-
ety of specific interventions12, which were inconsistently clus-
tered in pairwise comparisons. For example, although CBT is
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an umbrella term for a plethora of heterogeneous strategies23,
different CBT protocols have been lumped together, and the
specific efficacy of each defining element or specific protocol
remains unclear24.
The objective of this network meta-analysis (NMA) was to
summarize the available evidence about the specific efficacy
of different preventive interventions in CHR-P individuals.
NMA offers additional benefits over standard pairwise analy-
ses in that the comparative efficacy of specific interventions
can be estimated and ranked, even when two treatments have
never been compared directly head-to-head25. Furthermore,
since NMA can improve the precision of estimates by allowing
integration of both direct and indirect treatment effect esti-
mates26, it is recommended over pairwise meta-analyses by
the World Health Organization as a basis for clinical guide-
lines27. Therefore, NMA should be considered the highest level
of evidence in CHR-P treatment guidelines28.
METHODS
The protocol for this study was registered on PROSPERO
(CRD42017069550). The study was conducted in accordance
with the PRISMA statement29.
Interventions included
We included all randomized controlled trials (RCTs) of phar-
macological and/or non-pharmacological interventions for
CHR-P individuals. We were a priori interested in the following
non-pharmacological interventions: CBT (various protocols),
psychoeducation, family therapy, supportive counselling, needs-
based interventions (NBI), and integrated psychological thera-
pies. We were also interested in the following pharmacological
interventions: antipsychotics (olanzapine, risperidone, zipra-
sidone, aripiprazole) and novel/experimental pharmacothera-
pies (omega-3 fatty acids and D-serine). As indicated in the
protocol, additional interventions emerging from the literature
search were also considered (e.g., glycine and cognitive reme-
diation).
The definition of the exact types of interventions is essential
to reduce heterogeneity and produce robust informative
results of direct clinical significance. As such, we first took
each trial and carefully identified the treatment components
that were characterizing each specific intervention, as detailed
below.
Needs-based interventions (NBI)
Since CHR-P patients recruited in clinical trials are help-
seeking adolescents and young adults accessing clinical serv-
ices, randomizing them to no treatment is not considered a
reasonable or ethical option30. Defining “treatment as usual”
in these samples is also challenging, because treatment is not
standardized and largely depends on local service configura-
tions and the availability of specific resources or competences.
We therefore used the most established and original defini-
tion of NBI employed by the founders of the CHR-P para-
digm, which focuses on the presenting symptoms and prob-
lems already manifest31. In accordance with this definition32,
NBI may include any of the following components: a) sup-
portive psychotherapy primarily focusing on pertinent issues
such as social relationships and vocational or family prob-
lems; b) case management, providing psychosocial assistance
with accommodation, education or employment; c) brief fam-
ily psychoeducation and support; d) medications other than an-
tipsychotics; and e) clinical monitoring and crisis management
31,33.
Cognitive behavioural therapy, French & Morrison
protocol (CBT-F)
The CBT-F protocol34 is based on the principles developed
by Beck35. The intervention is formulation-driven, problem-
focused and time-limited, with manualized strategies selected
on the basis of the patient’s prioritized problem. The key com-
ponents include building engagement, collaborative goal-
setting and formulation, normalizing experiences, evaluating
appraisals and core beliefs, and behavioural experiments34,36.
Cognitive behavioural therapy, van der Gaag
protocol (CBT-V)
The protocol developed by van der Gaag et al37 essentially
includes the French & Morrison protocol34, but with two addi-
tional components. These comprise psychoeducation about
dopamine system supersensitivity and training/behavioural
experiments on cognitive biases that may contribute to para-
noia38. Further behavioural goals include sustaining school
and work attendance, enhancing social relationships, and re-
ducing cannabis use37.
Integrated psychological interventions, Bechdolf protocol
(IPI)
The protocol developed by Bechdolf et al39 contains a num-
ber of components, including individual CBT-F34, manualized
group social skills training, computerized cognitive remedia-
tion to address thought and perception deficits, and manual-
ized psychoeducational multi-family group sessions39,40.
Family-focused therapy, Miklowitz protocol (FFT)
A family-focused therapy (FFT) protocol, initially de-
signed for those with or at risk of bipolar disorder, was
adapted by Miklowitz et al41 for the CHR-P population. The
key components include psychoeducation and development
of a prevention plan with the patient and family, sessions
where the patient and family practice skills for better com-
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munication, and sessions focusing on enhancing problem
solving skills41.
Pharmacological interventions
Pharmacological interventions included currently licensed
medications, novel or experimental pharmacotherapies, and
nutritional supplements.
Placebo
The placebo designation was reserved for placebo pills admin-
istered as pharmacological control conditions. Placebos were
designed to match the active drug intervention in appearance
but without the pharmacological compound of interest.
Nodes for the network meta-analysis
The specific interventions listed above were pooled into
“nodes” for the network meta-analysis. Nodes were defined by
the linear combination of any of the above specific interven-
tions. Each individual pharmacological treatment was assign-
ed to its own node. As indicated in the protocol, different dos-
ages of the same drug/molecule were classed under the same
node. Placebo was initially considered as a separate node from
NBI. However, in line with the protocol, sensitivity analyses
investigated the effect of alternate clustering of nodes (see sta-
tistical analysis).
Search strategy and selection criteria
We performed a multi-step literature search using the fol-
lowing keywords: (risk OR prodromal OR prodrom* OR ultra
high risk OR clinical high risk OR high risk OR genetic high
risk OR at risk mental state OR risk of progression OR progres-
sion to first-episode OR prodromally symptomatic OR basic
symptoms) AND (psychosis) AND (RCT OR randomized con-
trolled trial OR placebo controlled trial OR trial).
First, systematic searches were conducted in the Web of Sci-
ence (which includes Web of Science Core Collection, BIOSIS
Citation Index, KCI - Korean Journal Database, MEDLINE,
Russian Science Citation Index, and SciELO Citation Index),
the Cochrane Central Register of Controlled Trials, and Ovid/
PsychINFO databases, until July 18, 2017, with no restrictions
on language or publication date.
Second, we used Scopus/Web of Science to search reference
lists of retrieved articles and previously conducted systematic
reviews and meta-analyses. We manually searched for pub-
lished and unpublished data in relevant conference proceed-
ings, trial registries and drug-approval agencies. In addition,
we contacted study authors for supplemental data and search-
ed the OpenGrey database for grey literature.
Abstracts identified by this process were then screened, and
full-text articles were retrieved for further inspection against
the inclusion and exclusion criteria (as detailed a priori in the
protocol). The literature search, study selection and data ex-
traction were conducted by two authors (CD, UP) independent-
ly. During all stages, in the case of disagreement, consensus
was reached through discussion with a third author (PFP).
Studies were eligible for inclusion when the following crite-
ria were fulfilled: a) original articles, abstracts or pilot studies;
b) RCTs (including cluster randomized trials, but excluding
cross-over studies); c) designed as blinded (either single- or
double-blind); d) conducted in CHR-P individuals as estab-
lished by validated assessments, i.e. Comprehensive Assess-
ment of At-Risk Mental States (CAARMS)42, Structured Inter-
view for Psychosis-risk Syndromes (SIPS)43,44, Positive and
Negative Syndrome Scale (PANSS)45, Brief Psychiatric Rating
Scale (BPRS)46, or Early Recognition Inventory (ERIraos)47; e)
comparing specific preventive interventions as defined above;
and f) sample size of 10 or greater48.
The exclusion criteria were: a) reviews/non-original data; b)
studies lacking at least two compared groups; c) studies of
first-episode psychosis or other non-CHR-P groups; d) lack of
data needed for meta-analytical computation of the primary
(transition) outcome (authors were contacted and asked to pro-
vide summary data); e) lack of proper randomization (quasi-
randomization, observational naturalistic studies); f) samples
size< 10; and g) articles presenting overlapping, redundant
data (for a particular outcome at the same time point). Specifi-
cally, in the case of overlapping samples, we used the largest
one. Studies that were designed as blinded but could not main-
tain blinding during follow-up (e.g., for psychological inter-
ventions) were not excluded.
Outcome measures and data extraction
The primary outcome was transition to psychosis. Due to
the variable effect of time on transition risk6,21, we stratified
outcomes and analyses into 6 and 12 month follow-up time
points. Sample sizes were based on the numbers randomized
to each arm, to prevent artificial inflation of transition risk6,49.
Participants who dropped out of individual studies after ran-
domization were classified as non-transitions6,10,14,50.
Where studies did not report sufficient data to extract the
primary outcome, we contacted the relevant authors. In the
case of non-response or where studies presented data graphi-
cally, numerical data were digitally extracted from the Kaplan-
Meier plots using a previously validated procedure51,52, as de-
fined in the protocol.
The secondary outcome was the acceptability of interven-
tions (discontinuation due to any cause), indexed as the num-
ber of participants who dropped out of each arm for any rea-
son following randomization, over the number randomized
53-55.
In addition, we extracted the following information for each
study: first author and year of publication, country, types of
outcomes, intervention and control descriptions, study design,
198 World Psychiatry 17:2 - June 2018
 [33]  
quality assessment (see below), intervention period and fol-
low-up duration, study arm details (sample size, mean age,
percent male), and diagnostic tools used for CHR-P diagno-
sis and determining transition to psychosis.
Quality of the evidence
Risk of bias
The Cochrane Risk of Bias tool56 was used to assess and
classify the risk of bias in each of the included studies, as per
criteria defined a priori. A judgement was made about whether
each study had a high, low or unclear risk of bias in each of the
following six domains: random sequence generation, alloca-
tion concealment, blinding of participants and study person-
nel, blinding of outcome assessments, incomplete outcome
data, and selective outcome reporting.
The overall risk of bias was classified as low if none of the
above domains was rated as high risk and three or less were
rated as unclear risk. It was classified as moderate if one
domain was rated as high risk, or none rated as high risk but
four or more rated as unclear risk. All other studies were classi-
fied as having a high risk of bias57.
To represent the quality of evidence associated with com-
parisons in the network meta-analysis, we used coloured
edges in the network plots, as recommended58.
GRADE
We assessed the certainty of evidence contributing to net-
work estimates of the primary outcome using the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) framework59. The GRADE method characterizes the
quality of a body of evidence on the basis of six factors: study
limitations, imprecision, heterogeneity, inconsistency, indi-
rectness, and publication bias59.
We tabulated the findings for the above six factors to aid in
the decision-making process for the downgrading of evidence.
If one of the factors was present for a comparison, then the
overall confidence rating for that comparison was considered
for downgrading by one or two levels (as appropriate). Each
comparison started as high quality/confidence (as based on
RCTs), and was downgraded to moderate, low or very low,
depending on the presence, severity and potential impact of
the aforementioned factors. These represented the final judge-
ments about the certainty of the evidence59,60.
Statistical analysis
Frequentist NMAs were conducted for transition and
acceptability outcomes using the network package in STATA
(version SE 14.2; StataCorp). First, a network plot was con-
structed for each outcome61 to ensure that nodes of the net-
work were sufficiently connected58. We then performed a NMA
assuming consistency and a common heterogeneity across all
comparisons in the network. This allowed us to derive a single
summary treatment effect (odds ratio, OR) for every possible
pairwise comparison of treatments, which takes account of all
evidence from the network of trials, including both direct and
indirect comparisons. Correlations in effect sizes induced by
multi-arm trials62 were accounted for58,63. The resulting relative
ORs with 95% confidence intervals (CIs) for each pair of treat-
ments were reported in league tables64.
The interventions were then ranked by the surface under
the cumulative ranking curve (SUCRA), which accounts for the
location as well as the variance of all relative treatment ef-
fects65. SUCRA is a numeric presentation of the overall ranking
and provides a single number (from 0 to 100%) associated with
each intervention66. The higher the SUCRA value, and the
closer to 100%, the higher the likelihood that an intervention is
in the top rank, and vice versa66. Cluster ranking methods58,65 –
using both transition and acceptability SUCRA values – were
used to order the treatments in league tables, in line with re-
cent guidance which requires interpretation of SUCRA only in
the context of NMA uncertainty, rather than at face value66.
Statistical significance was set at p< 0.05.
We assessed the assumption of consistency by calculating,
for each closed loop, an inconsistency factor (differences
between direct and indirect evidence) along with 95% CIs and
associated p values. We plotted the results graphically as the
ratio of ORs (RORs) and 95% CIs for each loop64. Inconsistency
was defined as disagreement between direct and indirect evi-
dence, with 95% CIs for RORs excluding 1.
Given the low power of the loop-specific approach and its
focus on local inconsistency (between direct and indirect evi-
dence), we also tested a full design-by-treatment model62 for
the primary outcome to evaluate inconsistency more globally,
including between trials with different designs (e.g., two-arm
vs. multi-arm). A NMA under the inconsistency model was
applied and a v2 test was used to infer about the statistical sig-
nificance of all possible inconsistencies in the networks67.
The transitivity assumption was examined by assessing the
distributions of potential effect modifiers for every compari-
son in the network, including percentage of males68, age69,
percentage exposed to antipsychotic medications at base-
line70, type of blinding and publication year6. The presence of
small-study effects was assessed by visual inspection of com-
parison-adjusted funnel plots59.
To evaluate the impact of study quality and our data analy-
sis procedures, we conducted sensitivity analyses for the pri-
mary outcome restricted to: a) studies with a low risk of bias
for the blinding of outcome assessments; b) studies whose data
were not digitally extracted (e.g., from Kaplan-Meier plots); and
c) published data only. We also repeated the analyses after ap-
plying alternate clustering of the following nodes: a) pooling NBI
and placebo; b) pooling different CBT protocols; c) pooling
different types of antipsychotic molecules, and d) separating
the different NBI components (i.e., supportive therapy vs. clin-
ical monitoring vs. other). Finally, network meta-regressions
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were planned in the case of substantial heterogeneity and at
least ten studies71 to test the impact of different CHR-P diag-
nostic instruments/criteria.
RESULTS
Characteristics of the included studies
1,556 references were found in the literature search, most of
which were not reporting RCTs in CHR-P individuals; 49 were
fully screened for the inclusion and exclusion criteria, resulting
in a final sample of 16 studies (Figure 1). There were only five,
four, two and three studies reporting data for 18, 24, 36 and
>36 month time points, respectively, and therefore all results
reported hereafter are for 6 and 12 months only.
The 16 studies used in the analyses of the primary outcome
contributed data on 2,035 patients, with a mean age of 20.16
2.8 years, and 57% were male (Table 1). The mean sample size
was 127 (range 44-304). Six studies were conducted in North
America, six in Europe, three in Australia and one was multi-
national. Two studies were three-arm and the rest were two-
arm trials. Two studies had a treatment duration of <6 months,
ten of 6 months, and four of 12 months. Of the 14 studies with
available information on sponsorship/funding, three31,75,81,82
acknowledged pharmaceutical company grants. The CAARMS
and the SIPS were the most common CHR-P diagnostic instru-
ments44 (six and seven studies, respectively).
For the 6-month analysis of the primary outcome, these 16
studies provided data on 20 direct comparisons between 11
different treatment nodes (Figure 2). Three studies provided
follow-up data only for the 6-month analysis, and therefore
the 12-month analysis consisted of 13 studies (N51,811), pro-
viding data on 17 direct comparisons between 8 different treat-
ment nodes (Figure 2). The network plots for the acceptability
outcome were the same at 12 months and similar at 6 months
(integrated psychological interventions was missing).
Primary outcome: transition
Results of the NMA showed a lack of evidence for clearly
superior efficacy of specific treatments in preventing transi-




Records excluded because not 




assessed for eligibility 
(N=49) 
Full-text articles excluded  
(N=33) 
• Study protocol (N=5)  
• No control group (N=3) 
• Not blinded (N=1) 
• Not fully randomized (N=1) 
• Sample size <10 (N=2)  
• Not CHR-P sample (N=1) 
• Not RCT (N=8) 
• Longer follow-up/overlap (N=2) 
• No useable data (N=10)  
Studies included in 
systematic review 
(N=16) 




Records identified through 
database searching 
(N=1,697) 
Additional records identified 
through other sources 
(N=3) 
Figure 1 PRISMA flow chart of the study selection process. CHR-P – clinical high risk for psychosis, RCT – randomized controlled trial
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tion, with no significant effects of any one intervention over
any others at 6 or 12 month time points (Figures 3 and 4).
Using NBI as a comparator, the OR and 95% CI for each treat-
ment (all OR< 1 favor the given treatment) at 6 months were:
0.06 (0.00-1.90) for integrated psychological interventions; 0.17
(0.01-2.69) for family-focused therapy1NBI; 0.22 (0.02-2.17) for
CBT-F1CBT-V1NBI; 0.29 (0.03-2.57) for olanzapine1NBI; 0.21
(0.04-1.08) for CBT-F1 risperidone1NBI; 0.52 (0.03-10.72) for
ziprasidone1NBI; 0.56 (0.03-11.51) for D-serine1NBI; 0.64
(0.15-2.68) for omega-31NBI; 0.73 (0.27-2.01) for CBT-F1NBI;
and 0.94 (0.15-5.73) for aripiprazole1NBI.
At 12 months, ORs against the NBI comparator were: 0.04
(0.00-1.06) for integrated psychological interventions; 0.15
(0.02-1.25) for olanzapine1NBI; 0.21 (0.03-1.60) for CBT-
F1CBT-V1NBI; 0.43 (0.11-1.68) for CBT-F1 risperidone1
NBI; 0.58 (0.23-1.47) for CBT-F1NBI; 0.64 (0.18-2.26) for
omega-31NBI; and 1.39 (0.26-7.28) for aripiprazole1NBI.
While almost all the interventions at both time points had
estimates favoring them over NBI, the differences were not
beyond chance, and the 95% CIs for the NMA estimates were
often very large, indicating substantial imprecision. The clus-
ter ranking (based on SUCRA values for transition and accept-
ability) at 6 and 12 months is illustrated by the ordering of
treatments in Tables 2 and 3.
No statistically significant inconsistency was evident at any
time point, with 95% CIs for all RORs compatible with zero in-
consistency (ROR51). However, only two loops were available.
Using the design-by-treatment interaction test62, we found no
evidence for significant inconsistency for 6 month (p50.90)
and 12 month (p50.93) networks.
Only two studies had an overall low risk of bias33,79; five had
unclear risk72-76, and nine had high risk30,31,36,37,39,41,77,78,81.
The edges (lines) in Figure 2 reflect the Cochrane risk of bias for
the blinding of outcome assessments, estimated as the level of bias
in the majority of trials and weighted according to the number of
studies in each comparison58. The GRADE assessment highlight-
ed low or very low confidence in almost all estimates, primarily
due to study limitations (high risks of bias) and imprecision.
The numbers of studies remaining (at 6 and 12 months,
respectively) after exclusion of those with a high or unclear
risk of bias for the blinding of outcome assessments were 10
and 8; after exclusion of those whose data were extracted by
digitizing Kaplan-Meier plots were 13 and 12; after exclusion
of unpublished studies were 13 and 11. The NMA model was
refitted accordingly and no differences in conclusions were ob-
served for any OR at any time point.
Repeating the analyses treating NBI1placebo as a separate
node to NBI, or separating the different NBI components, had
no effect on the NMA estimates, and therefore we used the
pooled NBI1placebo in the main analysis (Table 1, Figures 2-
4). Similarly, pooling together different CBT protocols or differ-
ent antipsychotic molecules in the same node produced no
significant results. There were not enough studies to allow
robust meta-regression analyses on the type of CHR-P instru-
ments. Visual inspection of funnel plots revealed no substan-
tive evidence of small-study effects.
Secondary outcome: acceptability
Acceptability data were available for 14 of 16 studies at
6 months (N51,848), and 12 of 13 studies at 12 months
(N51,752). There were no significant differences in accept-
ability between any treatment comparisons at 6 or 12
months (Figures 3 and 4). The SUCRA cluster ranking (for
transition and acceptability) is illustrated in those figures.
Figure 2 Network plots of direct comparisons in the network meta-analysis for transition outcome at 6 (on the left) and 12 months (on the
right). The width of the lines is proportional to the number of trials comparing each pair of treatments and the size of each node is proportional
to the number of studies testing the specific treatment. The color of the lines represents the comparison-specific bias level for the blinding of
outcome assessments in the majority of trials (black5 low risk, dark grey5unclear risk, light grey5high risk). NBI – needs-based interven-
tions (including placebo), IPI – integrated psychological interventions, FFT – family-focused therapy, Dser – D-serine, CBT – cognitive behav-
ioural therapy, CBT-F – French & Morrison CBT protocol, CBT-V – van der Gaag CBT protocol, RIS – risperidone, Om3 – omega-3 fatty
acids, ZIP – ziprasidone, OLA – olanzapine, ARI – aripiprazole.



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This is the first network meta-analysis exploring the efficacy
of specific interventions for the prevention of psychosis in
CHR-P individuals. Adopting strict inclusion criteria, a total of
16 RCTs, with 2,035 patients, were included in the analyses.
There were not enough studies to analyze data with a NMA
approach beyond 6 and 12 month follow-ups. Two networks
were established at 6 and 12 months, including 11 and 8 nodes,
respectively. Network meta-analyses showed no clear evidence
of superior efficacy for any specific intervention at any time
point. The results were not affected by biases, inconsistency or
small-study effects.
The main finding of the current study is that there is a lack
of evidence to favor specific effective interventions to pre-
vent psychosis in CHR-P individuals. Our analyses were
based on a detailed protocol, which defined the exact type of
interventions and nodes a priori. This was done with the aim
of providing robust informative results of direct clinical sig-
nificance. For example, deconstructing the efficacy of differ-
ent types of CBT that are based on different protocols83
seems necessary to inform accurate and evidence-based clin-
ical guidelines for patients, clinicians and policy makers. Our
NMA comparing the different CBT protocols is also timely,
since authors have recently claimed that the “black box” of
CBT should be unpacked into its specific therapeutic compo-
nents23,24,84-86.
In a similar fashion, our NMA represents the first attempt at
deconstructing – through sensitivity analyses – the effect of
different components (including placebo) that characterize
NBI, which is usually employed as the control condition in
this field. We also restricted our literature search to include
only RCTs designed to be blinded, and studies that strictly
used CHR-P assessment instruments, to minimize selection
biases. Therefore, to date, our study represents the most fine-
grained analysis that has deconstructed the specific effect of
preventive interventions for psychosis.
Negative (non-significant) results are rarely published in
psychiatric literature87, which is affected by excess of statisti-
cal significance88-92. In fact, interpreting negative findings is
particularly challenging, because absence of evidence is not
evidence of absence93. In particular, when large CIs are
observed (as in Figures 3 and 4), some sizeable effects may still
have been missed. Nevertheless, our work represents the most
powered data synthesis in this field. For example, the meta-
analysis by Stafford et al15 – on which current clinical guide-
lines are based – analyzed 11 studies, but one of them includ-
ed an open-label trial (N5124)94 and another did not assess
participants against standard CHR-P criteria (N579)20, leaving
nine studies (N51,043) that are in common with the current


















































































































(0.14 to 3.78) ARI + NBI
Acceptability Transition Comparison 
Figure 4 Relative effect sizes for transition to psychosis and acceptability (dropout for any reason) at 12 months, odds ratios (95% CI). Com-
parisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treat-
ment and the row-defining treatment. Treatments are reported in descending order (from top left to bottom right) as per the cluster ranking for
transition and acceptability. For transition, an OR less than 1 favors the column-defined treatment. For acceptability, an OR less than 1 favors
the row-defined treatment. All 95% CIs include the null hypothesis OR51. CBT – cognitive behavioural therapy, CBT-F – French &Morrison
CBT protocol, CBT-V – van der Gaag CBT protocol, NBI – needs-based interventions (including placebo), RIS – risperidone, IPI – integrated
psychological interventions, ARI – aripiprazole, OLA – olanzapine, Om3 – omega-3 fatty acids.
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NMA. Since that meta-analysis, seven new trials involving 992
new CHR-P participants (an increase of more than 50%) have
been published, all of which reported non-significant ef-
fects41,72-74,76,78-80. Since our NMA included these new data, it
is more powered than previous pairwise analyses.
In the context of power considerations, indirect evidence,
when combined with direct evidence through NMA, increases
the power and precision of treatment effect estimates com-
pared to pairwise analyses26. Furthermore, when we pooled
different CBT protocols or antipsychotic molecules in the
same node – thus increasing the statistical power – no signifi-
cant results were still observed. Overall, the core result of our
NMA is more congruent with the evidence emerging from the
most recent trials, compared to previous evidence syntheses.
The current lack of evidence to support specific preventive
treatments is also consistent with the fact that the three largest
interventional studies in this field have all produced negative
findings95. Earlier studies that dominated the conclusions of
some previous meta-analyses (e.g., the omega-3 trial33) were
likely false positives. There is also converging lack of signifi-
cant benefits on other clinical outcomes besides transition to
psychosis, such as attenuated symptom severity14,15,96, func-
tioning10,14,18, depressive comorbidities15, distress14, and qual-
ity of life14,15.
These findings, taken together, are particularly problematic
given the conceptual concerns over the clinical validity and
significance of the dichotomous concept of transition within
the CHR-P paradigm97,98. More to the point, it is not clear
whether the currently tested treatments are only delaying the
onset of psychosis as opposed to altering the course of the dis-
order7. Long-term outcome trials are scarce and the results are
conflicting.
The additional caveat is that the exact mechanism of action
of the tested preventive treatments is – at best – poorly de-
fined, due to lack of an established and validated pathophysio-
logical model underlying the onset of psychosis in CHR-P
samples. A lack of mechanistic models forces researchers to
proceed with empirical attempts that may eventually prove
unsuccessful, as has ultimately been the case for omega-3 fatty
acids76. However, as our ability to stratify CHR-P individuals
into more homogenous subtypes improves, so may our suc-
cess in testing specific treatments targeted to underlying bio-
logical and psychological mechanisms99.
Our findings may have an impact on research and clinical
practice. In times of scarce resources, our NMA can help to
focus the next generation of research on the most promising
interventions. Although our ranking analysis should be inter-
preted cautiously66,100 in the context of non-superiority of any
intervention compared to any other, it suggests that CBT-F,
which currently represents the most widely adopted interven-
tion, may not be the best candidate (of relevance, the largest
CBT-F trial to date provided non-significant results77). On the
other hand, the apparent promising profile of integrated psy-
chological approaches could be the target of future replica-
tions.
Future research in this area will need to test novel interven-
tions that may act on underlying psychological or neurobio-
logical processes associated with the onset of psychosis.
Although there are no clinically valid CHR-P biomarkers yet
available101, several international consortia are ongoing (PRO-
NIA102, NAPLS103, PSYSCAN104) with the aim of developing
them. At the same time, it seems warranted to address the
clinical heterogeneity1,6,49,105,106 that may prevent the discov-
ery of reliable preventive treatments, and to improve the
design of the next generation of trials. For example, it is appar-
ent that unstructured recruitment processes and risk enrich-
ment procedures in samples undergoing CHR-P assessment
have a substantial role in determining the actual level of risk
for psychosis in these individuals107-109, leading to underpow-
ered and non-significant trials95. On a clinical side, individuals
meeting CHR-P criteria may be informed that, at present,
there is no evidence for specific treatments being more effec-
tive than any others, and current options should be carefully
weighted on a personal basis depending on an individual’s
needs.
This study has some limitations. First, only 16 RCTs were
included, reflecting the paucity of high-quality studies avail-
able in the CHR-P field. However, capitalizing on the increased
power and precision of NMA26, the Cochrane group has con-
ducted such analysis in even smaller databases, including as
few as three to seven studies110-113. Furthermore, sufficient
data were available for 6 and 12 month networks only, which
precluded insight into whether treatments may have some
effectiveness in the longer term. As a result of the sparse litera-
ture, many nodes were not well connected, with the corollary
of limited ability to check for inconsistency, more imprecise
estimates and wide 95% CIs.
In addition, the quality of NMA rests on the quality of in-
cluded studies, many of which were found to be at high or un-
clear risk of bias, with GRADE confidence estimates predom-
inantly low or very low – suggesting that true effects may be
substantially different from the estimates. This is particularly
the case for trials including any psychological interventions.
We addressed this issue through a strict and detailed assess-
ment of biases and sensitivity analyses. Going forward, given
that all comparisons in the NMA were downgraded due to
study limitations (risk of bias) and imprecision, the addition of
high-quality studies with adequate sample sizes is needed to
improve these confidence ratings.
A final limitation is that, whilst dropout due to any cause
was available from the majority of trials, this is a rather crude
measure of treatment acceptability, and a more proximal
index, such as specific adverse effects, may have revealed sig-
nificant differences between treatments, in particular for trials
of antipsychotic molecules. However, these outcomes are rare-
ly reported in the CHR-P literature.
In conclusion, there is currently no evidence to favor spe-
cific interventions for the prevention of psychosis. Further
experimental research in this field is needed.
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2.2. COCHRANE RISK OF BIAS 
 
World Psychiatry does not allow supplementary material so for completeness, details 
of the risk of bias assessment are presented below.  
 
Risk of bias of the included studies 
Only 2 studies had an overall low risk of bias (Amminger et al, 2010; Woods et al, 
2017), 5 had unclear risk (Bechdolf et al, 2016; Cadenhead et al, 2017; Kantrowitz et 
al, 2015; McGlashan et al, 2006; McGorry et al, 2017), and 9 had a high risk 
(Addington et al, 2011; Bechdolf et al, 2012; van der Gaag et al, 2012; McGorry et al, 
2002; Miklowitz et al, 2014; Morrison et al, 2004, 2012; Stain et al, 2016; Yung et al, 
2011) (Figure 2–1 below). In terms of individual bias domains (Figure 2–2), as may 
be expected from RCTs, 12/16 (75%) of studies were rated as a low risk of bias for 
both random sequence generation and allocation concealment, with the remaining 
studies having an unclear risk in these domains. However, 13/16 (81%) of studies had 
a high risk of bias owing to incomplete outcome data, which has previously been noted 
as an issue in CHR-P research due to high attrition. An inherent issue with RCTs of 
psychological therapies is the inability to blind participants and therapists to the 
treatment received, which is reflected by 9/16 (56%) of the studies having a high risk 
of performance bias. However, 6 studies (38%) had a low risk of performance bias—
these were exclusively studies of pharmacological treatments, where it is possible to 
implement a true placebo-controlled double-blind design. Nevertheless, the blinding of 
outcome assessments—arguably one of the key bias domains—compared more 
favourably, with approximately 11 (69%), 3 (19%), and 2 (13%) studies having a low, 
unclear, and high risk of bias, respectively. 
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Network plots of direct comparisons for the network meta-analysis (transition outcome) 
at 6 and 12 months, showing risk of bias for outcome assessment blinding.  
 
The width of the lines is proportional to the number of trials comparing each pair of 
treatments and the size of each node is proportional to the number of studies testing the 
specific treatment. The colour of the lines represents the comparison-specific bias level, 
estimated as the risk of bias level for the blinding of outcome assessments in the majority 
of included studies in each comparison (green = low risk, yellow= unclear risk, red= 
high risk).  
 
Figure 2–3. Network plots of direct comparisons for the network meta-analysis for 




Treatment abbreviations (throughout this thesis). CBT-F = French & Morrison’s CBT 
protocol (French and Morrison, 2004); CBT-V = van der Gaag et al's CBT protocol (van 
der Gaag et al, 2012); NBI = Needs-based interventions; RIS = risperidone; Dser = D-
serine; FFT = Family-focused therapy (Miklowitz et al, 2014); IPI = Integrated 
Psychological Interventions (Bechdolf et al, 2012); ARI = aripiprazole; OLA= 














Figure 2–4. Network plots of direct comparisons for the network meta-analysis 












3. NETWORK META-ANALYSIS – ATTENUATED 
PSYCHOTIC SYMPTOMS 
3.1. PAPER 2 – NETWORK META-ANALYSIS – ATTENUATED PSYCHOTIC 
SYMPTOMS 
 
Davies C, Radua J, Cipriani A, Stahl D, Provenzani U, McGuire P, et al (2018). 
Efficacy and acceptability of interventions for attenuated positive psychotic 
symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. 
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Background: Attenuated positive psychotic symptoms represent the defining features
of the clinical high-risk for psychosis (CHR-P) criteria. The effectiveness of each available
treatment for reducing attenuated positive psychotic symptoms remains undetermined.
This network meta-analysis (NMA) investigates the consistency and magnitude of the
effects of treatments on attenuated positive psychotic symptoms in CHR-P individuals,
weighting the findings for acceptability.
Methods: Web of Science (MEDLINE), PsycInfo, CENTRAL and unpublished/gray
literature were searched up to July 18, 2017. Randomized controlled trials in CHR-P
individuals, comparing at least two interventions and reporting on attenuated positive
psychotic symptoms at follow-up were included, following PRISMA guidelines. The
primary outcome (efficacy) was level of attenuated positive psychotic symptoms at 6 and
12 months; effect sizes reported as standardized mean difference (SMD) and 95% CIs in
mean follow-up scores between two compared interventions. The secondary outcome
was treatment acceptability [reported as odds ratio (OR)]. NMAs were conducted for both
primary and secondary outcomes. Treatments were cluster-ranked by surface under the
cumulative ranking curve values for efficacy and acceptability. Assessments of biases,
assumptions, sensitivity analyses and complementary pairwise meta-analyses for the
primary outcome were also conducted.
Results: Overall, 1,707 patients from 14 studies (57% male, mean age = 20)
were included, representing the largest evidence synthesis of the effect of preventive
treatments on attenuated positive psychotic symptoms to date. In the NMA for
efficacy, ziprasidone + Needs-Based Intervention (NBI) was found to be superior to
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NBI (SMD = −1.10, 95% CI −2.04 to −0.15), Cognitive Behavioral Therapy-French
and Morrison protocol (CBT-F) + NBI (SMD = −1.03, 95% CI −2.05 to −0.01), and
risperidone + CBT-F + NBI (SMD = −1.18, 95% CI −2.29 to −0.07) at 6 months.
However, these findings did not survive sensitivity analyses. For acceptability, aripiprazole
+NBI was significantly more acceptable than olanzapine+NBI (OR= 3.73; 95%CI 1.01
to 13.81) at 12 months only. No further significant NMA effects were observed at 6 or 12
months. The results were not affected by inconsistency or evident small-study effects,
but only two studies had an overall low risk of bias.
Conclusion: On the basis of the current literature, there is no robust evidence to favor
any specific intervention for improving attenuated positive psychotic symptoms in CHR-P
individuals.
Keywords: psychosis, risk, interventions, symptoms, network meta-analysis, treatments
INTRODUCTION
Indicated prevention in people at Clinical High Risk for Psychosis
(hereafter CHR-P) (1) represents one of the first attempts to alter
the course of the most severe psychiatric disorder and thereby
improve the lives of many young people (2, 3). Recent meta-
analytical evidence has suggested that it is potentially the only
eﬀective way to reduce the duration of untreated psychosis, which
is a key factor determining outcomes (4). CHR-P individuals
accumulate several risk factors for psychosis (5), leading to
subtle symptoms (6) and functional impairments (7) that trigger
help-seeking behaviors (8). CHR-P individuals have around
20% risk [eTable 4 from Fusar-Poli et al. (9)] of developing
psychosis [but not any other non-psychotic disorder (10, 11)]
at 2 years. After two decades of CHR-P research, the paradigm
is at standstill (12). The principal limitations of knowledge are:
(i) poor penetrance of detection strategies for identifying at-
risk individuals (13, 14), (ii) the prognostic accuracy of CHR-
P tools in clinical use (15) being substantially dependent on
idiosyncratic sampling and recruitment strategies (16–20), and
(iii) an unclear eﬀect of preventive treatments. Our research
group has previously addressed the first two limitations, and
only more recently have we completed a meta-analysis that
has investigated the consistency and magnitude of the eﬀects
of treatments to prevent psychosis in CHR-P individuals. We
used a network meta-analytic approach, which allows head-to-
head comparisons to be performed across diﬀerent preventive
treatments, and which is the recommended evidence synthesis
method for informing treatment guidelines (21). The key result
of our analysis was that there is no evidence to favor any
specific preventive treatment for CHR-P individuals over any
others (22). This finding is not completely surprising, given that
all of the most recent trials in this area were negative (23–
31). Therefore, currently, there is no convincing evidence that
indicated interventions implemented in CHR-P individuals can
eﬀectively prevent the onset of psychosis. The impact of available
preventive interventions on the underlying neurobiology that
characterizes the CHR-P state and the onset of psychosis is
similarly unclear (3). We have fully discussed these findings
and the limitations of our analysis in our previous report (22).
Here, we complement our previous meta-analysis by focusing
on outcomes other than the onset of new psychotic disorders.
It is indeed apparent that CHR-P individuals may present with
problems other than the development of psychosis at follow-up,
such as the persistence of subthreshold psychotic symptoms (32).
In particular, attenuated positive psychotic symptoms represent
the defining features of the core CHR-P criteria. Meta-analytical
evidence indicates that around 85% (95% CI 79% to 90%) of
CHR-P individuals meet the intake criteria because of attenuated
positive psychotic symptoms [see eFigure 1 in Fusar-Poli et al.
(9)]. The severity and frequency of attenuated positive psychotic
symptoms are carefully measured by experienced clinicians using
specific semi-structured [and not self-administered (33)] CHR-
P instruments (34). Investigating the eﬀect of treatments on
attenuated positive psychotic symptoms may also be associated
with empirical research benefits. For example, it has been
suggested that using continuous outcomes -such as attenuated
positive psychotic symptoms- rather than the binary transition
to psychosis may overcome the problems of arbitrary thresholds
defining a categorical onset of psychosis (35). Investigating
the impact of interventions on attenuated positive psychotic
symptoms is also relevant for informing clinical guidelines. For
example, the National Institute for Health and Care Excellence
(NICE) guidelines recommend cognitive behavioral therapies
(CBT) for presenting symptoms (36), but there is no clear
evidence which can reliably support this recommendation. The
other relevant outcome for CHR-P individuals is the acceptability
of treatments. Given the relatively high proportion of false
positives with respect to transition to psychosis, it is essential that
treatments have a benign side eﬀect profile, are well tolerated and
acceptable to this patient group.
To address these gaps in knowledge, we present here a network
meta-analysis investigating the consistency and magnitude of
the eﬀects of preventive treatments for reducing attenuated
positive psychotic symptoms in CHR-P individuals, weighting
the findings for acceptability.We focus on randomized controlled
trials (RCTs) to avoid the selection biases associated with
observational studies. Our primary aim was to test whether any
specific treatments are any more or less eﬀective (compared to
any others) in improving attenuated positive psychotic symptoms
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in CHR-P individuals, and to provide an evidence-based ranking
of treatments on the basis of eﬃcacy and acceptability. We
intended that this work would contribute to the rigorous
evidence-based assessment of the strengths and limitations of
the CHR-P paradigm (12). Our overarching vision is that by
understanding the limitations of current knowledge—which is
an essential prerequisite to finding ways of overcoming them—
the CHR-P field can advance with the development of refined




In a first step we listed the preventive interventions of
interest. The current study included all RCTs involving
non-pharmacological and/or pharmacological interventions
administered to CHR-P individuals. We focused on the following
types of treatments: CBT (diﬀerent protocols), integrated
psychological therapies, psychoeducational interventions,
supportive counseling, family therapy, needs-based interventions
(NBI), antipsychotic molecules (aripiprazole, ziprasidone,
risperidone, olanzapine) and any novel/experimental
therapeutics (D-serine and omega-3 fatty acids). Although
these interventions had been defined a priori, we also allowed
the inclusion of additional treatments that were emerging
from the most recent literature search. In a second step, we
carefully reviewed the available systematic reviews and meta-
analyses to operationalize specific definitions of the preventive
treatments in CHR-P individuals. This is an essential step to
address heterogeneity across diﬀerent types of interventions
and to characterize the specific nodes that were composing our
network. We defined each treatment component as indicated in
the following paragraphs.
Needs-Based Interventions (NBI)
CHR-P individuals enrolled in clinical trials are traditionally
young people who are experiencing subtle symptoms and
functional impairment (7) and who are therefore seeking help
for their problems (8). Accordingly, it is felt unethical to
randomize them to a pure placebo or “no treatment” condition
(37). In this scenario it is also diﬃcult to provide an exact
definition of “treatment as usual,” because although treatment
guidelines do exist (36), in reality treatment implementation
is determined by local health service priorities, resources and
configurations as well as availability of specialist training. We
therefore decided on a pragmatic approach and adopted the
operationalization of NBI provided by the founders of the CHR-
P paradigm (38). This definition focuses on the symptoms
and problems already presented by the help-seeking individual
(39), and may encompass any of the following components: (a)
needs-based supportive psychotherapy for problems with, for
example, relationships, work or family; (b) case management
for resolving issues with education, housing or employment; (c)
brief family psychoeducation and general advice; (d) diﬀerent
types of medications other than antipsychotics; and (e) clinical
monitoring alone or coupled with crisis management (38, 40).
Cognitive Behavioral Therapy, French and Morrison
Protocol (CBT-F)
The CBT-F protocol (41), like the majority of CBT protocols,
is grounded on the principles established by Beck (42).
The intervention is problem-focused and time-limited, with
treatment strategies selected based on the formulation of each
patient’s presenting problems but from a range of permissible,
manualized strategies. Although each person’s therapy will be
tailored to their presenting needs, the core components include
building engagement, collaborative goal-setting and formulation,
normalizing psychotic-like experiences, evaluating core beliefs,
and diﬀerent types of behavioral experiments (41, 43).
Cognitive Behavioral Therapy, van der Gaag Protocol
(CBT-V)
The protocol developed by van der Gaag et al. (44) is based
on the French and Morrison protocol (41), which is then
expanded by the addition of two novel components that target
cognitive biases. The first additional component is education on
dopamine system super-sensitivity and its relation to attenuated
psychotic symptoms and exaggeration of cognitive biases, with
the aim of normalizing aberrant perceptual experiences and
reducing associated distress. The individual is taught how
biases in cognition, such as selective attention, confirmation
bias and jumping-to-conclusions contribute to the formation of
delusions and paranoia (44). The second component involves
exercises/behavioral experiments to correct these biases through
examination of initial appraisals and testing of alternative
explanations (45). Further aims of CBT-V include supporting
school attendance and employment, improving relationships
with friends and relatives, and if applicable, reducing cannabis
use (44).
Integrated Psychological Interventions, Bechdolf
Protocol (IPI)
The protocol developed by Bechdolf et al. (46) is a multi-
component package of care. In addition to manualized
and time-limited individual CBT-F (41), IPI also includes
manualized group skills training, which focuses on scheduling
and monitoring leisure activities, training in social skills,
problem-solving and mastery of diﬃcult situations, and
developing “keeping well” strategies (46). The third component
was computerized cognitive remediation to address thought and
perception deficits (basic symptoms), and a final component
included multi-family psychoeducation group sessions, which
aimed to reduce interpersonal conflict and associated stress by
helping family members better understand the CHR-P state
(46, 47).
Family-Focused Therapy, Miklowitz Protocol (FFT)
The family-focused therapy (FFT) protocol by Miklowitz et al.
(28) was originally developed for individuals with or at risk
of bipolar disorder. The FFT was then adapted for CHR-
P individuals, which has three broad stages. The first stage
of FFT encompasses psychoeducation and the development
of a patient-family prevention plan, which helps to increase
understanding of the stressors contributing to attenuated positive
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and negative symptoms, while also detailing coping strategies
and behavioral activation goals. The second stage focuses on
enhancing constructive patient-family communication, and the
third stage consists of improving problem-solving skills (28).
Psychopharmacological Interventions
Pharmacological interventions included licensed medications,
experimental pharmacotherapies as well as nutritional
supplements.
Placebo
The placebo component was reserved for pharmacological
placebos administered in the control arms of randomized
controlled trials.
Node Composition
We carefully identified the specific interventions (as listed above)
for each arm of every study, which were then linearly combined
to compose the precise treatment “nodes” of our network.
As discussed above, this definition of nodes is an essential
prerequisite for performing a robust NMA that can be of clinical
relevance. Each pharmacological treatment was assigned to its
own node, but diﬀerent dosages of the same molecule were
categorized within the same node. While placebo was initially
considered as a separate node from NBI, after performing
sensitivity analyses to explore the eﬀect of pooling them together,
we decided to combine them in the same node (see below for
details).
Search Strategy and Selection Criteria
The first step of our literature search involved systematic
electronic searches in the Web of Science (which includes Web
of Science Core Collection, BIOSIS Citation Index, KCI-Korean
Journal Database, MEDLINE, Russian Science Citation Index
and SciELO Citation Index) and Ovid/ PsychINFO databases,
the Cochrane Central Register of Controlled Trials and the
NHS Centre for Reviews and Dissemination (CRD), using the
following keywords: (risk OR prodromal OR prodrom∗ OR
ultra-high risk OR clinical high risk OR high risk OR genetic
high risk OR at risk mental state OR risk of progression OR
progression to first-episode OR prodromally symptomatic OR
basic symptoms) AND (psychosis) AND (RCT OR randomized
controlled trial OR placebo controlled trial OR trial). The
searches were conducted up to 18th July 2017 and no language
restrictions were applied. In a second step, we used Scopus/Web
of Science to screen the reference lists of articles identified in
the previous step and those of existing systematic reviews and
meta-analyses. For comprehensiveness, we also searched the
reference lists of relevant clinical guidelines. In a third step,
we looked for published and unpublished material in relevant
conference proceedings, trial registries (e.g., https://clinicaltrials.
gov) or regulatory agencies. The OpenGrey database (http://
www.opengrey.eu) was used to identify unpublished material
from the gray literature.
The above search strategies led us to identifying potential
abstracts of interest. The abstracts were then screened for
potential inclusion and those that survived this initial filter
were downloaded as full-text articles. These were then carefully
inspected against the full inclusion and exclusion criteria which
are described below.
In line with the PRISMA guidance, two independent
researchers conducted the literature search, study selection and
data extraction (48). During the above steps, disagreement
between extractors was addressed through discussion with a third
researcher until consensus was obtained. We defined the specific
inclusion and exclusion criteria to ensure that the population
represented in the final database would be broadly representative
of the target CHR-P population as a whole (49).
Our inclusion criteria were (a) being an original article,
abstract or pilot study; (b) being a randomized controlled trial
(including cluster randomized trials, but excluding cross-over
studies); (c) being designed as blinded (either single- or double-
blind); (d) being conducted in CHR-P individuals with CHR-P
criteria ascertained through the use of internationally validated
psychometric assessments, i.e., the Comprehensive Assessment of
At-Risk Mental States (CAARMS) (6), the Structured Interview
for Psychosis-risk Syndromes (SIPS) (50), the Positive and
Negative Syndrome Scale (PANSS) (51), the Brief Psychiatric
Rating Scale (BPRS) (52), or the Early Recognition Inventory
(ERIraos) (53); (e) comparing specific preventive interventions
as defined in the sections above; (f) providing suﬃcient data to
perform meta-analytic computation; (g) providing a sample size
of 10 or greater (54).
Our exclusion criteria were defined as (a) being a review or
reporting non-original data; (b) lacking at least two compared
groups, such as open-label trials in a single group of CHR-
P patients exposed to treatment; (c) investigating patient
samples aﬀected with an established first-episode psychosis
or any at-risk group other than CHR-P samples; (d) lacking
suﬃcient data needed to perform the essential meta-analytical
computations; (e) design lacking proper randomization, such
as quasi-randomization or observational naturalistic studies -
however, studies that were initially conceived and designed
as blinded but could not maintain blinding during follow-up
(e.g., for psychological interventions) were not excluded; (f)
including a sample size smaller than 10 (i.e., N = 9 or less); (g)
presenting overlapping data (i.e., for the same outcome at the
same time point as data that was already included)-in the case
of overlapping data/samples, we preferred the data relating to the
largest sample size.
Outcome Measures and Data Extraction
Due to the variable eﬀect of time on clinical outcomes in these
samples (9, 55), analyses for time-dependent outcomes were
conducted. The primary outcome (eﬃcacy) was the level of
attenuated positive psychotic symptoms at follow-up, indexed
by the relevant subscales of validated assessments, such as the
PANSS, CAARMS, BPRS and SIPS. For each arm of every
study, we extracted the mean and standard deviation (SD) of
these scores at 6 and 12 month follow-up time points. Where
studies did not report suﬃcient data to extract the primary
outcome, we used DigitizeIt software (http://www.digitizeit.de/)
to extract data presented graphically (means and 95% confidence
intervals (CIs) for each follow-up time point). When necessary,
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SDs were back-calculated using standard formulae. If none of
the aforementioned were available, we estimated follow-up data
using information available from the published paper and using
assumptions established in previous literature. Sample sizes were
based on the numbers randomized to each arm.
A high benefit-to-harm ratio is essential when adopting
preventive strategies that may lead to the unnecessary treatment
of false positives. We therefore selected the acceptability
of interventions (discontinuation due to any cause) as our
secondary outcome measure. In line with previous authoritative
publications, we defined the acceptability of interventions as
the number of participants who dropped out of each arm for
any reason following randomization, over those randomized at
baseline (56–58).
In order to describe our population, assess the transitivity
assumption (see below), address the risk of bias and conduct
meta-regression analyses, we also extracted details on the
first author and year of publication of each trial, country
where the trial was conducted, types of outcomes reported,
definitions of intervention and control arms (in line with the
treatment components described above), trial design, risk of
bias assessment, duration of each intervention and follow-up,
sample size, mean age, percent male, and the psychometric CHR-
P instrument used to ascertain attenuated positive psychotic
symptoms.
Risk of Bias
The assessment of bias is of paramount importance for rigorously
interpreting the results of evidence synthesis studies and for
testing their robustness. We used the Cochrane Risk of Bias
tool (59) to classify the risk of bias in each study using a priori
defined criteria. Using these standardized criteria, we evaluated
whether each trial was at high, low or unclear risk of bias
across six specific domains. These included random sequence
generation, allocation concealment, blinding of participants and
study personnel, blinding of outcome assessments, incomplete
outcome data, and selective outcome reporting. Once these
domains were assessed, the Cochrane Risk of Bias tool allowed
production of an overall risk of bias classification of high, low or
unclear. The overall rating of low risk was assigned when none of
the six domains were found to be at high risk and if three or less
domains were found to be at unclear risk. The overall rating of
moderate risk was assigned when one domain was found to be at
high risk; or no domains were found to be at high risk but four or
more were found to be at unclear risk. In all other cases, the trial
was classified as having an overall high risk of bias (60).
Statistical Analysis
Network Meta-Analysis
Frequentist NMAs were conducted for both primary (attenuated
positive psychotic symptoms) and secondary (acceptability)
outcomes at 6 and 12 months using the network package in
STATA (version SE 14.2). Eﬀect sizes for the primary outcome
were calculated and reported as the standardized mean diﬀerence
Hedges’ adjusted g (SMD) and 95% CIs in mean follow-up scores
between two compared interventions, using the pooled SD at
follow-up (61). Follow-up data are considered preferable when
measuring continuous outcomes that are diﬃcult to measure
(62). Eﬀect sizes for the secondary outcomewere reported as odds
ratio (OR) and 95% CIs. We first constructed network plots -
for each outcome- to ensure that the geometry of the networks
were suﬃciently connected (63, 64). We then performed a NMA
assuming consistency and a common heterogeneity across all
comparisons in the network. This allowed us to derive a single
summary treatment eﬀect (SMD for attenuated positive psychotic
symptoms; OR for acceptability) for every possible pairwise
comparison of treatments. This summary eﬀect draws on all
evidence from the network of trials, including direct and indirect
evidence. Correlations in eﬀect sizes induced by multi-arm trials
were accounted for (63, 65). The resulting relative SMDs or ORs
with 95% CIs for each pair of treatments were reported in league
tables (66). Statistical significance was set at p< 0.05.
When performing NMA it is possible to rank an outcome
of interest using the Surface Under the Cumulative RAnking
curve (SUCRA) procedure. Such an approach allows integration
of both the location and the variance of any relative eﬀect
on the outcome of interest (67). In simple terms, the SUCRA
procedure summarizes the overall ranking of each intervention
through a single number ranging from 0 to 100% (68). In
this manuscript, the higher the SUCRA value, the higher the
likelihood that an intervention will be in the top rank, and
vice versa (68). In line with our objective, we performed cluster
ranking (63, 67) of the SUCRA values for attenuated positive
psychotic symptoms and acceptability (at 6 and 12 months,
separately) and presented the results in two-dimensional plots
(64). These plots aid visualization of the relative balance between
a treatment’s ranking across diﬀerent outcomes, and show the
clustering of treatments into meaningful groups as determined
by hierarchical cluster analysis (63, 64).
Consistency in a network refers to the equivalence of direct
and indirect estimates of the same treatment comparison pairs,
and can be investigated in each closed loop of evidence (66). We
assessed this assumption by calculating an inconsistency factor
along with 95% CIs (truncated at 0) and associated p-values for
each closed loop of the primary outcome (63). Inconsistency was
defined as disagreement between direct and indirect evidence,
with 95% CIs for inconsistency factors excluding zero. Because
the loop-specific approach focuses on local inconsistency and
has low power, we also tested a full design-by-treatment model
(69) for the primary outcome to evaluate global inconsistency.
This entailed performing a NMA under the inconsistency model
and using the χ2-test to estimate the statistical significance of all
possible inconsistencies in the networks (70).
Transitivity was examined by assessing the distributions of
potential eﬀect modifiers across comparisons in the networks.
These eﬀect modifiers encompassed the following items: percent
male, age, percent exposed to antipsychotic medications at
baseline, type of blinding and publication year.
The presence of small-study eﬀects was assessed by visual
inspection of comparison-adjusted funnel plots (71). In this
analysis we used NBI (or when not available, CBT-F + NBI) as
the reference. We assumed that small-study eﬀects, if present,
would be expected to exaggerate the eﬀectiveness of the “active”
(or newer/experimental) treatment, rather than NBI or CBT-F
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+ NBI, which currently represent the most widely implemented
interventions for this patient group.
Complementary Analyses
Sensitivity analyses were performed to address the impact of
study quality and our data analysis strategy. Specifically, we
repeated the NMA analyses on attenuated positive psychotic
symptoms using only: (a) studies with a low risk of bias for the
blinding of attenuated positive psychotic symptom assessments;
(b) studies whose meta-analytical data (i.e., mean and SD of
attenuated positive psychotic symptoms) were not estimated
using assumptions established in previous literature; and (c)
published trials only (i.e., excluding conference proceedings).
In addition, we repeated the NMA after pooling NBI and
placebo nodes and after pooling diﬀerent types of antipsychotic
molecules. To ensure that the use of follow-up scores did not
unduly influence our results, we repeated the analyses using SMD
calculated from change score and pooled baseline SD, which
is recommended when a full ANCOVA model is not feasible
(62). Furthermore, we complemented the sensitivity analyses
through network meta-regression analyses. These were planned
only when substantial heterogeneity was observed and when at
least 10 independent trials were available (72) for each outcome
of interest. These meta-regressions were planned to investigate
the potential impact of the diﬀerent CHR-P psychometric
instruments used for measuring attenuated positive psychotic
symptoms (34).
For the primary outcome, we also conducted conventional
pairwise meta-analyses (random eﬀects model) of every direct
treatment comparison using the metan package in STATA. The
random eﬀects meta-analyses were stratified by (a) follow-up
time (6 or 12months), and (b) pairwise intervention comparisons
(i.e., each type of treatment vs. its control was treated as
a meta-analysis, no overall summary eﬀect computed across
comparisons of diﬀerent treatments). The resultingmeta-analytic
SMDs together with 95% CIs and measures of heterogeneity (I2)
were calculated and presented in tables. When pairwise groups
had more than three contributing studies, we performed leave-
one-out sensitivity analyses to explore the robustness of the
results to influential individual studies.
RESULTS
Characteristics of Trials and Patients
Our initial literature search identified 1,556 references. However,
most of them did not report on RCTs in CHR-P individuals. As
indicated in Figure 1, 49 of them were eventually downloaded
and fully inspected against the inclusion and exclusion criteria,
which resulted in a final sample of 14 studies. We found only
three, three, two and two trials reporting the outcome data of
interest at 18, 24, 36, and >36 month time points, respectively.
Consequently, the current meta-analysis focuses only on the 6
and 12 month time points. The 14 studies used in the analyses
contributed data on a total of 1707 patients, with a mean age
of 20.1 ± 2.9 years, and of whom 57% were male (Table 1).
The mean sample size was 122 (range 44–304). Five studies
were conducted in North America, five in Europe, three in
Australia and one was multi-national. Two trials adopted a three-
arm design while all of the others employed a two-arm design.
Two of the included studies were identified from conference
proceedings and gray literature/clinical trial databases (24, 30).
Two studies had a treatment duration of <6 months, eight
of 6 months, and four of 12 months. Three of the 12 trials
that reported enough information to identify the source of
sponsorship or funding acknowledged pharmaceutical company
involvement. The SIPS was the most common assessment used
for measuring attenuated positive psychotic symptoms (N = 6).
Only two studies had an overall low risk of bias (30, 40),
four had unclear risk (24, 26, 27, 73) and the remaining eight
had high risk; the full risk of bias assessment is presented in
Figure 2.
For the primary outcome, eight studies provided data for
both 6 and 12 month networks, three only provided data for 6
months, and another 3 only for 12 months, resulting in 11 studies
contributing data for the 6 month analysis, and 11 to the 12
month analysis. For the 6 month analysis, 11 studies (N = 1459)
provided data on 15 direct comparisons between 8 diﬀerent
treatment nodes (Figure 3A). For the 12 month analysis, 11
studies (N = 1483) provided data on 15 direct comparisons
between 7 diﬀerent treatment nodes (Figure 3B).
At 6 months, seven studies provided the required follow-
up symptom data directly or indirectly, two provided means
and SD graphically (28, 40), and for two studies symptom data
were estimated on the basis of available data and assumptions
established in previous literature (27, 30). At 12 months, nine
studies provided the required data directly or indirectly, one
provided data graphically (40), and for one study symptom data
were estimated on the basis of available data and assumptions
established in previous literature (27).
All studies, except one (38), provided data for the secondary
outcome (acceptability) at both 6 and 12 months. Network plots
for the acceptability outcome were the same as those for the
primary outcome (Figure 3).
Pairwise Meta-Analysis
Pairwise meta-analysis results for the primary outcome are
presented in Table 2. Only three pairwise intervention vs. control
groups had two or more studies: CBT-F + NBI vs. NBI; omega-
3 + NBI vs. NBI; and risperidone + CBT-F + NBI vs. NBI.
The remaining pairwise intervention vs. control groups were
composed of single studies.
At 6 months, there was no significant diﬀerence between
CBT-F + NBI vs. NBI alone (SMD = −0.06, 95% CI −0.26 to
0.13; 5 studies, N = 652). However, there was meta-analytical
evidence of a greater reduction in attenuated positive psychotic
symptoms in CBT-F + NBI vs. NBI alone at 12 months
(SMD = −0.22, 95% CI −0.37 to −0.07; 6 studies, N = 712).
Leave-one-out sensitivity analyses showed that this eﬀect was
dependent on the presence of one study (74). When this study
was removed, the combined eﬀect at 12 months became non-
significant (SMD = −0.12, 95% CI −0.32 to 0.08; 5 studies,
N = 424). The non-significant summary eﬀect at 6 months did
not become significant throughout any iteration of the leave-one-
out analyses.
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FIGURE 1 | PRISMA flow chart of the study selection process. CHR-P, clinical high risk for psychosis; RCT, randomized controlled trial.
Two studies compared omega-3+NBI to NBI alone, but both
6 and 12 month summary eﬀect estimates were not significant
(6 month SMD = −0.48, 95% CI −1.62 to 0.67, 2 studies,
N = 385; 12 month SMD = −0.38, 95% CI −1.38 to 0.63, 2
studies,N = 385). Significant heterogeneity was detected between
these two studies at both 6 (I2 = 95%, p < 0.001) and 12
(I2 = 94%, p< 0.001) month time points. Statistical investigation
of potential sources of heterogeneity using meta-regression was
precluded by the limited number of studies.
Combined therapy with risperidone + CBT-F + NBI was not
significantly diﬀerent from NBI alone at either 6 (SMD = 0.02,
95% CI −0.33 to 0.37, 2 studies, N = 130) or 12 months
(SMD = 0.00, 95% CI −0.38 to 0.38, 2 studies, N = 130). While
available data on all further pairwise treatments vs. controls are
listed in Table 2 for completeness, they represent single studies
and thus cannot be considered meta-analytic results.
Network Meta-Analysis – Effect on
Attenuated Positive Psychotic Symptoms
Results of the NMA are presented in Tables 3, 4. At 6 months,
ziprasidone + NBI was found to be significantly more eﬀective
at reducing attenuated positive psychotic symptoms compared to
NBI alone (SMD = −1.10, 95% CI −2.04 to −0.15); compared
to CBT-F + NBI (SMD = −1.03, 95% CI −2.05 to −0.01); and
compared to risperidone + CBT-F + NBI (SMD = −1.18, 95%
CI −2.29 to −0.07). There were no other significant eﬀects of
any one intervention over any others (Table 3). Using NBI as a
comparator, the relative treatment eﬀect estimates (all SMD < 0
favor the given treatment) at 6 months were: ziprasidone +
NBI (SMD = −1.10, 95% CI −2.04 to −0.15); omega-3 +
NBI (SMD = −0.42, 95% CI −1.01 to 0.16); aripiprazole +
NBI (SMD = −0.18, 95% CI −0.90 to 0.53); family-focused
therapy + NBI (SMD = −0.41, 95% CI −1.22 to 0.41); CBT-F
+ NBI (SMD = −0.07, 95% CI −0.44 to 0.31); D-serine + NBI
(SMD=−0.10, 95% CI−1.05 to 0.84); and risperidone+ CBT-F
+ NBI (SMD= 0.08, 95% CI−0.50 to 0.67).
At 12months, there was no evidence that any one intervention
was superior over any others, with all 95% CIs crossing zero
(Table 4). Using NBI as a comparator, the relative treatment
eﬀect estimates (all SMD < 0 favor the given treatment) at 12
months were: olanzapine + NBI (SMD = −0.53, 95% CI −1.28
to 0.22); omega-3 + NBI (SMD=−0.30, 95% CI−0.77 to 0.17);
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TABLE 1 | Characteristics of included studies.



















Country % exposed to
antipsychotics
at baseline
Addington et al. (37) CBT-F + NBI [27]
NBI [24]
51 6, 12 6 6, 12, 18 71 20.9 SIPS SB-RCT Canada 0
Amminger et al. (40) Omega-3 + NBI [41]
NBI [40]





128 12 12 6, 12, 18,
24
63 26.0 PANSS SB-RCT Germany 0
Bechdolf et al. (24) ARI + NBI [96]
NBI [55]
CBT-F + NBI [129]
280 6, 12 12 6, 12 66 24.4 SIPS SB-RCT Germany 3.4
Kantrowitz et al. (26) D-serine + NBI [20]
NBI [24]
44 6 4 4 66 19.4 SIPS DB-RCT US 11.4
McGlashan et al. (73) OLA + NBI [31]
NBI [29]
60 12 12 12, 24 65 17.7 SIPS DB-RCT US, Canada 10
McGorry et al. (38) RIS + CBT-F + NBI [31]
NBI [28]
59 6, 12 6 6, 12,
36–48
58 20.0 BPRS SB-RCT Australia 0
McGorry et al. (27) Omega-3 + NBI [153]
NBI [151]
304 6, 12 6 6, 12 46 19.2 BPRS DB-RCT Multi-national 0
Miklowitz et al. (28) FFT + NBI [66]
NBI [63]
129 6 6 6 57 17.4 SIPS SB-RCT US, Canada 20.9
Morrison et al. (43) CBT-F + NBI [37]
NBI [23]
60 12 6 6, 12, 36 69 22.0 PANSS SB-RCT UK 0
Morrison et al. (74) CBT-F + NBI [144]
NBI [144]
288 6, 12 6 6, 12, 18,
24
63 20.7 CAARMS SB-RCT UK 0
Stain et al. (29) CBT-F + NBI [30]
NBI [27]
57 6, 12 6 6, 12 40 16.3 CAARMS SB-RCT Australia 0
Woods et al. (30, 31) ZIP + NBI [24]
NBI [27]
51 6 6 6 64 22.3 SIPS DB-RCT US 0
Yung et al. (76) and
McGorry et al. (77)
CBT-F + NBI [44]
RIS + CBT-F + NBI [43]
NBI [28]
115 6, 12 12 6, 12 39 18.1 BPRS SB-RCT Australia 0
CBT-F, cognitive behavioral therapy (French and Morrison protocol); NBI, eeds-based interventions (including placebo); IPI, integrated psychological interventions; ARI, aripiprazole;
OLA, olanzapine; RIS, risperidone; FFT, family-focused therapy; ZIP, ziprasidone; SIPS, Structured Interview for Psychosis-risk Syndromes; PANSS, Positive and Negative Syndrome
Scale; BPRS, Brief Psychiatric Rating Scale; CAARMS, Comprehensive Assessment of At-Risk Mental States; SB-RCT, single-blind randomized controlled trial; DB-RCT, double-blind
randomized controlled trial.
aripiprazole+NBI (SMD=−0.23, 95% CI−0.78 to 0.33); CBT-
F + NBI (SMD = −0.15, 95% CI −0.43 to 0.13); risperidone
+ CBT-F + NBI (SMD = −0.04, 95% CI −0.52 to 0.44); and
integrated psychological interventions (SMD = 0.20, 95% CI
−0.45 to 0.84).
Inconsistency and Small-Study Effects
There was no statistically significant inconsistency in the 6 or 12
month networks. The 95% CIs for all inconsistency factors were
compatible with zero inconsistency. However, it is important to
note that only two loops were available at both 6 and 12 months,
which may have limited our ability to detect inconsistency.When
we used the design-by-treatment interaction model, there was no
evidence for significant inconsistency in the 6 (p = 0.92) or 12
month (p= 0.92) networks.
Visual inspection of comparison-adjusted funnel plots
suggested no clear small-study eﬀects (publication biases),
with a regression line almost flat at 6 months (Figure S1A in
Supplementary Material) and completely flat at 12 months
(Figure S1B in Supplementary Material).
Sensitivity Analyses for NMA of Primary Outcome
We tested the robustness of the core NMA findings (that
ziprasidone + NBI is superior to NBI alone, CBT-F + NBI,
and risperidone + CBT-F + NBI at 6 months) through various
sensitivity analyses. At 6 months, two studies (27, 30) were
based on estimated follow-up data, one of which was the single
ziprasidone + NBI vs. NBI study (30). Repeating the analyses
after removal of the latter study (30) inherently meant that there
was now no ziprasidone+ NBI node and all estimates were non-
significant. Removal of the other study -by McGorry et al (27)-
did not aﬀect the current results at 6 or 12 months; however,
one change of note is that at 12 months, CBT-F + NBI became
significantly more eﬀective than NBI, which is interesting in light
of the pairwise significance of CBT-F+NBI vs. NBI at 12months,
and lack thereof in the main NMA analyses.
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FIGURE 2 | Risk of bias summary. Review authors’ judgements about each risk of bias item for each included study. Green circles (+) indicate low risk of bias; yellow
circles (?) indicate unclear risk; red circles (−) indicate high risk of bias.
The ziprasidone+NBI results were not robust to the removal
of two studies (38, 76) at high or unclear risk of bias for the
blinding of outcome assessments, which resulted in only the
ziprasidone + NBI vs. NBI comparison remaining significant.
Repeating the analyses after removing unpublished studies (24,
30), pooling together diﬀerent antipsychotic molecules, and
using change scores instead of follow-up scores all abolished
the ziprasidone + NBI results. Repeating the analyses treating
NBI + placebo as a separate node to NBI had some eﬀect
on the NMA estimates at 6 months (ziprasidone + NBI was
now superior only to NBI + placebo) and had no eﬀect at 12
months; we therefore used the pooled NBI + placebo in the
main analysis (Tables 1–4, Figures 3, 4). There were too few
studies to allow robust meta-regression analyses on the type
of instruments used to measure attenuated positive psychotic
symptoms.
Network Meta-Analysis – Effect on
Acceptability
There were no significant diﬀerences in acceptability between any
treatments at 6 months (Table 3). At 12 months, aripiprazole
+ NBI was significantly more acceptable than olanzapine +
NBI (OR = 3.73; 95% CI 1.01 to 13.81). There were no
further significant diﬀerences at 12 months (Table 4). However,
at both time points, the 95% CIs for the comparisons were
often very wide, indicating substantial imprecision in the
estimates.
Frontiers in Psychiatry | www.frontiersin.org 9 June 2018 | Volume 9 | Article 187
 [59]  
Davies et al. Interventions for Attenuated Psychotic Symptoms
FIGURE 3 | Network plots of direct comparisons at 6 (A) and 12 (B) months.
The width of the lines is proportional to the number of trials comparing each
pair of treatments and the size of each node is proportional to the number of
studies testing the specific treatment. Numbers represent the number of
studies contributing data to each comparison. ARI, aripiprazole; NBI,
needs-based interventions (including placebo); CBT-F, cognitive behavioral
therapy (French and Morrison protocol); Dser, D-serine; FFT, family-focused
therapy; Om3, omega-3 fatty acids; RIS, risperidone; ZIP, ziprasidone; IPI,
integrated psychological interventions; OLA, olanzapine.
Network Meta-Analysis – Cluster Ranking
for Attenuated Positive Psychotic
Symptoms and Acceptability
The cluster ranking plots of SUCRA values for attenuated positive
psychotic symptoms (eﬃcacy) and acceptability are illustrated
in Figure 4A (for 6 months) and Figure 4B (for 12 months).
However, it should be noted that although the treatments were
cluster ranked, there was no statistically significant diﬀerence
between any treatments (with the exception of ziprasidone +
NBI) in the main network meta-analysis results (see Tables 3, 4
for details).
Three distinct clusters were found in the cluster ranking at
6 months (Figure 4A). Notably, while ziprasidone + NBI had
the highest SUCRA for eﬃcacy (94%), it was also the most
poorly tolerated, having the lowest SUCRA value for acceptability
(23%). In a second cluster, omega-3 + NBI and family-focused
therapy + NBI had similar SUCRA scores for eﬃcacy (67%
and 63%, respectively), however, they diﬀered markedly in their
SUCRA for acceptability; family-focused therapy + NBI had
the highest acceptability SUCRA of all treatments (70%), while
that of omega-3 + NBI was mid-range (49%). The third cluster
comprised the remaining treatments, whose SUCRA values for
eﬃcacy were all below 50%, but whose acceptability SUCRAs
varied from 62% for aripiprazole + NBI, to 37% (the worst) for
NBI.
At 12 months, four distinct clusters were found (Figure 4B).
Similar to above, while olanzapine + NBI was ranked highest
of all treatments for eﬃcacy SUCRA (82%), it also scored
worst for acceptability (13%). A second cluster, with a more
balanced profile of eﬃcacy and acceptability SUCRA values,
comprised aripiprazole + NBI, omega-3 + NBI and CBT-F
+ NBI. Of these, omega-3 + NBI had the highest SUCRA
value in terms of eﬃcacy (70%) but lower acceptability (57%),
aripiprazole + NBI had slightly lower eﬃcacy (60%) but
the highest acceptability of all treatments (91%), and CBT-
F + NBI had mid-range values for both outcomes. NBI and
risperidone + CBT-F + NBI were found in a third, intermediate
cluster with low mid-range SUCRA values. The final cluster
was composed of integrated psychological interventions, with
SUCRA values of 19% and 26% for eﬃcacy and acceptability,
respectively.
DISCUSSION
To the best of our knowledge, this is the first network meta-
analysis to have explored the eﬀect of preventive treatments on
attenuated positive psychotic symptoms in CHR-P individuals.
Focusing exclusively on RCTs to minimize selection biases, we
included a total of 14 non-overlapping studies, for a total database
of 1,707 CHR-P individuals, representing the largest evidence
synthesis of this topic to date. By using themost updated evidence
we defined two networks at 6 and 12 months, on which we
performed the core analyses. These two networks included 8 and
7 nodes, respectively. There were not enough studies to generate
networks beyond these time points. Overall, our network meta-
analyses indicated no robust evidence of superior eﬃcacy for any
specific intervention on attenuated positive psychotic symptoms
at any time point, with the exception of ziprasidone + NBI,
which was superior to NBI alone, CBT-F+ NBI, and risperidone
+ CBT-F + NBI. However, the evidence specifically relating to
ziprasidone + NBI was based on a single study only and did
not survive sensitivity analyses. The results were not aﬀected
by inconsistency or evident small-study eﬀects (publication
biases).
The main finding of the current study is that there is a lack
of evidence to favor specific eﬀective interventions for reducing
attenuated positive psychotic symptoms in CHR-P individuals.
While ziprasidone+NBI demonstrated some superiority in the 6
month network meta-analyses, these results are not robust. First,
the eﬃcacy of ziprasidone + NBI comes from only one as-yet
unpublished study. Second, the results did not survive most of
the sensitivity analyses. Finally, in the cluster ranking, it was clear
that while ziprasidone+NBIwas themost eﬃcacious in reducing
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Total N SMD (g) Lower 95%CI Upper 95%CI Heterogeneity
Treatment Control I2 Q P
6 ARI + NBI NBI 1 (24) 96 55 −0.22 −0.56 0.11 – 0.00 –
ARI + NBI CBT-F+NBI 1 (24) 96 129 −0.06 −0.33 0.20 – 0.00 –
CBT-F + NBI NBI 5 (24, 29, 37, 74, 76) 374 278 −0.06 −0.26 0.13 24.2 5.27 0.26
Dser + NBI NBI 1 (26) 20 24 −0.10 −0.70 0.49 – 0.00 –
FFT + NBI NBI 1 (28) 66 63 −0.41 −0.76 −0.06 – 0.00 –
Om3 + NBI NBI 2 (27, 40) 194 191 −0.48 −1.62 0.67 94.8 19.4 <0.001
RIS + CBT-F + NBI CBT-F+NBI 1 (76) 43 44 0.37 −0.05 0.80 – 0.00 –
RIS + CBT-F + NBI NBI 2 (38, 76) 74 56 0.02 −0.33 0.37 0.00 0.72 0.40
ZIP + NBI NBI 1 (30) 24 27 −1.10 −1.69 −0.50 – 0.00 –
12 ARI + NBI NBI 1 (24) 96 55 −0.22 −0.55 0.12 – 0.00 –
ARI + NBI CBT-F+NBI 1 (24) 96 129 −0.08 −0.34 0.18 – 0.00 –
CBT-F + NBI NBI 6 (24, 29, 37, 43, 74, 77) 411 301 −0.22 −0.37 −0.07 0.00 3.27 0.66
IPI NBI 1 (46) 63 65 0.20 −0.15 0.54 – 0.00 –
OLA + NBI NBI 1 (73) 31 29 −0.53 −1.05 −0.02 – 0.00 –
Om3 + NBI NBI 2 (27, 40) 194 191 −0.38 −1.38 0.63 93.5 15.49 <0.001
RIS + CBT-F + NBI CBT-F+NBI 1 (77) 43 44 −0.07 −0.49 0.35 – 0.00 –
RIS + CBT-F + NBI NBI 2 (38, 77) 74 56 0.00 −0.38 0.38 16.2 1.19 0.28
Underlined bold text within the SMD and 95% CI columns indicates statistically significant meta-analytic treatment effect. SMD below 0 favors the given treatment condition. ARI,
aripiprazole; NBI, needs-based interventions (including placebo); CBT-F, cognitive behavioral therapy (French & Morrison protocol); Dser, D-serine; FFT, family-focused therapy; Om3,
omega-3 fatty acids; RIS, risperidone; ZIP, ziprasidone; IPI, integrated psychological interventions; OLA, olanzapine. Dashes (–) indicate no heterogeneity estimate due to having only
one contributing study (and thus cannot be considered a true meta-analytic result).
attenuated positive symptoms, it was poorly tolerated with the
lowest ranking for acceptability. Similarly, the only significant
result in pairwise analyses was for CBT-F + NBI vs. NBI at 12
months. Again, this was found to be reliant on the inclusion
of one particular study (74) in sensitivity analyses. Given that
the data relating to the CBT-F + NBI element are identical
in both the pairwise and network meta-analyses, the driving
factor for the disparity (in significance of CBT-F + NBI vs.
NBI in pairwise vs. network meta-analyses) likely emerges from
the additional data about NBI that the NMA had gained from
the rest of the network (i.e., the relative eﬀectiveness of NBI as
derived indirectly from the other -direct- comparisons). Support
for this explanation comes from the finding that, when one
particular study (27) was removed from the 12 month network
(in sensitivity analyses), the CBT-F + NBI vs. NBI comparison
became significant. Inspection of the data for this removed study
(27) showed that it had the largest NBI arm (N = 151) of all
trials, and although the study-specific SMD was not significant,
the SMD was favoring NBI over the comparative intervention
(omega-3 + NBI). This suggests that the relative eﬀectiveness
of NBI may have been underestimated by the direct (pairwise)
CBT-F + NBI vs. NBI estimates compared to the NMA-derived
estimates.
Overall, our negative results are concordant with several lines
of evidence pointing toward ineﬀective treatments for CHR-P
individuals. Beyond the lack of evidence for specific treatments
reducing the risk of developing psychosis -as determined by our
earlier study (22)-, another recently published network meta-
analysis found no evidence that any treatments were better
than any others in improving attenuated negative symptoms in
CHR-P individuals (78, 79). The lack of impact on attenuated
negative symptoms is in line with meta-analytical evidence
showing that full-blown negative symptoms are refractory to
any kind of treatment (72). More to the point, there is not
even evidence that current preventive treatments can ameliorate
clinical outcomes such as functional level (80–83), depressive
comorbidities (83), distress (81) and quality of life (81, 83) in
CHR-P individuals. It is possible that the lack of evidence for
eﬀective treatments to reduce transition to psychosis may be
secondary to low statistical power for testing this outcome. In
turn, this can be caused by the recruitment strategies adopted
by recent RCTs that have focused on individuals that were
poorly risk enriched, causing a dilution of the final risk for
psychosis (23). On the contrary, the lack of evidence for eﬀects
on attenuated positive psychotic symptoms cannot simply be
attributed to low statistical power. Rather, it is possible that
the available treatments are not disease-modifying because
they are not targeting the core pathophysiological processes
underlying the onset of psychosis in CHR-P individuals (3). It
is also possible that eﬀective preventive treatments do exist, but
we are currently unable to detect them because of the large
noise and between-subject heterogeneity that is observed. For
example, the level of attenuated positive psychotic symptoms
varies considerably across diﬀerent CHR-P subgroups. We have
previously found that CHR-P individuals meeting the short-
lived psychotic episode subgroup have the highest risk of
developing psychosis (about 40–50% at 2 years) (9, 84), those
meeting the attenuated psychotic symptoms subgroup have
an intermediate risk (about 20% at 2 years) (9), and those
meeting the genetic risk subgroup have a low risk (about
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TABLE 3 | Network meta-analytic relative treatment effects for efficacy and acceptability at 6 months.


















































































































Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. For
the primary outcome (attenuated positive psychotic symptoms) estimates, results are SMD (95% CI), where SMD below 0 favors the column-defined treatment. For acceptability, results
are OR (95% CI), where OR < 1 favors the row-defined treatment. Significant results are in bold. The order of treatments in the diagonal is arbitrary and does not reflect ranking. ZIP,
ziprasidone; NBI, needs-based interventions (including placebo); Om3, omega-3 fatty acids; FFT, family-focused therapy; ARI, aripiprazole; Dser, D-serine; CBT-F, cognitive behavioral
therapy (French & Morrison protocol); RIS, risperidone.
Comparison.
Efficacy (attenuated psychotic symptoms; SMD [95% CI]).
Acceptability (dropout; OR [95% CI]).
TABLE 4 | Network meta-analytic relative treatment effects for efficacy and acceptability at 12 months.























































































Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment.
For the primary outcome (attenuated positive psychotic symptoms) estimates, results are SMD (95% CI), where SMD below 0 favors the column-defined treatment. For acceptability,
results are OR (95% CI), where OR < 1 favors the row-defined treatment. Significant results are in bold. The order of treatments in the diagonal is arbitrary and does not reflect ranking.
OLA, olanzapine; NBI, needs-based interventions (including placebo); Om3, omega-3 fatty acids; ARI, aripiprazole; CBT-F, cognitive behavioral therapy (French & Morrison protocol);
RIS, risperidone; IPI, integrated psychological interventions.
Comparison.
Efficacy (attenuated psychotic symptoms; SMD [95% CI]).
Acceptability (dropout; OR [95% CI]).
3% at 2 years) (9). In a subsequent prospective cohort study,
we confirmed that CHR-P individuals meeting the short-lived
psychotic episode subgroup criteria have a very high risk
of developing persistent psychotic episodes (85). Additional
ongoing analyses revealed that these three subgroups are
associated with diﬀerent clinical needs and use of mental health
services. These results led us to propose clinical stratification
of the CHR-P population across diﬀerent subgroups (1), which
has been endorsed by other leading researchers in this area
(2, 86). However, because most trials were conducted before
such knowledge emerged, response to preventive treatment was
not stratified across these diﬀerent subgroups and we have
been unable to control for this variable in meta-regression
analyses. The clinical heterogeneity of this population is further
amplified by the heterogeneous accumulation of risk factors
for psychosis (5), which is reflected in a variable enrichment
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FIGURE 4 | Cluster-ranking of treatments according to SUCRA values for
efficacy and acceptability at 6 (A) and 12 (B) months. Colors reflect treatments
belonging to the same cluster. Please note that although the treatments have
been ranked, there is no statistical difference between them -with the
exception of ziprasidone+NBI for efficacy- (see Tables 3,4 for further details).
ARI, aripiprazole; NBI, needs-based interventions (including placebo); CBT-F,
cognitive behavioral therapy (French and Morrison protocol); Dser, D-serine;
FFT, family-focused therapy; Om3, omega-3 fatty acids; RIS, risperidone; ZIP,
ziprasidone; IPI, integrated psychological interventions; OLA, olanzapine.
of risk to psychosis (17) and diﬀerent clinical outcomes. The
latter may include the development of psychosis, persistence of
symptoms and comorbidities, or recovery (32). Overall, the above
considerations indicate that the “one-size-fits-all” approach to
oﬀering preventative strategies to CHR-P individuals is unlikely
to work, namely due to the heterogeneity of the CHR-P state.
This raises the possibility that the available treatments have been
ineﬀective because they were applied to all CHR-P subjects,
rather than to stratified subgroups. For example, a true preventive
eﬀect may be diﬃcult to detect in those at low risk or in
those who are responding to placebo or low-level needs-based
interventions.
These findings may be informative for future research.
For example, they suggest that a stratified precision medicine
approach may improve the apparent eﬀectiveness of available
treatments. Identifying specific factors that predict response
to preventive treatments at the individual subject level may
substantially advance clinical care for CHR-P individuals by
personalizing their preventive interventions. This could be
achieved using the existing RCT data under an individual
participant data network meta-analytic approach. These
advanced meta-analytical approaches allow the stratification
of treatment response through the development of predictive
risk estimation tools (87) and could potentially produce a
breakthrough advancement of clinical knowledge in this
area. Our research group has recently completed the protocol
for an individual participant data network meta-analyses
(PROSPERO 2018 CRD42018089161) which is due to start
imminently. At the same time, the lack of convincing
evidence for eﬀective treatments should foster refreshed
collaborative eﬀorts to test innovative novel treatments for
CHR-P individuals. It is important to note that challenges
in developing eﬀective preventive treatments are not specific
to the CHR-P field but are common across other branches
of clinical medicine, such as in the prevention of dementia.
Promising compounds are on the horizon. For example, the
first ever industry-funded RCT for CHR-P individuals will
be investigating the eﬃcacy of a phosphodiesterase inhibitor
to prevent psychosis (88). Of relevance, to partially reduce
the clinical heterogeneity discussed above, this RCT will
focus only on CHR-P individuals presenting with attenuated
positive psychotic symptoms and who are enriched in risk
as determined by a specific risk stratification algorithm (89).
Another promising candidate treatment is cannabidiol, which
was found to be well tolerated and reduced symptoms in
an early-phase trial in CHR-P individuals, although the
full report is not yet available (90, 91). A larger-scale RCT
of cannabidiol is due to start at our institute in the near
future. The discovery and development of more eﬀective
treatments for attenuated positive psychotic symptoms also
requires an improved regulatory platform to reliably sustain
the next generation of research. For example, while the
DSM-5 includes a newly introduced diagnostic category for
attenuated psychosis syndrome (92), there will be no similar
diagnostic category in the ICD-11. Diagnostic controversies,
as well as diﬀerent methods of ascertainment of attenuated
psychotic symptoms [for a comparative analysis of diﬀerent
CHR-P instruments see (34)] are unlikely to facilitate the
large-scale collaborations that are necessary to overcome the
current limitations.
There are some important limitations to our work. First,
the interpretation of negative findings is always challenging. In
fact, as noted by leading authors, absence of evidence is not
evidence of absence (93). Such an observation is particularly
relevant in the case of large CIs, such as those that have been
observed in the current analyses (see Tables 3, 4). Therefore,
some sizeable eﬀects may still have been missed by our analyses.
Furthermore, only 14 RCTs were included, reflecting the scarcity
of studies available in this field. Although network meta-analyses
are characterized by increased power and precision (94), the
geometry of the networks in the current study limited our
ability to test for inconsistency, and potentially resulted in more
Frontiers in Psychiatry | www.frontiersin.org 13 June 2018 | Volume 9 | Article 187
 [63]  
Davies et al. Interventions for Attenuated Psychotic Symptoms
imprecise estimates and wide 95%CIs. An additional limitation is
that the overall quality of our networkmeta-analysis is dependent
on the quality of each included study, most of which were at
high or unclear risk of bias. We partially controlled for this
problem through assessment of biases and sensitivity analyses.
The final limitation concerns the use of dropout for any reason
as a proxy measure for acceptability. While this measure is
generally accepted in network meta-analyses of RCTs (56–58),
it is a rather crude and spurious outcome measure. The use
of a more specific side eﬀect outcome could have revealed
more subtle diﬀerences in acceptability across the available
treatments. We have been unable to analyse any specific side
eﬀects because these were infrequently reported in the available
literature.
CONCLUSIONS
In conclusion, on the basis of the most comprehensive evidence
synthesis to date, there is currently no robust evidence to
favor specific interventions for improving attenuated positive
psychotic symptoms in CHR-P individuals.
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3.2. PART 1 INTERIM SUMMARY 
To conclude Part 1 of this thesis, the studies presented in Papers 1 and 2 have 
demonstrated a lack of evidence for any of the previously tested treatments having 
superior efficacy relative to any others (Davies et al, 2018a, 2018b). These results 
advance knowledge by challenging the prevailing view that CBT is more efficacious 
than other currently available treatment options (NICE, 2014). Given that both network 
meta-analyses included “needs-based interventions”, which can be considered the 
lowest level and nonspecific intervention, the current favouring of CBT over all other 
treatments does not appear to be supported by evidence. However, absence of evidence 
is not evidence of absence (Altman and Bland, 1995) and a number of potential 
methodological factors that may be driving these findings have been discussed, such as 
the declining transition risks observed in the latest studies, which in turn may lead to 
underpowered and negative (non-significant) findings. Nevertheless, the lack of 
significantly superior efficacy in terms of attenuated psychotic symptoms cannot be 
secondary to low statistical power, which may suggest, rather, that current treatments 
lack efficacy. 
 
As in psychiatry more broadly, what is being increasingly recognised is that there is 
unlikely to be one unifying pathophysiological model accounting for the onset of 
psychosis in all individuals (Millan et al, 2016; Paulus and Thompson, 2019). Rather, 
different CHR-P individuals likely accumulate heterogeneous risk factors for psychosis 
(Fusar-Poli et al, 2017b; Radua et al, 2018) which alters their neurobiology in similarly 
heterogenous ways, but each constellation of pathophysiological processes (in true 
positives) ultimately ends in the presentation of psychosis—potentially by converging 
on one or more final common pathways. This represents the “many-to-one” and “one-
to-many” mapping issue (Paulus and Thompson, 2019), whereby the brain has many 
ways of producing the same symptoms, and conversely, similar brain dysfunctions can 
produce a range of different symptoms (Paulus and Thompson, 2019). It therefore 
follows that the “one-size-fits-all” approach to CHR-P treatment (and indeed 
recruitment for clinical trials) is unlikely to work and may be a major factor in the 
failing of current treatment trials. However, more personalised (even at group level) 
treatment, targeted to specific pathophysiological processes or neural circuits, may, in 
future, provide the breakthrough advancement in efficacy the field needs. For example, 
omega-3 supplementation may prove effective if administered to those who show 
baseline alterations in membrane fatty acid levels and inflammatory markers (Kane and 
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Correll, 2017). In future, indicated treatment (and recruitment to specific clinical trials) 
could be driven by a biologically-informed rationale based on the presence of specific 
biomarkers. This stratification will require increased understanding of the 
neurobiological mechanisms underlying psychosis onset within specific strata of 
individuals (with similar underlying neurobiological alterations). In the meantime, 
however, and in the absence of full knowledge of the precise pathophysiology, it 
remains important to find novel (or repurposed) treatments with relevant mechanisms 
of action based on our current understanding. Part 2 of this thesis aims to address this 
issue. 
 [69] 
PART 2 – POTENTIAL NOVEL TREATMENTS 




4.1. POTENTIAL NOVEL COMPOUNDS 
As discussed in Part 1 of this thesis, the lack of apparent efficacy of current 
interventions indicates that treatments with novel mechanisms of action are needed. 
Experimental medicine methods, by which a potential candidate compound is tested in 
vivo against a biomarker or neurobiological target associated with the disease of 
interest, have become a key approach for examining the potential therapeutic benefits 
of a drug. This can be achieved using placebo-controlled pharmacological challenge 
and neuroimaging in CHR-P individuals. The success (or failure) of compounds to 
engage their targets at this proof-of-concept stage can provide invaluable support for 
early go/no-go decisions for later-phase clinical trials. At the time when the studies 
within this thesis were conceived, there were a number of potential therapeutics that 
could have been investigated using these methods. The main possibilities were 
cannabidiol, omega-3, antidepressants, and oxytocin, which will be briefly reviewed 
before two experiments using a novel candidate compound are presented. 
 
4.1.1. CANNABIDIOL 
Cannabidiol is a major constituent of cannabis sativa. In contrast to the psychoactive 
(and psychotogenic) cannabinoid Δ9-tetrahydrocannabinol (THC) (D’Souza et al, 
2005), the non-psychoactive compound cannabidiol shows anxiolytic and potential 
antipsychotic properties (Zuardi et al, 2012). Findings that administration of 
cannabidiol reduced psychotic symptoms in patients with established psychosis 
(Leweke et al, 2012; McGuire et al, 2018) has led to the suggestion that it may also 
have therapeutic potential in those at CHR-P. Interest in cannabidiol is enhanced by its 
unique (albeit not fully understood) mechanism of action compared to established 
antipsychotics, as well as its distinct lack of serious adverse effects (Zuardi et al, 2012). 
However, at the time when the experiments in this thesis were designed, an RCT using 
cannabidiol and magnetic resonance imaging (MRI) in CHR-P individuals was already 
underway at our institute. This study recently reported that, in 33 CHR-P individuals 
and 19 controls performing a verbal learning fMRI task, cannabidiol normalised 
activation in brain regions found to be altered in those at CHR-P under placebo 
conditions (such as the striatum, medial temporal cortex and midbrain)—regions that 
are strongly implicated in the onset of psychosis (Bhattacharyya et al, 2018). These 
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early results support the view that cannabidiol may be an effective treatment strategy. 
A large-scale, multi-site RCT to assess efficacy is now underway. 
 
4.1.2. OMEGA-3 
Similarly, when these experiments were first conceived, there was published evidence 
suggesting promising efficacy of omega-3 supplementation for preventing transition to 
psychosis (Amminger et al, 2010). However, two very large replication trials were 
already underway at other research centres (Cadenhead et al, 2017; McGorry et al, 




As reviewed in Part 1 of this thesis, no RCTs of antidepressants have yet been 
conducted but a number of naturalistic studies suggest that they are acceptable, well 
tolerated and tend to be associated with reduced transition relative to antipsychotics 
(albeit in the context of non-random assignment, antipsychotic nonadherence and likely 
confounders) (Cornblatt et al, 2007). Given that depression and stress have been 
associated with psychotic symptoms, if antidepressants improve mood, reduce negative 
appraisals and alter individuals’ experience of—and response to—psychosocial stress, 
then this might be one way in which antidepressants improve CHR-P outcomes (Fusar-
Poli et al, 2007). An ongoing trial is now testing the potential efficacy of antidepressant 
interventions (fluoxetine) in CHR-P populations (Nelson et al, 2018b; STEP, 2018). 
 
4.1.4. OXYTOCIN 
Oxytocin is a hormone and neuropeptide involved in the regulation of social, emotional 
and autonomic functions, and has been the subject of intense investigation for the 
potential treatment of numerous neuropsychiatric disorders characterised by social or 
emotional impairments, such as autism spectrum disorder and schizophrenia (Meyer-
Lindenberg et al, 2011). Oxytocin can be delivered intranasally and a large body of 
evidence suggests that it has neurophysiological (Wigton et al, 2015), anxiolytic 
(Neumann and Slattery, 2015), prosocial (Domes et al, 2007) and potential 
antipsychotic properties (Feifel et al, 2010). Positive findings from the first studies in 
established psychosis (Pedersen et al, 2011) naturally led to the suggestion that it may 
be a promising strategy in those at CHR-P. In addition, due to its peripheral roles in 
birth and lactation, it is already licensed and used routinely in the NHS (NICE, 2008). 
 
 [72] 
4.1.5. INTERIM SUMMARY 
Taking the available options together, oxytocin was chosen as the candidate compound 
for experimental investigation in CHR-P individuals. The decision was based on the 
following factors: (a) first synthesised in 1952 and as a medicine currently used in the 
NHS, we have extensive data on its adverse effects, safety and tolerability—
repurposing into another branch of medicine would therefore be streamlined (and 
benign side effect profiles are themselves of critical importance in CHR-P groups); (b) 
relatedly, by virtue of repurposing a licensed treatment, if it were found to be promising 
then there would be quicker time-to-translation, lower associated costs and reduced 
regulatory barriers; (c) oxytocin has a fundamentally different mechanism of action to 
any of the other options currently available, and to any treatment currently used in 
CHR-P individuals—while this is also true of cannabidiol and omega-3, oxytocin was 
the only option not being investigated elsewhere; (d) our institute has long-standing 
expertise in investigating the neurophysiological effects of oxytocin in the healthy 
human brain (Paloyelis et al, 2016); and (e) furthermore, oxytocin is currently being 
studied in relation to a number of neuropsychiatric disorders; a better understanding of 
the neurophysiological basis for its effects in CHR-P individuals may also benefit 
mental health treatment for other patient populations. 
4.2. THE OXYTOCINERGIC SYSTEM 
4.2.1. WHAT IS OXYTOCIN? 
Oxytocin, a highly evolutionarily conserved neuropeptide and hormone, is well known 
for its role in birth and lactation. However, it also has central effects; it is a robust 
inhibitor of the hypothalamic–pituitary–adrenal (HPA) axis (Stoop, 2012; Windle et al, 
2004) and is a key neuromodulator of complex social cognition and behaviours (Meyer-
Lindenberg et al, 2011). For example, in humans, research has implicated oxytocin in 
emotion recognition, social memory, social reward, theory of mind (or ‘mentalising’), 
empathy, trust, autonomic fight or flight response, fear and social stress (Zink and 
Meyer-Lindenberg, 2012). 
 
4.2.2. SYNTHESIS & RELEASE 
Oxytocin is synthesised in magnocellular neurons of the paraventricular (PVN) and 
supraoptic (SON) nuclei of the hypothalamus (Figure 4–1) (Meyer-Lindenberg et al, 
2011). Following synthesis, oxytocin is stored in large dense-core vesicles which can be 
secreted from any part of a neuron, including the axon, soma and dendrites (into the 
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extracellular space/within the blood-brain barrier for central release), or from axon 
terminals in the posterior pituitary (which lie outside the blood-brain barrier for 
peripheral release) or terminals in other forebrain/midbrain regions (Johnson and Young, 
2017; Knobloch et al, 2012; Stoop, 2012). Oxytocin is also produced by parvocellular 
neurons within the PVN, which have direct axonal projections to numerous brain regions 
(e.g. amygdala, hippocampus, striatum, bed nucleus of stria terminalis and brainstem 
(Figure 4–1) (Knobloch et al, 2012; Meyer-Lindenberg et al, 2011)), although these data 
are not available specifically for humans (Stoop, 2012). Thus, oxytocin delivery is 
thought to occur in a multimodal manner via two modes of release: (i) slow “unwired” 
dendritic secretion into the local hypothalamic environment with passive diffusion to 
global/distal regions (spread neuromodulation), and (ii) faster “wired” precise axonal 
release to targeted brain regions expressing oxytocin receptors (point-to-point 
transmission) (Landgraf and Neumann, 2004; Stoop, 2012).  
 
Figure 4–1. Neurophysiology of oxytocin and vasopressin. 
 
Reprinted by permission from Springer Nature © 2011: Nature Reviews Neuroscience 
(Meyer-Lindenberg et al, 2011). ACC, anterior cingulate cortex; BNST, bed nucleus of the 
stria terminalis; NAc, nucleus accumbens; SCN, suprachiasmatic nucleus. 
 
 
4.2.3. RECEPTOR DISTRIBUTION 
Oxytocin receptors have been detected in many cortical/subcortical brain regions in 
animals which are relevant to psychosis pathophysiology (e.g. hippocampus, amygdala, 
thalamus, neocortex) (Loup et al, 1991). However, significant species-specific 



















Electrical potentials that are 
generated in the brain as a 
consequence of the 
synchronized activation of 
neuronal networks by external 
stimuli. These evoked 
potentials are recorded at the 
scalp and consist of precisely 
timed sequences of waves or 
‘components’.
Trier Social Stress test 
(TSST). A standardized 
psychosocial laboratory 
stressor that includes public 
speaking and mental 
arithmetic.
investigation21–24; this is an important issue that needs 
to be resolved for translational success to be achieved. 
A straightforward alternative approach is to measure 
neuropeptides from cerebrospinal fluid, which might 
better reflect their availability in the brain10. However, 
this invasive method is not feasible for routine use in 
humans. Thus, most studies have used intranasal deliv-
ery of peptides to investigate the central actions of 
neuropeptides in humans, as this provides a direct 
pathway to the brain1,10.
Basic cognitive processe . Among the first studies using 
intranasal neuropeptide administration were experi-
ments on cognitive processes such as memory and 
attention, and associated brain responses. Some of these 
studies reported enhancing effects of AVP on cogni-
tive functioning in healthy young participants25 and the 
elderly26. Another study showed that AVP administra-
tion increases the amplitude of several components of 
the late event-related brain potentials, which are thought to 
reflect higher order cognitive processing27. Furthermore, 
intranasal AVP delivery enhanced performance and 
associated event-related potentials in a simple reaction 
time task25,28. Results from studies that directly compared 
the effects of OXT and AVP suggest that the two might 
have opposite roles, with the former impairing memory 
and learning processes and the latter improving cognitive 
performance29.
Social stress. Stressful social interactions normally trigger 
behavioural and physiological responses to adapt to these 
situations. Activation of the hypothalamus–pituitary– 
adrenal axis, with the secretion of corticotrophin- 
releasing hormone (CRH), adrenocorticotropic hormone 
(ACTH) and cortisol, is a major endocrine component 
of this adaptive stress response. One study showed that 
healthy males who received social support and a single 
dose of OXT during preparation for the Trier Social Stress 
test (TSST)30 showed the lowest cortisol response to the 
TSST, whereas subjects who received no social support 
Figure 1 | Neurophysiology of OXT and AVP. Oxytocin (OXT) and arginine vasopressin (AVP) are synthesized in 
magnocellular neurons in the paraventricular and supraoptic nuclei of the hypothalamus, and are processed along the 
axonal projections to the posterior lobe of the pituitary, where they are stored in secretory vesicles and released into 
peripheral circulation (inset). In addition to this release from axonal terminals, there is dendritic release of OXT and AVP 
into the extracellular space, resulting not only in local action but also in diffusion through the brain to reach distant targets 
(shown by the dotted arrows)186. Furthermore, smaller parvocellular neurons in the paraventricular nucleus also produce 
OXT and AVP and project directly to other regions in the brain. As is the case for all eutherian mammals, humans have four 
receptors for OXT and AVP: OXT receptor, AVP receptor 1A (AVPR1A), AVPR1B and AVPR2. In the brain, OXT and AVP 
travel along the axonal projections from parvocellular neurons of the hypothalamus to different areas — including the 
amygdala, hippocampus, striatum, suprachiasmatic nucleus, bed nucleus of stria terminalis and brainstem — where they 
act as neuromodulators or neurotransmitters, and thereby influence neurotransmission in these areas. For example, OXT 
and AVP modulate neural populations in the central amygdala43. AVP also binds to AVPR1B  in the anterior pituitary, 
fostering (together with corticotropin-releasing hormone (CRH)) the secretion of adrenocorticotropic hormone (ACTH) 
and hence, promoting the secretion of cortisol. Thus, both peptides have peripheral and central functions. However, the 
central and peripheral release are not necessarily associated and the distribution of OXT and AVP receptors in the human 
brain has not been fully explored so far. ACC, anterior cingulate cortex; BNST, bed nucleus of the stria terminalis; NAc, 
nucleus accumbens; SCN, suprachiasmatic nucleus.
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distributions remain mostly unclear. However, recent work on the distribution of 
oxytocin receptor gene (OXTR) and CD38 (a gene involved in oxytocin secretion) 
messenger ribonucleic acid (mRNA) expression suggests that humans do have similar 
receptor distributions (Quintana et al, 2019a). Compared to average brain expression, 
oxytocin-pathway gene expression was found to be enriched in the olfactory region, 
caudate, putamen, pallidum, thalamus, hippocampus, parahippocampal cortex and 
amygdala, and decreased expression was found in the cerebellum (Quintana et al, 
2019a), although not all findings survived multiplicity correction. It is worth noting that 
oxytocin can also bind vasopressin receptors (of which there are three) but does so with 
approximately 100-fold weaker affinity (Manning et al, 2012). Until recently, there was 
no selective radiotracer that could penetrate the blood-brain barrier for imaging the 
oxytocinergic system in humans in vivo (Smith et al, 2012). Early studies using 
autoradiography in human postmortem tissue showed radiotracer receptor binding in 
the brainstem (Freeman et al, 2016), amygdala, anterior cingulate, hypothalamus 
(Boccia et al, 2013), basal nucleus of Meynert, globus pallidus, ventral pallidum and 
septal nuclei (Loup et al, 1991). However, due to the high degree of cross-affinity for 
oxytocin and vasopressin receptors, these methods are not considered sufficiently 
selective and the differing methods used (i.e. various antibodies or ligands) have given 
rise to conflicting results. Recently, a novel oxytocin receptor tracer has been developed 
for probing nose-to-brain transport uptake in vivo (Beard et al, 2018). A significant 
signal was found in the olfactory bulb (implying direct nose-to-brain transport via nerve 
fibres) but the tracer was not able to penetrate deeper brain tissue (Beard et al, 2018). 
Results of further research in this field are awaited.  
 
4.2.4. RECEPTOR FUNCTION 
Although only one ‘type’ of oxytocin receptor exists, binding of oxytocin to its receptor 
(which is G-protein coupled) can initiate one of a number of complex intracellular 
cascades, mediated by the coupling of different G proteins—thought to underlie its 
differential functional effects in different brain regions (for detailed review, see (Stoop, 
2012)). Preclinical work suggests that the majority of oxytocin receptors are located on 
GABAergic interneurons (or poised at GABAergic synapses) to control inhibitory 
transmission (Marlin et al, 2015; Mitre et al, 2016). The inhibitory effects of oxytocin 
binding are thought to be caused by enhanced excitability of amygdala (Huber et al, 
2005; Knobloch et al, 2012), hippocampal (Harden and Frazier, 2016; Owen et al, 
2013; Raam et al, 2017) and prefrontal cortical (Nakajima et al, 2014) GABAergic 
interneurons (likely amongst other regions), leading to increased GABA release and 
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therefore inhibition. In the rat amygdala, for example, administration of oxytocin is 
associated with analogous effects to benzodiazepines (although they act on different 
components of the circuit) and when co-administered, oxytocin potentiates the effects 
of benzodiazepines such that lower doses can be used (Viviani et al, 2010). Other work 
suggests that oxytocin suppresses glutamatergic neurotransmission in infralimbic 
cortex by decreasing presynaptic glutamate release via a cannabinoid-1 receptor 
dependent mechanism (Ninan, 2011). Oxytocin receptors are also expressed on 
excitatory glutamatergic cells (Raam et al, 2017) and serotonergic neurons (Dölen et 
al, 2013; Yoshida et al, 2009).  
 
4.2.5. PHARMACOKINETICS/ELIMINATION HALF-LIFE 
Centrally-released endogenous oxytocin is metabolised by aminopeptidases in brain 
tissue and any remainder is cleared via flow into subarachnoid space and/or transport 
into blood (Stoop, 2012). In humans, the elimination half-life of oxytocin in 
cerebrospinal fluid (CSF) is relatively long (compared to classical neurotransmitters) 
at ~20 minutes, 2–3 mins in plasma and ~1 minute in brain (Ludwig and Leng, 2006). 
In mostly small, initial studies, intranasally delivered oxytocin was found to increase 
plasma concentrations (Burri et al, 2008) with peaks at 10–40 minutes post-
administration (Gossen et al, 2012; Landgraf, 1985; Striepens et al, 2013), but a recent 
study reported significant peaks in the CSF beginning only after 75 minutes (Striepens 
et al, 2013).  
 
4.2.6. VASOPRESSIN 
It is worth noting that arginine vasopressin, the cousin nonapeptide of oxytocin, is 
generally thought to have diametrically opposing physiological effects to oxytocin 
(Neumann and Landgraf, 2012). Vasopressin has similar binding affinities for oxytocin 
and vasopressin receptors, but oxytocin has 100-fold higher affinity for oxytocin (vs 
vasopressin) receptors (Stoop, 2012). Despite cross-reactivity of oxytocin with 
vasopressin (particularly 1a) receptors, receptor distributions differ markedly (Stoop, 
2012) and it is thought that the distribution patterns allow for social cognitive and 
behavioural states to be precisely balanced by the coordinated release of the two 
peptides (with distinct spatial distributions) (Landgraf and Neumann, 2004; Neumann 
and Landgraf, 2012). For example, in the amygdala, vasopressin and oxytocin receptors 
are differentially expressed in different subnuclei (which subserve different functions), 
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enabling the precise modulation of different behavioural phenomena (i.e. balance of 
approach/avoidance behaviour) (Huber et al, 2005).  
 
Importantly, the cross-reactivity of oxytocin is a critical factor for consideration in 
studies using intranasal oxytocin as a candidate therapy—if not enough oxytocin is 
delivered then there may be no observed effects, but if too much is given (with oxytocin 
saturating oxytocin receptors and now binding vasopressin receptors), the measurable 
effect of oxytocin at its receptor may be cancelled out by the opposing physiological 
effects of oxytocin binding to vasopressin receptors (Galbusera et al, 2017).  
 
4.2.7. NOSE-TO-BRAIN TRANSPORT OF INTRANASAL OXYTOCIN 
Intranasal oxytocin is thought to reach the brain via a number of potential pathways, 
including (1) the olfactory pathway, and (2) the trigeminal pathway, in addition to 
systemic circulation via (3) the peripheral pathway (Figure 4–2 below; for review see 
(Quintana et al, 2018)). Some authors have questioned whether such nose-to-brain 
transport exists and suggest that any central effects are secondary to large increases in 
peripheral oxytocin levels that then either cross the blood-brain barrier or act on the 
gastrointestinal tract, heart or reproductive system (Leng and Ludwig, 2016). If this is 
the case, then studies that compare intranasally delivered oxytocin to peripherally 
administrated (i.e. intravenous) oxytocin should produce the same profile of effects. A 
number of studies have now tested this notion in rodents (Galbusera et al, 2017; 
Williams et al, 1994), primates and humans (Martins et al, 2019; Quintana et al, 2016, 
2017), and there is converging evidence that peripheral doses do not recapitulate the 
full central (neural) effects of intranasally delivered oxytocin. For example, in order to 
determine whether intranasal administration represents a privileged route for the central 
delivery of oxytocin, a recent, well-designed study contrasted two methods of intranasal 
administration (a standard nasal spray and a nebuliser) to intravenous administration 
(Martins et al, 2019). The authors reported a number of important findings. First, that 
the oxytocin-induced decreases in cerebral blood flow (CBF) in the amygdala and 
anterior cingulate cortex (ACC), after both intravenous and nasal spray administration, 
could be explained by increases in oxytocin plasma concentrations, which suggests that 
neural effects are not solely derived from direct nose-to-brain transport (Martins et al, 
2019). However, changes in oxytocin plasma concentrations could not account for any 
of the other oxytocin-induced changes observed in CBF (with either the nasal spray or 
nebuliser), providing robust pharmacodynamic evidence consistent with the existence 
of direct nose-to-brain transport in humans (Martins et al, 2019). Finally, compared to 
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the nasal spray, nebuliser-administered oxytocin (which is thought to improve 
deposition of oxytocin to nasal regions putatively involved in direct nose-to-brain 
transport) resulted in markedly different patterns of CBF changes, which the authors 
suggest may be due to increased amounts of oxytocin reaching the brain (Martins et al, 
2019). Further discussion of the effects of oxytocin on CBF in humans is presented in 
section 4.3.4 (on page 83). 
 
Finally, as previously mentioned, a novel oxytocin receptor radiotracer was recently 
developed for directly probing nose-to-brain transport in humans (Beard et al, 2018). 
A significant signal was found in the olfactory bulb (supporting direct nose-to-brain 
transport via nerve fibres) but this tracer was not able to penetrate deeper brain tissue 
(Beard et al, 2018). Results from further radiotracer studies are awaited.  
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Figure 4–2. Intranasal oxytocin pathways and destinations. 
 
 
Reprinted from (Quintana et al, 2015) with permission from Elsevier. 
 
Caption: Oxytocin (OT) can access the following destinations after intranasal 
administration; the amygdala from deposition on the olfactory epithelium, through the 
olfactory bulb then via axonal projections as well as diffusion through the cerebrospinal 
fluid (CSF) (1), brainstem via deposition on the respiratory epithelium trigeminal nerve 
fibres (2), the periphery via blood capillaries in the olfactory and respiratory epithelia 
(3). Delivery of OT via olfactory and trigeminal pathways may stimulate the production 
of endogenous OT from the paraventricular nucleus (PVN), delivering OT to both the 
prefrontal and brainstem regions, as well as systemic circulation (4). 
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4.3. OXYTOCIN, PSYCHOSIS & THE CHR-P STATE 
In addition to the introductions of Paper 3 (starting on on page 93) and Paper 4 (on page 
118), in this section I present a review of previous oxytocin research relating to CHR-
P psychopathology and pathophysiology. First, given the lack of research in those 
specifically at CHR-P, the results of RCTs (which have assessed symptoms) in patients 
with established psychotic disorders are reviewed. This is followed by evidence linking 
oxytocin’s effects on social, emotional and autonomic functioning with the CHR-P 
state, and a brief review of related functional magnetic resonance imaging (fMRI) 
studies. Finally, I conclude this introduction by presenting results from more 
quantitative MRI methods which allow examination of the neurophysiological effects 
of oxytocin on indices of neural function strongly linked to psychosis onset.  
 
4.3.1. SYMPTOMS OF PSYCHOSIS 
Initially, oxytocin was considered a promising compound for treating both positive and 
negative symptoms of psychosis (Feifel et al, 2015). Numerous studies have now been 
conducted in patients with established psychotic disorders (mostly schizophrenia) 
although the results have been decidedly mixed (Bradley and Woolley, 2017). For 
example, in a crossover trial of adjunctive oxytocin (40IU twice/day) vs placebo 
(N=15), oxytocin significantly reduced Positive and Negative Syndrome Scale 
(PANSS) scores (both positive and negative) by the three-week study endpoint (Feifel 
et al, 2010). Another study (N=20) reported improved positive symptoms, paranoia and 
general psychopathology within the oxytocin group from baseline to follow up after 
two weeks of 24IU oxytocin (twice/day) (Pedersen et al, 2011). One study of 20IU/day 
oxytocin over 3 weeks found no difference in positive, negative or global symptoms, 
except for improved negative symptoms in the subset of inpatients (Lee et al, 2013). A 
larger RCT (N=40) titrating to 40IU (twice/day) for 8 weeks found significant effects 
on positive, negative, general and total PANSS scores (Modabbernia et al, 2013). 
However, in an 8-month crossover RCT of 40IU oxytocin (N=32), there were no effects 
on positive or negative symptoms, or any other measured outcome (Dagani et al, 2016). 
A recent study of 55 patients (24IU twice/day for 12 weeks) reported no effects on 
positive, negative, general or total PANSS scores (Jarskog et al, 2017), although a 
significant change-from-baseline improvement in negative symptoms was observed in 
the oxytocin group. Support for beneficial effects on negative symptoms was found in 
one further study (Gibson et al, 2014), although two others report no effect on positive 
or negative symptoms (Cacciotti-Saija et al, 2015; Davis et al, 2014). Such conflicting 
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results have prompted a number of meta-analyses. While an early meta-analysis 
concluded that oxytocin was superior to placebo for decreasing general PANSS scores 
(Oya et al, 2016), a more recent and sophisticated Bayesian meta-analysis concluded 
that oxytocin does not improve any aspect of schizophrenia psychopathology (positive, 
negative, general or total symptoms) (Williams and Bürkner, 2017). 
 
While the meta-analytic results relating to symptoms are sobering, there are a number 
of important factors which likely contribute to the negative or inconsistent findings. 
This includes the fact that all of the aforementioned studies took an ‘add-on’ approach, 
using adjunctive oxytocin or placebo in patients already receiving (and usually stable 
on) antipsychotic medication. Three of the studies investigated oxytocin in addition to 
social skills training (Cacciotti-Saija et al, 2015; Davis et al, 2014; Gibson et al, 2014). 
Concomitant antipsychotic treatment may create a ‘ceiling’ beyond which any further 
benefits are difficult to observe. Indeed, due to the smaller effect size associated with 
add-on studies, the required sample sizes are much larger than have been used in 
practice (Shilling and Feifel, 2016). A related point is that in the absence of 
monotherapy RCTs (which are unlikely to gain ethical approval for patients with 
established psychosis), direct estimates of oxytocin’s efficacy cannot be derived (Feifel 
et al, 2015). In addition, it has been suggested that antipsychotics interact with or 
moderate the effects of oxytocin, and given that all trials were add-on studies, this could 
underlie some of the non-significant findings and high levels of between-study/subject 
heterogeneity (Bradley and Woolley, 2017). These limitations also underscore the 
benefits of assessing potential novel treatments in those at CHR-P; most CHR-P 
individuals are antipsychotic naïve (Fusar-Poli et al, 2015b) and monotherapy trials are 
generally considered acceptable (usually combined with needs-based interventions).  
 
4.3.2. SOCIAL, EMOTIONAL & AUTONOMIC FUNCTIONING 
Given the substantial evidence from preclinical studies for oxytocin’s role in social and 
affiliative behaviours (Neumann and Landgraf, 2012; Stoop, 2012), the leap to 
conceptualising oxytocin as a potential therapy for human disorders characterised by 
social dysfunction is perhaps not surprising. Impairments of social cognition, which 
include emotional recognition, theory of mind, social perception and attributional style 
(Green et al, 2008), are a primary cause of disability in psychosis (Fett et al, 2011) and 
respond poorly to current treatments. Emotion dysregulation and social cognition 
problems are also common in individuals at CHR-P (Fusar-Poli et al, 2012b), are a key 
source of distress and contribute strongly to loss of functioning (Barbato et al, 2013; 
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Cotter et al, 2017; Van Donkersgoed et al, 2015). Studies also report evidence of HPA 
axis alterations in CHR-P individuals, including enhanced stress sensitivity/intolerance 
(DeVylder et al, 2012), altered cortisol response (Corcoran et al, 2012; Day et al, 2014; 
Walker et al, 2010) and high levels of anxiety (McAusland et al, 2017) which are 
associated with later transition to psychosis (Owens et al, 2005).  
 
Oxytocin has numerous prosocial, anxiolytic and antipsychotic-like effects in animals 
(Caldwell et al, 2009; Feifel and Reza, 1999; Lee et al, 2005) and is a robust inhibitor 
of the HPA axis (Windle et al, 2004). In healthy individuals, offline studies show that 
oxytocin improves theory of mind performance (Domes et al, 2007) whilst decreasing 
arousal and aversion towards negative or threatening social stimuli (Eckstein et al, 
2015) (for review see (Zink and Meyer-Lindenberg, 2012)). Oxytocin also improves 
performance (Domes et al, 2007) in the ‘Reading the Mind in the Eyes’ Test (RMET) 
(Baron-Cohen et al, 2001), a task commonly used in social cognition research to index 
ability to interpret mental states from social cues from the eye region, and in which 
CHR-P individuals show impaired functioning (Zhang et al, 2016). In patients with 
psychosis, oxytocin improves emotional processing and social cognition, particularly 
higher-order social cognition (Brambilla et al, 2016; Davis et al, 2013, 2014; Guastella 
et al, 2015; Pedersen et al, 2011). However, not all studies show significant effects 
(Halverson et al, 2019) and hope of oxytocin’s potential for improving social cognition 
in established psychosis has been somewhat stifled by recent negative meta-analytic 
findings (Bürkner et al, 2017).  
 
How oxytocin brings about these emotional processing and social cognition effects at 
the neural level is less clear. Oxytocin can increase attention to biologically relevant 
stimuli (Gordon et al, 2016), memory for social stimuli (Guastella et al, 2008b; Maroun 
and Wagner, 2015) and eye-gaze (Auyeung et al, 2015; Guastella et al, 2008a), 
seemingly via its modulation of limbic (and particularly amygdala subnuclei) activity 
(Gamer et al, 2010). Eye-gaze is a fundamental form of human communication and 
amount of eye-gaze is predictive of successful inference of others’ intentions and the 
meaning of social situations (Guastella et al, 2008a; Klin et al, 2002). These effects 
offer one mechanism by which oxytocin may improve inference of others’ mental state 
and enhance emotion recognition.  
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4.3.3. FUNCTIONAL NEUROIMAGING 
Despite the markedly mixed findings regarding the effects of oxytocin on symptoms 
and behaviour, evidence that oxytocin can modulate brain function, as measured using 
blood-oxygenation-level-dependent (BOLD) response fMRI, is much less ambiguous 
(Grace et al, 2018; Wigton et al, 2015; Zink and Meyer-Lindenberg, 2012). Individuals 
at CHR-P show altered neural responses to various social (and non-social, see below) 
cognitive stimuli in fMRI studies, particularly in emotion recognition/regulation (Tseng 
et al, 2016; van der Velde et al, 2015) and response to threat (Wolf et al, 2015). Early 
fMRI studies demonstrated that the amygdala, a crucial node for social and emotion 
processing, appears to be a main target for oxytocin-mediated effects (Bethlehem et al, 
2013; Eckstein et al, 2015; Kirsch, 2005). Impaired processing of emotional stimuli in 
early and established psychosis has been associated with amygdala dysfunction 
(Anticevic et al, 2012; Modinos et al, 2015b; Pinkham et al, 2011; Taylor et al, 2012), 
and altered amygdala connectivity has been observed across the psychosis spectrum 
(Anticevic et al, 2014). Oxytocin robustly modulates amygdala activation (Wigton et 
al, 2015) as well as the functional connectivity of the amygdala to other important 
nodes of social/emotional cognition and the stress response, such as the precuneus 
(Kumar et al, 2015), anterior cingulate cortex (ACC) (Riem et al, 2012), medial 
prefrontal cortex (Sripada et al, 2013) and brainstem (Kirsch, 2005). Many of these 
areas and other prefrontal, limbic and temporal regions are differentially engaged by 
CHR-P subjects (Brüne et al, 2011; Takano et al, 2017) and other high-risk individuals 
(Marjoram et al, 2006; Mohnke et al, 2016) during social cognition fMRI tasks. 
However, whether oxytocin increases or decreases the BOLD signal appears to vary by 
context, specific fMRI task, brain region, sex of the population under study and 
potentially many other variables, such as ingroup-outgroup status and oxytocin receptor 
genotype (Bartz et al, 2011; Grace et al, 2018; Wigton et al, 2015; Zink and Meyer-
Lindenberg, 2012).  
 
In addition, resting state functional connectivity between amygdala and prefrontal 
cortex, and between amygdala and brainstem, is altered in high risk populations 
(Anticevic et al, 2014; Gee et al, 2012) and is thought to be a neural correlate of 
autonomic dysfunction and social-cognitive deficits (Rosenfeld et al, 2011). In healthy 
individuals and those with other disorders characterised by social dysfunction, 
numerous studies have demonstrated effects of oxytocin on connectivity between 
various nodes relevant to CHR-P pathophysiology, including the hippocampus, 
amygdala, striatum, cerebellum, ACC, precuneus and other regions known to be 
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involved with social and emotional processing (Bethlehem et al, 2013; Dodhia et al, 
2014; Eckstein et al, 2017; Gorka et al, 2014; Grace et al, 2018; Riem et al, 2012; Zhao 
et al, 2018). 
 
Oxytocin has also been found to modulate other (non-social) cognitive processes such 
as spatial and episodic memory and cognitive flexibility (Bradley and Woolley, 2017; 
Chini et al, 2014) and further key targets for oxytocin-mediated fMRI effects include 
the striatum, midbrain, and hippocampus (Baumgartner et al, 2008; Bethlehem et al, 
2013; Hu et al, 2015; Rilling et al, 2012, 2014; Zhao et al, 2018)—regions critically 
implicated in the onset of psychosis and the functioning of which are key targets for 
novel pharmacotherapies (Lieberman et al, 2018; Millan et al, 2016).  
 
4.3.4. NEUROPHYSIOLOGICAL NEUROIMAGING 
The neuroimaging evidence for oxytocin’s effects has, until recently, been limited to 
BOLD fMRI studies. These have been invaluable in showing that oxytocin acutely 
modulates brain function in key regions linked to psychosis pathophysiology, but they 
are limited by the need to contrast “active” and “baseline” conditions and so only tell 
us about relative effects during specific social, emotional or other cognitive tasks. That 
is, effects of oxytocin in such paradigms are restricted to modulatory effects confined 
within the neural networks engaged by the task (Galbusera et al, 2017).  
 
More recently, the neurophysiological effects of oxytocin have been of increasing 
interest to researchers. As with fMRI, methods such as Arterial Spin Labelling (ASL) 
and Proton Magnetic Resonance Spectroscopy (1H-MRS) are more sensitive methods 
for assessing the effects of drugs than behavioural studies. That is, they can illuminate 
potential disease target-engaging effects even when there may be no observable 
difference at the behavioural or symptom level. Another benefit is that both ASL and 
1H-MRS provide results of absolute quantitation and tell us about the effects of drugs 
in the ‘resting state’ (i.e. in the absence of a specific cognitive task or other 
manipulation). In the case of ASL, this also allows researchers to look for effects across 
the brain without being spatially limited to those regions engaged by a specific 
cognitive fMRI task.  
 
Oxytocin and Arterial Spin Labelling (ASL)  
In the absence of Positron Emission Tomography (PET) receptor studies, the 
spatiotemporal profile of effects of exogenously administered oxytocin in living human 
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brain has—until recently—been relatively unclear. In rodents, however, a study of 
cerebral blood volumes showed that intranasal oxytocin rapidly elicits (a) transient 
activation of numerous cortical regions, (b) sustained activation of hippocampal and 
forebrain regions, and (c) multi-band power increases in hippocampal local field 
potential recordings (Galbusera et al, 2017). Evidence that oxytocin may have similar 
regional effects in humans came from a study that mapped the oxytocinergic network 
using ASL (as a non-invasive pharmacodynamic biomarker) combined with intranasal 
oxytocin vs placebo in parallel groups of healthy males (Paloyelis et al, 2016). Here, 
they found that oxytocin induced widespread increases in resting cerebral blood flow 
(rCBF, also termed ‘perfusion’) in regions that (a) are thought to express oxytocin 
receptors (Quintana et al, 2019a), (b) are known mediators of social and emotional 
processing (Adolphs, 2003; Meyer-Lindenberg et al, 2011), and (c) are key regions 
implicated in psychosis pathophysiology (Allen et al, 2016; Lieberman et al, 2018; 
Millan et al, 2016; Smieskova et al, 2010). Specifically, in a large left-lateralised 
subcortical cluster, oxytocin modulated (increased) perfusion in the caudate nucleus, 
ventral striatum, pallidum, amygdala, hippocampus, hypothalamus and ventral 
midbrain (Paloyelis et al, 2016). Other clusters of increased perfusion included the 
ACC, large prefrontal and temporal cortical clusters and the cerebellum. This study also 
reported the temporal dynamics of oxytocin administration, showing sustained effects 
from 25–78 minutes post-administration, with a peak response at 39–51 minutes 
followed by a gradual diminution thereafter (Paloyelis et al, 2016). In a more recent 
(within-subject crossover) study, the same authors found that oxytocin decreased 
perfusion in a left-lateralised limbic cluster which included the hippocampus, amygdala 
and insula, and in clusters spanning the ACC, frontal cortex, brainstem and cerebellum; 
increased perfusion was observed in further frontal, parietal and temporal regions 
(Martins et al, 2019).  
 
The subcortical findings are of particular interest to CHR-P research because 
accumulating evidence suggests that altered cerebral perfusion in these regions is 
central to the development of psychosis, and compounds that can modulate perfusion 
(particularly in the hippocampus) have been suggested as promising therapeutic 
strategies (Lieberman et al, 2018). In fact, one of the only neuroimaging findings to 
have been replicated in CHR-P groups to date is that hippocampal perfusion is 
increased in CHR-P individuals relative to controls, and in those with poor vs good 
clinical outcomes (Allen et al, 2016, 2018; Schobel et al, 2013) (for full discussion see 
Introduction, Paper 3 – Oxytocin ASL, starting on page 93). Research is also starting 
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to report altered perfusion in additional regions. For example, relative to healthy 
controls, CHR-P individuals show reduced prefrontal but increased striatal blood flow, 
with striatal blood flow significantly (positively) associated with levels of attenuated 
psychotic symptoms (Kindler et al, 2018).  
 
While the known effects of oxytocin on cerebral blood flow appear directly relevant to 
the therapeutic targets indicated in those at CHR-P, no study has tested the effects of 
oxytocin on cerebral perfusion in this patient population. Such an investigation would 
elucidate potential therapeutic properties of oxytocin and, if successful, would provide 
proof-of-concept evidence for larger clinical trials in this patient group.  
 
Oxytocin and Proton Magnetic Resonance Spectroscopy (1H-MRS) 
Another component of the most established models of psychosis onset is that of 
disturbed neurochemical metabolites, particularly the neurotransmitter glutamate. 
Accumulating evidence suggests that the pathophysiological processes underlying 
psychosis onset may be driven by dysregulated glutamate neurotransmission 
(Lieberman et al, 2018), with hypofunction of N-methyl-D-aspartate receptors 
(NMDAR) on !-aminobutyric acid (GABA)-ergic interneurons leading to disinhibition 
of pyramidal cells, and via polysynaptic projection pathways from the hippocampus to 
the midbrain/striatum, to midbrain hyperdopaminergia (Lisman et al, 2008; Modinos 
et al, 2015a). In animals, oxytocin has been found to modulate this neural circuit by 
enhancing the signal-to-noise ratio of pyramidal cell firing via the targeting of 
GABAergic interneuron function (Owen et al, 2013; Zaninetti and Raggenbass, 
2000)—dysfunction of which are strongly implicated in psychosis onset (Lieberman et 
al, 2018; Lisman et al, 2008; Modinos et al, 2015a).  
 
Evidence for neurochemical perturbations in CHR-P individuals—and the potentially 
relevant properties of oxytocin—are reviewed in full in Paper 4 (see Introduction, 
Paper 4 – Oxytocin 1H-MRS, starting on page 118). However, in brief, numerous 
studies have reported alterations in glutamate (or glutamate plus glutamine; Glx) levels 
in people at high risk of psychosis vs controls, particularly in the hippocampus 
(Bloemen et al, 2011; Shakory et al, 2018), frontal cortex (Merritt et al, 2016), ACC 
(Stone et al, 2009; Tibbo et al, 2004) and thalamus (Stone et al, 2009). Within CHR-P 
samples, baseline hippocampal glutamate is elevated in those who transition (vs those 
who do not) and in those with poor (vs good) functional outcomes (Bossong et al, 
2019). Novel pharmacotherapies that can modulate the glutamate system—or 
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associated neural circuits—have therefore become a target for drug development 
(Lieberman et al, 2018; Millan et al, 2016). Whether oxytocin can modulate metabolite 
concentrations in CHR-P individuals is unknown. 
4.4. RATIONALE & EXPERIMENTAL METHODS 
4.4.1. TREATMENT TARGETS & STUDY DESIGN 
Converging evidence suggests that hippocampal and neurochemical dysfunction plays 
a key role in the onset of psychosis, and novel compounds that can modulate 
hippocampal perfusion and glutamatergic function are of significant interest to the 
CHR-P field. As discussed in full in Paper 3, altered hippocampal perfusion is among 
the few MRI findings to have been replicated in CHR-P groups, and as a proposed 
driver of psychosis onset, represents a disease-modifying target. While animal and 
initial human work suggest that oxytocin may modulate hippocampal function and 
neurochemistry in those at CHR-P, this has never been tested before.   
 
In order to investigate the neurophysiological effects of oxytocin in people at CHR-P, 
in the experiments that follow in Paper 3 and Paper 4, I compare the effects of oxytocin 
vs placebo on (a) hippocampal perfusion using ASL, and (b) neurochemical metabolites 
using 1H-MRS, in a double-blind, placebo-controlled, crossover MRI study. As 
discussed in section 4.3.4, these two MRI modalities were selected based on their ability 
to measure two key indices of neural dysfunction implicated in the onset of psychosis. 
If oxytocin demonstrates an ability to alter hippocampal perfusion or neurochemical 
metabolite levels, this would provide proof-of-concept evidence of disease-target 
engagement for larger clinical trials. This methodological approach (termed 
experimental medicine), whereby one tests the ability of a compound to engage specific 
(often intermediate) targets linked to disease (such as hippocampal perfusion), has 
specifically been recommended for use with oxytocin and CHR-P research (Bradley 
and Woolley, 2017; Lieberman et al, 2018). While the full background and methods 
are reported in Paper 3 and Paper 4, an overview of the two experimental techniques 
and a general power calculation are presented below.  
 
4.4.2. POWER CALCULATION 
The primary outcome was the within-subject effect of oxytocin vs placebo on 
hippocampal perfusion. At the time of designing the study, there was no direct effect 
size (for effects of oxytocin on perfusion in humans) from previous studies on which to 
base our power calculations. However, a meta-analysis of the neurophysiological 
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effects of oxytocin in controls performing social cognition fMRI tasks reported 
combined effect sizes (d) of 0.82 and 1.56 (large effects) in the amygdala and temporal 
lobes, respectively (Wigton et al, 2015). A power calculation using G*Power3 
indicated that 30 subjects in a matched-pairs design was sufficient to detect an effect 
size (dz) of 0.53 (medium effect size), for α=0.05 (two-tailed) and β=0.20 (power of 
80%). 
 
4.4.3. ARTERIAL SPIN LABELLING – METHODS 
ASL is an MRI technique for measuring cerebral perfusion (cerebral blood flow, CBF) 
in living human brain (Grade et al, 2015). The technique uses the water protons in 
arterial blood as an intrinsic tracer, thereby omitting the need for an exogenous contrast 
agent (such as gadolinium, which is used in dynamic susceptibility contrast perfusion 
imaging) and is thus non-invasive (Alsop et al, 2015). In contrast to fMRI, this 
technique gives results of absolute quantitation; the difference in signal between the 
tagged and untagged images (see below) represents blood flow in a specific 
voxel/region across a specific unit of time. The units are therefore given in millilitres 
of blood per 100g of tissue per minute (ml/min/100g). As depicted in Figure 4–3, 
specific “slabs” or planes of arterial blood, selected by gradient magnetic fields, are 
“tagged” (or “labelled”) by the application of a 180-degree radiofrequency (inversion) 
pulse as they travel through the neck towards the brain. This causes the protons in the 
tagged blood to invert 180 degrees (i.e. the longitudinal magnetisation [T1] is inverted). 
After a specific period of time (called the post-labelling delay), the signal is measured. 
This gives time for the labelled blood from the neck to reach the brain slice of interest. 
Displacement of the original blood (where the spins were fully relaxed, i.e. there was 
static tissue magnetisation) with the labelled blood (with its inverted spins) causes a 
reduction in the longitudinal magnetisation, which creates a measurable signal. After 
collection of this labelled image, the procedure is repeated but without the initial 
inversion of the magnetisation, to acquire an unlabelled (control) image. Subtraction of 
the labelled from the unlabelled image results in a difference image (the perfusion-
weighted image), where each voxel has an associated quantitative value representing 
perfusion in that voxel. In pharmacological challenge studies, two perfusion images, 
one from each drug condition, can then be statistically compared to find the absolute 
difference in cerebral perfusion caused by the experimental manipulation (i.e. oxytocin 
vs placebo).   
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Figure 4–3. Arterial Spin Labelling (ASL) perfusion MRI: basic concept. 
 
Caption: Arterial blood is labelled or tagged and, after a delay, moves into the imaging 
plane or volume, during which time there is T1 decay of the label. Snapshot images are 
acquired in labelled and control conditions and subtracted, yielding a difference image with 
intensity proportional to cerebral blood flow (CBF).  
 
Reprinted by permission from Springer Nature © 2007: Neurotherapeutics (Wolf and 
Detre, 2007).  
 
 
One issue with ASL is the relatively low signal-to-noise ratio, which means that the 
difference images need to be collected many times and later averaged in post-
processing. This led to development of “pseudo-continuous ASL” (pCASL) which 
offers enhanced signal-to-noise ratio, superior labelling efficiency and is recommended 
for clinical imaging by consensus guidelines (Alsop et al, 2015). ASL measures are 
also sensitive to other factors that can affect blood blow, such as use of caffeine, 
nicotine and drugs of abuse, and are highly sensitive to motion artefacts (i.e. from head 
movement) and susceptibility artefacts (e.g. from signal dropout at air-tissue interfaces, 
such as sinuses) (Grade et al, 2015). However, a major benefit of ASL is the high degree 
of correlation between metabolism (e.g. as measured with fluorodeoxyglucose FDG-
PET) and perfusion. Thus, if researchers are interested in pathophysiology related to 
altered energy metabolism (as in proposed models of psychosis onset, where increased 
glutamate is thought to drive excitation, which increases metabolic demand and thus 
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blood flow), then such metabolic dysfunction will be reflected by—and can therefore 
be measured noninvasively by—altered cerebral perfusion. 
 
4.4.4. PROTON MAGNETIC RESONANCE SPECTROSCOPY – METHODS 
Single voxel 1H-MRS is an MRI technique used to noninvasively quantify the 
concentrations of tissue metabolites/neurotransmitters within a predetermined voxel of 
interest. Metabolites must have a concentration of at least 0.5 nanomolar (nM) and 
typically 0.5-10 millimolar (mM) to be detected (Van Der Graaf, 2010). For this reason, 
although many chemicals can technically be detected using 1H-MRS, in practice, at 3 
Tesla (3T) we are usually restricted to (and interested in) glutamate, glutamate plus 
glutamine (commonly termed Glx), choline, creatine, n-acetylaspartate (NAA) and 
myo-inositol. GABA can only be assessed using specific spectral editing techniques 
(e.g. MEGA-PRESS).  
 
1H-MRS capitalises on the resonant frequency of protons (1H). The main magnet is 
used to induce a strong static magnetic field (B0), causing protons in the tissue to align 
themselves in the direction of the applied field (B0) (Van Der Graaf, 2010). In this 
orientation, the protons are said to be in a low-energy (alpha) state with their magnetic 
moments aligned parallel to the static magnetic field. The protons precess (spin) about 
their axis (resonate) at a frequency determined by the Larmor equation, which itself 
depends on the external magnetic field (B0) and the local chemical environment (i.e. 
which molecular group is carrying the proton). The molecular group to which a proton 
belongs affects the local magnetic field because of circulating electron clouds—
electrons generate small magnetic fields and thus produce small shifts in precession 
(resonant) frequency. This is termed chemical shift: the difference in precession 
frequency resulting from differing chemical environments, which is expressed in units 
of parts per million (ppm). When a radiofrequency pulse is applied, the protons (still in 
the alpha state) are excited (absorb energy) and flip into a high-energy (beta) state, with 
their magnetic moments aligned anti-parallel to the static magnetic field. However, 
protons can only absorb energy (frequencies) which ‘match’ the difference in energy 
required to flip between its low and high-energy states (i.e. energy with the resonant 
frequency). As the protons return to their low-energy state, they emit energy at the 




In short, protons in different chemical environments have to absorb, and therefore emit, 
different resonant frequencies (amounts of energy) to switch between the low and high-
energy states. This allows their discrimination and can be plotted in resulting spectra 
(Figure 4–4), with the specific frequency of the chemical shift (ppm) on the x-axis, and 
with the metabolite concentration (number of absorptions) as signal amplitude on the 
y-axis. 
 
Figure 4–4. Example Proton Magnetic Resonance Spectroscopy (1H-MRS) spectra. 
 
 
Volume selection  
Volume selection uses 3 slice-selector radiofrequency pulses (in the 3 orthogonal 
planes, thus exciting a specific 3D volume of tissue) to control the spatial origin of the 
detected signal. Specifically, a radiofrequency pulse and a gradient pulse are applied in 
the first direction (e.g. X, which excites a whole slab), then the second direction (e.g. 
Y, which excites a column from the slab), and finally in the third direction (e.g. Z, 
which excites a specific cube from the column of the slab)—the intersection of these 
planes determines the 3D voxel.   
 
Water suppression  
Water is the most abundant source of protons in the brain. As such, it produces the 
greatest spectral peak (amplitude) which obscures the signal from the metabolites of 
interest. Water suppression methods, such as CHESS (the most common method) apply 
radiofrequency pulses targeted to the resonant frequency of the water peak, thus 
eliminating the water signal (Haase et al, 1985).  
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Acquisition sequences  
There are a number of different 1H-MRS acquisition sequences for obtaining spectra, 
with STEAM and PRESS the most common. In short, the difference between them is 
that STEAM uses 3 pulses all at 90 degrees, while PRESS uses 90, -180 and -180 degree 
pulses, both again with gradients in each plane for 3D voxel selection (Van Der Graaf, 
2010). PRESS has benefits over STEAM in that the signal-to-noise ratio is larger 
(because the 180-degree pulses give a signal two times the magnitude than that of 
STEAM), albeit slice selection is worse with PRESS due to the longer echo time 
required for the 180-degree pulses (Van Der Graaf, 2010). A number of quantification 
software packages are now available. LCModel is among the most popular; a model is 
fitted to the data to determine the concentrations of each metabolite (Provencher, 1993). 
Concentrations are often arbitrary and so scaling to an internal reference (such as 
creatine, which tends to be stable) is often used, with metabolite levels reported as a 
ratio to creatine (often denoted “metabolite/Cre”). Another approach is to correct the 
metabolite levels for the proportion of white matter (WM), grey matter (GM) and CSF 
within the voxel (often called CSF or voxel tissue-corrected) (see Paper 4 for method). 
4.5. SUMMARY, AIMS & HYPOTHESES 
Hippocampal hyperperfusion and altered levels of neurochemical metabolites represent 
two key pathophysiological targets for CHR-P treatment strategies. Previous evidence 
indicates that oxytocin may have neurophysiological effects within these two domains 
(Aoki et al, 2015; Benner et al, 2018; Martins et al, 2019; Paloyelis et al, 2016). 
Oxytocin has also been shown to improve symptoms and normalise various indices of 
brain activation and connectivity in patient populations (as reviewed in section 4.3). 
However, oxytocin has never been tested in CHR-P individuals, either ‘offline’ or using 
MRI. Conducting these experiments in CHR-P groups rather than patients with 
established psychotic disorders is advantageous because they are (generally) 
antipsychotic naïve (Fusar-Poli et al, 2015b), lack illness chronicity and intervening 
early (before more severe or enduring neural changes take place) is thought to be the 
approach with maximum therapeutic potential (Millan et al, 2016).  
 
Part 2 of this thesis aims to: 
- investigate whether oxytocin can modulate hippocampal perfusion in people at 
CHR-P using ASL in a double-blind, placebo-controlled, crossover study of 
acute 40IU intranasal oxytocin (Paper 3, starting on page 93).  
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- evaluate whether oxytocin can modulate concentrations of neurochemical 
metabolites—particularly glutamate and Glx—in the hippocampus, anterior 
cingulate cortex and thalamus, using 1H-MRS in double-blind, placebo-
controlled, crossover study of 40IU intranasal oxytocin in CHR-P individuals 
(Paper 4, starting on page 118). 
 
Hypotheses: 
- ASL study (Paper 3)  
Our primary hypothesis was that oxytocin would modulate hippocampal 
perfusion in CHR-P subjects. We did not hypothesise a specific effect direction 
because the aim of this study was to demonstrate disease-target (hippocampal) 
engagement. Secondary predictions were that its effects would be particularly 
evident in the Cornu Ammonis 1 (CA1) subregion of the hippocampus, and that 
it would also influence blood flow outside the hippocampus in regions 
implicated in social and emotional processing.  
 
- 1H-MRS study (Paper 4)  
Our primary hypothesis was that oxytocin would modulate glutamate and Glx 
concentrations (scaled to creatine) in the left hippocampus, anterior cingulate 
cortex and left thalamus, and our secondary hypotheses tested for effects on 








5. OXYTOCIN – ASL STUDY 
5.1. PAPER 3 – OXYTOCIN ASL 
 
Davies C, Paloyelis Y, Rutigliano G, Cappucciati M, De Micheli A, Ramella-Cravaro 
V, et al (2019). Oxytocin modulates hippocampal perfusion in people at clinical high 
























Copyright © The Author(s) 2019. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY 4.0). The license can be 
viewed at: https://creativecommons.org/licenses/by/4.0/legalcode. No changes were 





Oxytocin modulates hippocampal perfusion in people at
clinical high risk for psychosis
Cathy Davies 1, Yannis Paloyelis 2, Grazia Rutigliano1, Marco Cappucciati1, Andrea De Micheli1,3, Valentina Ramella-Cravaro 1,
Umberto Provenzani1,4, Mathilde Antoniades3,5, Gemma Modinos 2,5, Dominic Oliver1, Daniel Stahl 6, Silvia Murguia7,
Fernando Zelaya2, Paul Allen5,8, Sukhi Shergill5, Paul Morrison5, Steve Williams2, David Taylor9, Philip McGuire3,5,10 and
Paolo Fusar-Poli1,3,4,10
Preclinical and human studies suggest that hippocampal dysfunction is a key factor in the onset of psychosis. People at Clinical
High Risk for psychosis (CHR-P) present with a clinical syndrome that can include social withdrawal and have a 20–35% risk of
developing psychosis in the next 2 years. Recent research shows that resting hippocampal blood ﬂow is altered in CHR-P individuals
and predicts adverse clinical outcomes, such as non-remission/transition to frank psychosis. Previous work in healthy males
indicates that a single dose of intranasal oxytocin has positive effects on social function and marked effects on resting hippocampal
blood ﬂow. The present study examined the effects of intranasal oxytocin on hippocampal blood ﬂow in CHR-P individuals. In a
double-blind, placebo-controlled, crossover design, 30 CHR-P males were studied using pseudo-continuous Arterial Spin Labelling
on 2 occasions, once after 40IU intranasal oxytocin and once after placebo. The effects of oxytocin on left hippocampal blood ﬂow
were examined in a region-of-interest analysis of data acquired at 22–28 and at 30–36minutes post-intranasal administration.
Relative to placebo, administration of oxytocin was associated with increased hippocampal blood ﬂow at both time points
(p= .0056; p= .034), although the effect at the second did not survive adjustment for the effect of global blood ﬂow. These data
indicate that oxytocin can modulate hippocampal function in CHR-P individuals and therefore merits further investigation as a
candidate novel treatment for this group.
Neuropsychopharmacology (2019) 0:1–10; https://doi.org/10.1038/s41386-018-0311-6
INTRODUCTION
At present, there is a lack of effective treatments for individuals at
Clinical High Risk of Psychosis (CHR-P [1]). Recent studies suggest
that existing interventions do not signiﬁcantly impact on
transition to psychosis [2], attenuated positive [3] or negative
symptoms [4], or social and functional outcomes [5]. Novel
treatments for this population are therefore needed [6].
A substantial body of scientiﬁc work places aberrant hippo-
campal structure and function at the core of neurobiological
mechanisms underlying the onset of psychosis [7]. Evidence from
post-mortem, neuroimaging and preclinical research suggests that
the onset of attenuated psychotic symptoms may be driven by
dysregulated glutamate neurotransmission in the Cornu Ammonis
1 (CA1) region of the hippocampus, which is thought to lead to
hypermetabolism and altered (increased) blood ﬂow [7–10].
Enhanced glutamatergic tone in CA1 induces allostatic adapta-
tions [11] in γ-aminobutyric acid (GABA)-ergic neurotransmission,
with consequent disinhibition of pyramidal neurons (Fig. 1) [12].
These changes may lead to disturbed neural excitation/inhibition
balance, and via polysynaptic projection pathways to the
midbrain/striatum, to midbrain hyperdopaminergia [13, 14]. As
the CHR-P state progresses to the ﬁrst episode of psychosis, the
functional perturbations once localised to (particularly the left)
CA1 may spread to extra-hippocampal regions such as the frontal
cortex [7, 8], and excitotoxic as well as atrophic processes
culminate in hippocampal volume loss—structural changes—
beginning in CA1 [15–17]. These ﬁndings are consistent with
evidence that CHR-P individuals show increased resting regional
cerebral blood ﬂow (rCBF) in the hippocampus relative to controls
[18, 19], and normalisation (reduction) of left hippocampal rCBF is
associated with remission from the CHR-P state [18]. Hippocampal
rCBF in CHR-P individuals has also been correlated with cortical
GABA levels [20].
The neuropeptide oxytocin is a key modulator of social, sexual
and emotional processes [21], including hypothalamic-pituitary-
adrenal axis regulation [22], emotion recognition [23], social
memory [24] and reward, and possesses anxiolytic [21, 22] and
prosocial properties [25, 26]. Previous work in healthy males [27]
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suggests that an acute dose of intranasal oxytocin signiﬁcantly
increases rCBF in limbic and midbrain regions, including the
hippocampus. Preclinical studies have also identiﬁed the hippo-
campus as a key target for oxytocin-mediated effects, with
oxytocin enhancing the signal-to-noise ratio of CA1 pyramidal cell
ﬁring by selectively targeting GABAergic interneuron function
[28, 29]—part of the neural circuit implicated in psychosis onset
[6, 12, 14]. Oxytocin is further linked to these mechanisms via its
role in neural circuit maturation in the pre- and peri-natal period,
responsible for the excitatory-to-inhibitory switching of GABAergic
signalling [30] and controlling dendrite complexity [31], synapse
density [31] and the onset of synchronous ﬁring in developing
hippocampal pyramidal neurons [32]. Preclinical research also
indicates that oxytocin can protect hippocampal CA1 plasticity
and memory from the effects of stress [33], which is also
implicated in the onset of psychosis [13].
The aim of the present study was to examine the acute effects
of oxytocin on hippocampal rCBF in CHR-P individuals. We focused
on the left (and not right) hippocampus because previous CHR-P
research has repeatedly implicated the left hippocampus in the
pathophysiology of psychosis risk [7, 8, 10, 18, 20, 34, 35], with left
(and not right) hippocampal rCBF associated with clinical
outcomes [18]. In addition, previous oxytocin research has
reported distinctly left-lateralised effects of oxytocin on cerebral
blood ﬂow [27]. In view of evidence that certain subregions of the
hippocampus may be particularly involved in the risk for
psychosis, and may be particularly inﬂuenced by oxytocin, we
also investigated whether the effects of oxytocin were speciﬁc to
different hippocampal subregions. Finally, we explored whether
oxytocin had additional effects outside the hippocampal region in
a whole-brain analysis. The a priori evidence for altered
hippocampal rCBF in CHR-P individuals vs controls comes from
the same clinical sample as the current study—recruited from the
Outreach And Support in South London (OASIS) service [36]—and
has already been replicated in a further sample recruited from this
clinic [18, 19]. Leveraging these ﬁndings, the current study
adopted a within-subject crossover design. Our ﬁrst hypothesis
was that oxytocin would modulate hippocampal rCBF in CHR-P
subjects. We did not hypothesise a speciﬁc effect direction
because the aim of this study was to demonstrate disease-target
(hippocampal) engagement. Secondary predictions were that its
effects would be particularly evident in the CA1 subregion, and
that it would also inﬂuence rCBF outside the hippocampus in
regions implicated in social and emotional processing.
PATIENTS & METHODS
Participants
The study received National Research Ethics Service approval (14/
LO/1692) and all subjects gave written informed consent. Thirty
male, help-seeking CHR-P individuals aged 18–35 were recruited
from two specialist early detection services—the OASIS [36] and
Tower Hamlets Early Detection Service (THEDS). A CHR-P status
was determined using the Comprehensive Assessment of At-Risk
Mental States (CAARMS) 12/2006 criteria [37]. Brieﬂy, subjects met
one or more of the following subgroup criteria: (a) attenuated
psychotic symptoms, (b) brief limited intermittent psychotic
symptoms (BLIPS, psychotic episode lasting < 1 week, remitting
Fig. 1 Simpliﬁed schematic of proposed neural circuit mechanisms of hippocampal pathophysiology in those at CHR-P. In (1), low glutamate
signal/input from hypofunctioning NMDARs (akin to ‘faulty homeostatic sensors’) leads GABAergic interneurons to seek to homeostatically
increase excitation by reducing inhibition (disinhibition) of glutamatergic pyramidal cells. However, by disinhibiting pyramidal cells (and thus
increasing glutamate signalling) in this dysfunctional neural environment, the potential homeostatic adaptation becomes allostatic (2). In (3),
enhanced excitation leads to an overdrive in the responsivity of midbrain dopamine neurons which project to the associative striatum (note
that the connection between hippocampal pyramidal cells and midbrain dopamine neurons is presented as monosynaptic but is actually
polysynaptic via the ventral striatum and ventral pallidum). Completing the (simpliﬁed) circuit, local glutamatergic tone is increased in (4) but
is not detected as such by hypofunctioning NMDARs on GABAergic interneurons. For detailed original diagrams and discussion of evidence
for this proposed circuit or its component processes, see [7, 11, 12, 14, 74]. Glu glutamate, NMDAR N-methyl-D-aspartate receptor, E/I
excitation/inhibition
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without treatment), or (c) either schizotypal personality disorder or
ﬁrst-degree relative with psychosis [37], all coupled with
functional decline. Individuals were excluded if there was a
history of previous psychotic disorder (with the exception of BLIPS,
some of whom may meet acute and transient psychotic disorder
criteria [38]) or manic episode, exposure to antipsychotics,
neurological disorder or current substance-use disorder, estimated
IQ < 70, acute intoxication on the day of scanning, and any
contraindications to magnetic resonance imaging (MRI) or
intranasal oxytocin or placebo. History of Axis I disorder(s) was
not an exclusion criterion due to the transdiagnostic nature of the
CHR-P state and the high prevalence of such diagnoses within
these populations [39].
Design, materials, procedure
We used a randomised, double-blind, 40 IU intranasal oxytocin vs
placebo single-dose challenge in a crossover design (1-week
wash out). During each challenge, subjects underwent an MRI
scan which started at 1130 h to minimise potential effects of
diurnal variation in oxytocin or vasopressin [27]. Anxiety was
measured using the State-Trait Anxiety Inventory (STAI) prior to
each scan (and prior to intranasal administration) so that pre-scan
anxiety score could be included in statistical models as a
covariate. For descriptive purposes, we also collected information
on medication history, use of alcohol (Alcohol Use Disorders
Identiﬁcation Test), tobacco and cannabis, functioning using the
Global Functioning Role and Social scales [40] and later transition
status. Intranasal administration followed recommended guide-
lines and a protocol adopted by a previous study conducted at
our institute [27]. Brieﬂy, participants self-administered one puff
(4 IU) of intranasal oxytocin or matched placebo every 30 s,
alternating between nostrils, until 40 IU had been administered
(Supplementary Materials and Methods). During the scan,
participants were asked to maintain their gaze on a centrally-
placed ﬁxation cross.
MRI acquisition and image processing
All scans were conducted on a General Electric Discovery MR750 3
Tesla system (General Electric, Chicago, USA) using a 32-channel
head coil. Measurement of Cerebral Blood Flow (CBF) was carried
out using a 3D pseudo-continuous Arterial Spin Labelling (3D-
pCASL) sequence during two consecutive runs: 22–28 (run 1) and
30–36 (run 2) min post-intranasal administration. The timing of the
two runs was selected based on previous ﬁndings of the
spatiotemporal proﬁle of oxytocin-induced cerebral blood ﬂow
changes in healthy males, which demonstrated sustained effects
over a ~20–73min period (post-intranasal administration) [27]. For
each subject, we also computed a mean (average) CBF map from
the CBF maps for runs 1 and 2. ASL data were preprocessed using
the Automatic Software for ASL Processing (ASAP) 2.0 toolbox [41]
running in Statistical Parametric Mapping version 12 (SPM12;
https://www.ﬁl.ion.ucl.ac.uk/spm/) on Matlab R2017a. 3D-pCASL
acquisition parameters and image preprocessing procedures were
conducted in line with previous studies and are detailed in the
Supplementary Materials and Methods.
Statistical analysis
Statistical analyses were performed in STATA SE14.2.
Pre-scan anxiety scores
For pre-scan anxiety (STAI) scores, missing data were imputed
using next-observation-carried-backward (Supplementary Materi-
als and Methods). Differences in pre-scan anxiety scores in the
oxytocin vs placebo conditions was assessed using a paired t-test.
In line with previous CHR-P studies [18, 19] and because anxiety
has been demonstrated to have systematic effects on CBF [42]
(including rCBF speciﬁcally in the hippocampus [43]), all analyses
included mean-centred pre-scan anxiety as a covariate.
Global cerebral blood ﬂow (CBF)
To measure global CBF signal, we used the ASAP toolbox to
extract average CBF values from a grey matter mask for each
subject. The ICBM-152 mask was obtained from the DARTEL
toolbox in SPM and thresholded to contain voxels with a >.25
probability of being grey matter. To ascertain whether global CBF
was signiﬁcantly different in the oxytocin relative to placebo
condition, we conducted repeated-measures analyses of covar-
iance (RM-ANCOVA) in STATA for run 1, run 2, and the mean of the
runs (separately), using pre-scan anxiety as covariate (Supplemen-
tary Materials and Methods). All subsequent analyses were
conducted with and without global CBF as covariate.
Hippocampal ROI rCBF
Effects of oxytocin on hippocampal rCBF were determined using a
region-of-interest (ROI) approach. A left hippocampal ROI was
deﬁned anatomically in MNI space using the cytoarchitectonic
probabilistic atlas [44] as implemented in the Anatomy toolbox
[45] in SPM (Figs. 2a, b). The ROI mask was composed of regions
CA1, CA2, CA3, dentate gyrus, and subiculum. Mean rCBF values
for the ROI were extracted for each subject using ASAP toolbox
and entered into RM-ANCOVAs in STATA (Supplementary Materi-
als and Methods). Our primary analyses tested for effects in each
of the two runs separately. However, due to the low signal-to-
noise ratio inherent in ASL data, we also conducted an analysis of
the mean effect across the two runs, which can help to reduce
noise if the effects are stable [27]. We contained the family-wise
error (FWE) rate at α= .05 using the Hochberg procedure, which is
a 'sharper' and more powerful version of the Bonferroni
adjustment and which allows non-independence between statis-
tical tests [46]. Original p values (two-tailed) are reported
alongside indication of Hochberg correction survival (i.e., whether
or not they remain signiﬁcant (survive) after accounting for FWE).
Effect sizes are reported as omega-squared (ω2).
Exploratory/supplemental analyses
We used analogous procedures to those described directly above
to extract mean rCBF values for each hippocampal subregion,
using separate masks for left CA1, CA2, CA3, dentate gyrus, and
subiculum (Fig. 3a; and Supplementary Materials and Methods).
No multiplicity correction was applied as subregion analyses were
exploratory. Finally, for completeness we examined whole-brain
effects in runs 1, 2 and the mean of the runs—separately—using
paired t-tests (second-level analysis) in SPM, with pre-scan anxiety
and with/without global CBF signal as nuisance covariates. We
conducted a whole-brain search using cluster level inference
(cluster forming threshold: p< .005; cluster reported as signiﬁcant
at p< .05 using FWE correction in SPM). Analyses were restricted
using the explicit ICBM mask again thresholded to contain voxels
with >.25 probability of being grey matter.
RESULTS
Sample characteristics
Demographic and clinical characteristics of the sample are
presented in Table 1. All participants completed the study with
no drop-outs. No adverse side effects were clinically observed.
One subject was removed due to protocol violations, leaving a
sample of N= 29. There was a signiﬁcant difference in pre-scan
(pre-intranasal administration) anxiety scores in the oxytocin vs
placebo condition (oxytocin [mean ± SE]= 37.4 ± 1.9; placebo=
33.4 ± 1.7; t(28)= 2.46, p= .020), which may have arisen by
chance or due to slightly more individuals receiving treatment
order oxytocin > placebo (N= 15) vs placebo > oxytocin (N= 14).
Global CBF
There was no signiﬁcant difference in global grey matter CBF values
(ml/100 g/min) in the oxytocin relative to the placebo condition in
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the mean of both runs (oxytocin [marginal mean ± SE]= 52.91 ± 0.91;
placebo= 50.23 ± 0.91; F(1,27)= 4.00, p= .056) or run 1 (oxytocin=
52.89 ± 0.94; placebo= 50.44 ± 0.94; F(1,27)= 3.14, p= .088), but a
signiﬁcant difference was observed in run 2 (oxytocin= 52.94 ± 0.90;
placebo= 50.03 ± 0.90; F(1,27)= 4.75, p= .038).
Hippocampal rCBF
rCBF values for all runs were log transformed due to deviations
from distributional assumptions for parametric tests. Compared to
placebo, oxytocin administration was associated with increased
hippocampal rCBF in run 1 (F(1,27)= 9.06, p= .0056; ω2= .223),
run 2 (F(1,27)= 4.96, p= .034; ω2= .124) and the mean of the two
runs (F(1,27)= 7.31, p= .012; ω2= .184), all of which survived
Hochberg multiplicity correction (Figure S1). After controlling for
global signal effects, oxytocin administration was associated with
increased hippocampal rCBF in run 1 (F(1,26)= 7.68, p= .010;
ω2= .198) which survived multiplicity correction (Fig. 2c). The
effects were no longer evident in run 2 (F(1,26)= 0.44, p= .51;
Fig. 2c) or in the mean of the runs (F(1,26)= 3.27, p= .082).
Exclusion of participants taking antidepressants (N= 8) and
benzodiazepines (N= 1) in sensitivity analyses made no material
change to the unadjusted effects on hippocampal rCBF (Supple-
mentary Materials and Methods).
Exploratory/supplemental analyses
Hippocampal subregions. Hippocampal subregion effects were
explored in run 1 only. Relative to placebo, oxytocin administra-
tion was associated with increased rCBF in all hippocampal
subregions, including CA1 (F(1,27)= 9.44, p= .0048; ω2= .232),
CA2 (F(1,27)= 9.33, p= .0050; ω2= .229), CA3 (F(1,27)= 6.83,
p= .014; ω2= .172), subiculum (F(1,27)= 7.61, p= .010; ω2= .191)
and particularly the dentate gyrus (F(1,27)= 10.11, p= .0037;
ω2= .246)(Figure S2). After controlling for global CBF effects,
oxytocin administration was associated with increased rCBF in CA1
(F(1,26)= 7.29, p= .012; ω2= .189), CA2 (F(1,26)= 6.32, p= .018;
ω2= .165), subiculum (F(1,26)= 6.03, p= .021; ω2= .157) and
dentate gyrus (F(1,26)= 7.40, p= .011; ω2= .192), but no differ-
ence was found in CA3 (F(1,26)= 3.20, p= .086)(Fig. 3b). As noted
above, these results were not corrected for multiple comparisons.
Whole-brain. Since there was no signiﬁcant difference in global
signal, unadjusted whole-brain results (including for the mean of
the runs) are reported in Table 2 (see Table S1 and Supplementary
Material for global signal-adjusted results). In run 1, oxytocin
administration was associated with increased perfusion in a large
predominantly left-lateralised cluster spanning the cerebellum,
hippocampus, parahippocampal gyrus and visual cortex, with a
peak in the cerebellum (pFWE < .05). There were no regions where
perfusion decreased after oxytocin. In run 2, oxytocin was
associated with increased perfusion in a large left-hemisphere
cluster spanning the thalamus, parahippocampal gyrus, hippo-
campus, and fusiform gyrus, with a peak in the parahippocampal
gyrus (pFWE < .05), and in a separate right-hemisphere cluster with
a peak in the superior parietal lobule (pFWE < .05).
DISCUSSION
This is the ﬁrst study to investigate the neurophysiological effects
of oxytocin in CHR-P individuals. The key ﬁnding was that a single
dose of intranasal oxytocin increased resting cerebral perfusion in
the hippocampus, a region critically implicated in the pathophy-
siology of the CHR-P state and the later onset of psychosis. This
Fig. 2 rCBF Effects in Left Hippocampus. a ROI mask for the left hippocampus (yellow) overlaid on a standard brain template, and (b) overlaid
on a representative subject-level cerebral blood ﬂow map in normalised space, and (c) bar charts showing mean hippocampal rCBF in the
oxytocin and placebo conditions in run 1 and run 2 after adjustment for global effects
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Fig. 3 rCBF in Left Hippocampal Subregions. a ROI masks for left hippocampal subregions: dentate gyrus (pink), subiculum (yellow), CA1
(cyan), CA2 (blue), and CA3 (green) displayed on a standard brain template, and (b) bar charts showing mean hippocampal subregion rCBF in
the oxytocin and placebo conditions in run 1 after adjustment for global effects
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ﬁnding is consistent with the only previous study of the effects of
oxytocin on rCBF, which found left-lateralised increases in a large
limbic cluster which included the hippocampus [27]. Our analysis
of hippocampal subregions indicated that the largest effects of
oxytocin were in the dentate gyrus and CA1 (although these
analyses were exploratory and require conﬁrmation and replica-
tion), while whole-brain analysis showed that oxytocin also
modulated perfusion in the thalamus, parietal cortex and
cerebellum.
Altered (increased) cerebral blood ﬂow represents a core
pathophysiological mechanism for psychosis onset [7–9] and is
one of the few neuroimaging ﬁndings to have been replicated in
independent CHR-P samples [8, 18, 19]. Increased hippocampal
activity is also a key feature of preclinical models of psychosis
[8, 12] and is thought to drive subcortical dopamine dysfunction
[14]. Increases in hippocampal rCBF may therefore represent a
disease-modifying target [7]. In view of this literature, our analyses
focused on the hippocampal region. The left side (alone) was
selected because previous CHR-P research has repeatedly
implicated the left hippocampus in the pathophysiology of
psychosis risk [7, 8, 10, 18, 20, 34, 35], with left (and not right)
hippocampal blood ﬂow associated with clinical outcomes (i.e.,
remission from a CHR-P state vs non-remission/transition to
psychosis) [18]. In addition, previous oxytocin research has
reported distinctly left-lateralised effects of oxytocin on cerebral
blood ﬂow [27].
We found that the effect of oxytocin on hippocampal rCBF in
run 2 became non-signiﬁcant after controlling for global signal.
This may have reﬂected poorer signal-to-noise ratio in run 2 than
run 1, as inspection of the raw data suggested there was greater
variance in both hippocampal rCBF and global CBF values.
Another possibility is that it was related to the much more
pronounced effects of oxytocin on global rCBF during run 2 than
in run 1. A ﬁnal consideration is that our ﬁndings were inﬂuenced
by the time course and dose-response effects of oxytocin, which
may follow an inverted U-shaped curve [47, 48].
In exploratory analyses, we found that oxytocin increased rCBF
in all of the hippocampal subregions that were examined, with the
largest effects in the dentate gyrus and in CA1 (other subregions
are discussed in the Supplementary Material). Previous neuroima-
ging research in CHR-P individuals suggests that CA1 is a key locus
of dysfunction [8, 15]. The CA1 region plays an integral role in
social and autobiographical memory [49] and CHR-P individuals
show impairments in these domains [50]. In healthy individuals,
oxytocin enhances social learning [51] and memory [24]. CA1
dysfunction is also at the centre of pathophysiological processes
implicated in the onset of psychosis [7]; transition and/or non-
remission from a CHR-P state is associated with enhanced CA1
perfusion and hypermetabolism [8, 18] and a gradual decline in
CA1 volume [15]. Compared to other hippocampal subregions,
CA1 has the highest number of GABAergic interneurons [15, 52]
and an N-methyl-D-aspartate receptor (NMDAR) expression proﬁle
which confers enhanced susceptibility to glutamatergic alterations
and excitotoxicity [53]—key features of the proposed neural
circuit underlying psychosis onset [7]. In preclinical studies,
oxytocin modulates this neural circuit by targeting GABAergic
interneuron function and enhancing the signal-to-noise ratio of
CA1 pyramidal cell ﬁring [28, 29].
In terms of the dentate gyrus, CHR-P individuals whose
symptoms had remitted were recently shown to have a long-
itudinal reduction in left hippocampal perfusion [18], which
reference to a cytoarchitectonic atlas [44, 45] indicates had its
peak coordinate in the left dentate gyrus. Another study reported
reduced dentate gyrus volumes in CHR-P patients vs controls [17].
The dentate gyrus is thought to function as a computational
pattern separator, with dysfunction here mechanistically linked to
NMDAR hypofunction [54] and generation of spurious associations
that may contribute to the onset of psychotic symptoms [55].
Patients with ﬁrst-episode psychosis show deﬁcits in pattern
separation, which can be recreated in healthy volunteers using
ketamine (NMDAR antagonist) challenge [54]. Interestingly,
oxytocin is thought to exert its facilitatory effects on social
recognition and behaviour via oxytocin receptors in the dentate
gyrus, which recruit pattern separation circuits to minimise
interference between similar social memories—at least in
preclinical models [56]. In rats, activation of oxytocin receptors
drives GABA release in the dentate gyrus in an action potential-
dependent manner [57], and exogenous oxytocin has stimulatory
effects on cell proliferation and adult neurogenesis, even under
conditions of stress and elevated glucocorticoids, which also
appears to be speciﬁc to the dentate gyrus [58]. These ﬁndings
further demonstrate that oxytocin engages key pathophysiologi-
cal circuits that are associated with the onset of psychosis.
We also investigated the effects of oxytocin at the whole-brain
level. We found that oxytocin was associated with increased
perfusion in large clusters spanning the hippocampus, para-
hippocampal gyrus and fusiform gyrus, as well as the cerebellum,
and in run 2, the thalamus. Effects in these regions are consistent
with previous work on (a) the effects of oxytocin on perfusion in
Table 1. Participant demographic and clinical characteristics
Variable Total sample
(N= 30)
Demographic Age, years; mean (SD) 23.2 (4.7)




Education, years; mean (SD) 13.2 (1.9)




Transition to psychosis (yes/no)c 4/26
Baseline anxiety scored; mean (SD) 35.6 (8.7)
GF social score; mean (SD) 6.8 (1.5)










Substance Use Current smoker (yes/no) 17/13
Cigarettes/day; mean (SD) 9.8 (6.0)
Cannabis usee; median (range) 2 (0–4)
Alcohol, AUDIT total; mean (SD) 7.2 (7.7)
aComprehensive Assessment of At-Risk Mental States (CAARMS) subgroup;
BLIPS brief limited intermittent psychotic symptoms, APS attenuated
psychotic symptoms, GRD genetic risk and deterioration
bSum of the global (severity) ratings for positive subscale items (P1-P4) of
the CAARMS
cThe 4 transitions occurred within 26 months but the follow up is still
ongoing
dMean of pre-scan anxiety scores across conditions as measured by the
State Trait Anxiety Inventory (STAI)
eCannabis use: 0= never, 1= experimental use (tried occasionally), 2=
occasional use (small quantities from time to time), 3=moderate use
(moderate quantities regularly / large amounts occasionally), 4= severe
use (frequently used large quantities, often to intoxication/debilitation).
AUDIT alcohol use disorders identiﬁcation test, CHR-P clinical high risk for
psychosis, GF global functioning (role and social) scale
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healthy individuals [27], (b) high levels of oxytocin pathway gene
expression and mRNA in the hippocampus, parahippocampal
gyrus and thalamus (preprint [59]), and (c) the role of these
regions in emotion processing and social cognition [21, 60, 61].
Increased perfusion was observed—albeit as part of a large
cluster—in the left posterior hippocampus (including CA1 and
dentate gyrus) at the whole-brain level across all runs, despite not
surviving adjustment for global signal effects. The left-lateralised
temporal lobe ﬁndings are in line with previous oxytocin work
[27, 47, 60, 62] and predominantly left-hemisphere ROIs used in
CHR-P neuroimaging studies [34, 63].
A separate healthy control group was not included in the
current study because two previous independent CHR-P samples
recruited from the same clinical service—the OASIS—have shown
that hippocampal perfusion is altered in CHR-P individuals vs
controls. These studies were large and the ﬁndings replicated,
thus providing a priori evidence of hippocampal rCBF alterations
in CHR-P individuals. Thus, we have used ROIs based on previous
studies that reﬂect validated CHR-P vs control differences.
However, future studies that include a parallel group of healthy
volunteers would allow examination of the speciﬁcity and
potential differential effects of oxytocin in CHR-P vs normative
samples, as well as aiding the interpretation of the direction
(increase vs decrease) of cerebral blood ﬂow effects. Because we
only tested one relatively mid-to-high range dose of oxytocin
(40IU, which may be sufﬁcient to cross-react with vasopressin
receptors to give a vasopressin-like effect [64, 65]), we were not
able to evaluate whether lower doses would show different effects
(i.e., reduction of hippocampal perfusion). Given that previous
studies have reported increased hippocampal perfusion in people
at CHR-P [8, 18, 19], it may well be that a reduction in perfusion is
the ultimate therapeutic target. These investigations were not
possible in the current study, which was primarily an acute
challenge to demonstrate disease-target engagement, but they
provide the ﬁrst evidence that intranasal oxytocin can alter
cerebral blood ﬂow in CHR-P individuals in target brain regions.
Furthermore, while initial evidence of direct nose-to-brain
transport has recently emerged [66], the exact mechanism by
which it enters the brain is not fully understood, and differences in
nasal anatomy and administration technique could inﬂuence the
amount of oxytocin that reaches the brain. Our crossover (and
counterbalanced order) design helped to control for this, but
future research could use novel devices which may provide a
more consistent and optimised delivery of oxytocin. Although
none of the CHR-P participants were taking antipsychotic
medication, a minority were taking antidepressants (N= 8) or
benzodiazepines (N= 1), which could have affected the results.
However, excluding these subjects did not alter the main results.
We also excluded female subjects due to sexual dimorphism in
oxytocinergic function [48, 60]. We did not include speciﬁc
behavioural or symptom data because the study was designed
(and therefore powered) to investigate the neurophysiological
basis for the effects of oxytocin and to primarily show disease-
target engagement. Finally, ﬁndings in CHR-P subjects can be
inﬂuenced by sampling biases that modulate the level of risk for
psychosis [67], but the level of risk in subjects from our local CHR-P
clinic [36] has remained stable over recent years [68].
CHR-P individuals show deﬁcits in social cognition [69] and
altered neural responses during social and emotion processing
fMRI tasks [70], which may contribute to a reduction in social and
occupational functioning. Because oxytocin can have prosocial
effects in healthy volunteers [23, 25] and in patients with
schizophrenia [71], and modulates brain activation during social
and emotion processing fMRI paradigms [72], this suggests that it
Table 2. Effects of oxytocin vs placebo on whole-brain CBF (without adjustment for global CBF effects)
Cluster Description Hemisphere k P(FWE-corr) Peak coordinates Peak description
x y z
Run 1, Oxytocin > Placebo
Left cerebellum, visual cortex, parahippocampal
gyrus, hippocampus, fusiform gyrus, lingual
gyrus; right cuneus, calcarine gyrus, visual cortex,
cerebellum
Left 3904 <.05 −26 −32 −36 Cerebellum (culmen)
−20 −46 −28 Cerebellum (culmen)
−24 −72 −2 Lingual gyrus
Run 1, Placebo > Oxytocin
None
Run 2, Oxytocin > Placebo
Left cerebellum, fusiform gyrus, parahippocampal
gyrus, hippocampus, lingual gyrus, thalamus;
right cerebellum
Left 3117 <.05 −36 −44 −8 Parahippocampal gyrus
−2 −80 −34 Cerebellum (pyramis)
−16 −58 −12 Cerebellum (culmen)
Right superior parietal lobule, precuneus,
calcarine gyrus, cuneus, visual cortex; left visual
cortex
Right 2394 <.05 22 −60 68 Superior parietal lobule
8 −48 74 Postcentral gyrus
4 −82 28 Cuneus
Run 2, Placebo > Oxytocin
None
Mean of the runs, Oxytocin > Placebo
Left cerebellum, parahippocampal gyrus,
hippocampus, fusiform gyrus, thalamus, lingual
gyrus, visual cortex; right cuneus, visual cortex,
cerebellum
Left 5348 <.05 −26 −32 −36 Cerebellum (culmen)
−26 −48 20 White matter
−30 −48 10 White matter
Mean of the runs, Placebo > Oxytocin
None
k number of voxels in the cluster, pFWE FWE-corrected p-value
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might—subject to future research—be useful as a novel treatment
in CHR-P subjects. However, while our results are promising in
showing that oxytocin can engage brain regions strongly
implicated in the onset of psychosis, they do not tell us about
effects on symptoms, functioning, social cognition or any other
CHR-P presentation, which limits the clinical interpretability of our
ﬁndings. These outcomes remain important avenues for future
research and we envisage that this study will provide the
neurophysiological evidence in support of future longer-term
clinical trials that can provide clinical validation. Furthermore,
oxytocin has a good side effect proﬁle; it is safe and well tolerated
[73] and none of our participants reported adverse effects. At
present, there are no licensed pharmacological treatments for this
group, and although psychological interventions have been
recommended, there is limited evidence that these are effective
[2, 3]. Developing effective treatments for CHR-P subjects thus
represents an unmet clinical need.
CONCLUSIONS
The present study indicates that a single dose of oxytocin can
signiﬁcantly modulate hippocampal perfusion in people at CHR for
psychosis. This suggests that oxytocin merits further investigation
as a candidate novel treatment for this group.
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Methods 
 
Design, Materials, Procedure 
Subjects were asked to abstain from using recreational drugs for at least one week prior 
to each MRI scan, and alcohol for at least 24 hours prior to each MRI scan. Urine 
screening was conducted before the scan for each participant. 
 
The blinded spray bottles used for each session (containing oxytocin or matched 
placebo) were visually identical and dispensed by the Maudsley Hospital Pharmacy. 
Intranasal administration followed recommended guidelines [6] and a protocol adopted 
by a previous study conducted at our institute [7]. After a demonstration of the intranasal 
administration from a researcher using a spray bottle containing water, participants self-
administered (in the presence of and with feedback from a researcher) one puff (4IU) of 
intranasal oxytocin (Syntocinon) or placebo every 30 seconds, alternating between 
nostrils, until 40IU (10 puffs) had been administered. The administration phase lasted 
approximately 4.5 minutes. A timer was started after the last puff had been administered 
and was used to coordinate the start of the first MRI sequence (see section below) run 
at 22 minutes post-administration (run 1), followed by the second run at 30 minutes (run 
2). 
 
Both the participants and researchers were blind to the (crossover) treatment sequence 
(AB or BA) allocation. A randomisation list was generated by the Maudsley Hospital 
Pharmacy, which determined whether a participant received oxytocin or placebo in their 
first study visit and vice versa for the second study visit. On recruitment of a study 
participant, an unblinded clinical trial pharmacist, who was not involved with the rest of 
the study, allocated the participant to one of the two sequences (AB, BA) based on the 
randomisation list. Allocation information was kept concealed in the Maudsley Hospital 
Pharmacy. 
 
MRI acquisition parameters and procedures 
All scans were conducted on a General Electric Discovery MR750 3 Tesla system 
(General Electric, Chicago, USA) at the Institute of Psychiatry, Psychology and 
Neuroscience, King’s College London, using a 32-channel head coil. Measurement of 
Cerebral Blood Flow (CBF) was carried out using a 3D pseudo-continuous Arterial Spin 
Labeling (3D-pCASL) sequence during two consecutive runs, from 22-28 (run 1) and 30-
36 (run 2) minutes post-intranasal administration. 
 
  [106] 
Labelling of arterial blood was achieved with a 1525ms train of Hanning-shaped radio 
frequency pulses in the presence of a net magnetic field gradient along the flow direction 
(the z-axis of the magnet). After a post-labelling delay of 2025ms, a whole brain volume 
was read using a 3D inter-leaved “stack-of-spirals” Fast Spin Echo readout [8], consisting 
of 8 interleaved spiral arms in the in-plane direction, with 512 points per spiral interleave. 
TE=11ms, TR=5135ms, and 56 slice-partitions of 3mm thickness were defined in the 3D 
readout. The in-plane FoV was 240×240mm. The spiral sampling of k-space was re-
gridded to a rectangular matrix with an approximate in-plane resolution of 3.6mm. The 
sequence used 4 control-label pairs. CBF maps were computed from the mean perfusion 
weighted difference image derived from the four control-label pairs, by scaling the 
difference image against a proton density image acquired at the end of the sequence, 
using identical readout parameters. This computation was done according to the formula 
suggested in the recent ASL consensus article [9]. The sequence used four background 
suppression pulses to minimise static tissue signal at the time of image acquisition. The 
entire acquisition time of the 3D-pCASL sequence was 6:20 minutes for each run. 
 
We also acquired a three-dimensional sagittal high-spatial-resolution Inversion Recovery 
Spoiled Gradient Echo (IR-SPGR) T1-weighted scan (TE=3.016ms, TR=7.31ms, 
TI=400ms, FoV=270mm). The final resolution of the image was 1.1 x 1.1 x 1.2mm. 
 
Image Processing 
ASL data were preprocessed using the Automatic Software for ASL Processing (ASAP) 
2.0 toolbox [10] running in Statistical Parametric Mapping version 12 (SPM12; 
https://www.fil.ion.ucl.ac.uk/spm/) and Matlab R2017a using the following procedure 
[11,12] for each run: (1) the origin of CBF and 3D T1-weighted images was realigned; 
(2) 3D T1-weighted images were segmented to generate a binary mask including only 
brain tissues; (3) CBF maps were co-registered to the corresponding 3D T1-weighted 
images; (4) extra-cerebral signal was removed from the CBF map by multiplication of the 
“brain only” binary mask, obtained in step 2, with the CBF map in the space of the T1 
image; and (5) T1-weighted scans and skull-stripped CBF maps were spatially 
normalised to MNI avg152 standard space. For each subject, a mean (average) CBF 
map was obtained from the two preprocessed CBF maps (runs 1 and 2) using the 
“imcalc” function in SPM12. Finally, CBF maps were spatially smoothed using a 6mm 






Pre-scan anxiety scores 
For pre-scan anxiety (STAI [13]) scores, across all subjects (N=29) combined, 4 
individual items out of a total of 580 (20-item scale x 29 subjects) were missing. These 
4 items were therefore imputed using next-observation-carried-backward [14]. 
Repeated-measures analyses of covariance (RM-ANCOVAs) in STATA 
Because pre-scan anxiety scores and global grey matter CBF were scan-level 
covariates, the data were prepared in STATA in long format, which allows specification 
of a covariate value for each level of the repeated factor (drug: oxytocin vs placebo). This 
procedure allows controlling for time-varying covariates within a paired-samples (here 
within-subject) design. 
Exploratory/supplemental analyses 
For runs with significant results at the level of the whole hippocampus (run 1 only), we 
used analogous procedures to those described for the whole hippocampal ROI to extract 
mean rCBF values for each hippocampal subregion individually. Separate masks for left 
CA1, CA2, CA3, dentate gyrus, and subiculum were anatomically defined using the 
cytoarchitectonic probabilistic atlas [15] in the SPM Anatomy [16] toolbox (see Figure 3A 
in the main text). Mean rCBF values for each subregion ROI were extracted and log 
transformed due to deviations from distributional assumptions for parametric tests. 
These values were then entered into RM-ANCOVAs in STATA. No multiplicity correction 
was applied as subregion analyses were exploratory. 
  [108] 
Results 
 
Sensitivity analyses - hippocampal rCBF 
Eight participants were taking antidepressants, one of which was also taking 
benzodiazepines. To ensure that inclusion of these cases was not unduly influencing our 
results, we repeated the primary analyses (left hippocampal ROI rCBF analyses) after 
exclusion of these 8 cases. Here, we found that compared to placebo, oxytocin 
administration was associated with increased hippocampal rCBF in run 1 
(F(1,19)=11.37, p=.0032), run 2 (F(1,19)=8.12, p=.010) and the mean of runs 
(F(1,19)=10.64, p=.0041), all of which survived Hochberg multiplicity correction. After 
controlling for global signal effects, oxytocin administration was associated with 
increased hippocampal rCBF in run 1 (F(1,18)=6.10, p=.024), however, this result did 
not survive multiplicity correction. The effects were also no longer evident in run 2 
(F(1,18)=1.01, p=.33) or in the mean of runs (F(1,18)=3.68, p=.071). 
 
 
Whole-brain results, adjusted for global effects 
Results adjusted for global effects are reported in Table S1 below. After controlling for 
global CBF effects, in run 1, oxytocin administration was associated with decreased 
perfusion in a cluster spanning the bilateral anterior cingulate and frontal cortices 
(pFWE<.05), a separate cluster in the right inferior frontal gyrus (pFWE<.05), and increased 
CBF in the left visual cortex (pFWE<.05) (and see Discussion below). There were no 
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Tables & Figures 
 
Table S1. Effects of oxytocin vs placebo on whole-brain CBF (with adjustment for global 
CBF effects) 




coordinates Peak Description 
x y z 
Run 1, Oxytocin > Placebo 
Left visual cortex, 
calcarine gyrus; right 
visual cortex 
Left 620 <.05 
-12 -72 16 Primary visual cortex  (V1, V2) 
-6 -80 28 Visual association cortex (dorsal V3) 
-14 -72 -2 Visual association cortex (ventral V3) 
Run 1, Placebo > Oxytocin 
Left anterior cingulate 
cortex/gyrus, frontal pole, 
superior medial frontal 
gyrus; bilateral mid orbital 
gyrus 
Left 581 <.05 
-2 36 26 Anterior cingulate cortex 
6 48 -12 Frontal pole 
-2 28 42 Superior medial frontal gyrus 
Right inferior frontal gyrus Right 383 <.05 
50 14 22 Inferior frontal gyrus (pars opercularis) 
48 28 22 Inferior frontal gyrus (pars triangularis) 
60 4 12 Rolandic operculum 
Run 2, Oxytocin > Placebo 
None        
Run 2, Placebo > Oxytocin 
None        
Mean of runs, Oxytocin > Placebo 
None        
Mean of runs, Placebo > Oxytocin 
None        
k, number of voxels in the cluster; PFWE, FWE-corrected p-value. 
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Figure S1. rCBF Effects in Left Hippocampus. Bar charts showing mean hippocampal rCBF 
in the oxytocin and placebo conditions in runs 1 and 2 without adjustment for global effects.  
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Figure S2. rCBF in Left Hippocampal Subregions. Bar charts showing mean hippocampal 
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Whole-brain results corrected for global signal effects 
While the temporal/cerebellar whole-brain results (as reported in the main text) were not 
observed after inclusion of global signal as a nuisance covariate, there were a number 
of clusters that were significant, including increased perfusion in visual cortex, but 
perhaps more surprisingly, we also observed decreased perfusion across the anterior 
cingulate cortex (ACC) and inferior frontal gyrus (IFG) in the oxytocin vs placebo 
condition. Postmortem immunohistochemical studies have found oxytocin receptors and 
fibres in the ACC [17], and numerous associations between oxytocin receptor gene 
polymorphisms and ACC volume [18] as well as ACC/IFG functional activation have 
been reported [19,20]. Our findings are also consistent with the attenuated engagement 
observed in these regions in functional MRI studies [21] after oxytocin. However, this 
contrasts with the previous oxytocin study in healthy males, which found increased 
perfusion in the ACC and IFG in response to oxytocin [7], but it should be noted that this 
previous study [7] was a between-group comparison. These differential effects of 
oxytocin on the ACC/IFG might also be explained by differences in baseline rCBF in 
prefrontal regions in CHR-P individuals relative to controls, as have recently been 
reported [22]. 
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Further hippocampal subregions 
While we were a priori interested in CA1, which we have discussed along with the dentate 
gyrus in the main text discussion, we also found increased perfusion after oxytocin in the 
subiculum and CA2 subregion. As noted in the introduction, converging lines of evidence 
implicate CA1 hypermetabolism/hyperperfusion as a driver of the pathophysiological 
processes underlying the onset of psychosis [2]. However, research has shown that 
longitudinally, this CA1-originating dysfunction appears to progressively spread to the 
subiculum (and then to extra-hippocampal regions such as the frontal cortex) at the time 
of onset of psychosis in CHR-P individuals who transition vs those who do not [23]. This 
is combined with volumetric and morphometric shape changes occurring from the time 
of a CHR-P state to the onset of frank psychosis, again with the greatest changes 
observed in the subiculum (and CA1)[23]. Another study found selectively reduced 
subiculum volumes and worse verbal recall scores in familial high-risk individuals vs low 
genetic risk controls, with recall performance significantly correlated with subicular 
volume [24]. In terms of the CA2 subregion, studies have reported reduced CA2/3 
volumes in non-remitted CHR-P individuals relative to healthy controls [25]. Reduced 
CA2/3 volumes [26,27] and greater longitudinal reductions in CA2/3 volume (which 
correlated with worsening general psychopathology scores over time) are also seen in 
patients with schizophrenia relative to healthy controls [28]. Intriguingly, oxytocin 
receptors are abundantly expressed in CA2 (at least in rodents) [29] and oxytocin 
receptor knock-out studies show that oxytocin signalling in CA2 is crucial for the 
persistence of long-term social recognition memory [30].
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Alterations in neurochemical metabolites are thought to play a role in the pathophysiology of 
psychosis onset. Oxytocin, a neuropeptide with prosocial and anxiolytic properties, modulates 
glutamate neurotransmission in preclinical models but its neurochemical effects in people at 
high risk for psychosis are unknown. We used proton magnetic resonance spectroscopy ( 1 H-MRS) 
to examine the effects of intranasal oxytocin on glutamate and other metabolites in people at 
Clinical High Risk for Psychosis (CHR-P) in a double-blind, placebo-controlled, crossover design. 
30 CHR-P males were studied on two occasions, once after 40IU intranasal oxytocin and once af- 
ter placebo. The effects of oxytocin on the concentration of glutamate, glutamate + glutamine 
and other metabolites (choline, N-acetylaspartate, myo-inositol) scaled to creatine were ex- 
amined in the left thalamus, anterior cingulate cortex (ACC) and left hippocampus, starting 
approximately 75, 84 and 93 min post-dosing, respectively. Relative to placebo, administra- 
tion of oxytocin was associated with an increase in choline levels in the ACC ( p = .008, Cohen’s 
d = 0.54). There were no other significant effects on metabolite concentrations (all p > .05). 
Our findings suggest that, at ∼75–99 min post-dosing, a single dose of intranasal oxytocin does 
not alter levels of neurochemical metabolites in the thalamus, ACC, or hippocampus in those 
at CHR-P, aside from potential effects on choline in the ACC. 
© 2019 Elsevier B.V. and ECNP. All rights reserved. 
1. Introduction
The onset of psychosis is usually preceded by attenuated 
psychotic symptoms ( Fusar-Poli et al., 2016b ) and a clin- 
ical presentation that can include social, cognitive and 
functional impairment ( Fusar-Poli et al., 2012a , 2013a , 
2015 ). Such individuals are said to be at Clinical High- 
Risk for Psychosis (CHR-P) ( Fusar-Poli, 2017 ) and have ap- 
proximately 20% risk of developing a first-episode psychosis 
over the following two years ( Fusar-Poli et al., 2016a ). The 
neurobiological mechanisms underlying psychosis onset re- 
main incompletely understood, but alterations in regional 
brain structure, function and neurochemical composition 
have been observed in CHR-P samples ( Allen et al., 2016; 
Bartholomeusz et al., 2017; Fusar-Poli et al., 2012b; Modi- 
nos et al., 2018a ). 
In particular, accumulating evidence suggests that 
the pathophysiological processes underlying psychosis onset 
may be driven by dysregulated glutamate neurotransmission 
( Lieberman et al., 2018 ), with hypofunction of N-methyl- 
D-aspartate receptors (NMDAR) on γ -aminobutyric acid
(GABA)-ergic interneurons leading to disinhibition of pyra- 
midal cells, and via polysynaptic projection pathways from
the hippocampus to the midbrain/striatum, to midbrain
hyperdopaminergia ( Fig. 1 ) ( Lisman et al., 2008; Modinos
et al., 2015 ). Glutamate is an ubiquitous neurotransmitter
with excitotoxic potential ( Farber et al., 1995 ), and ani- 
mal models have demonstrated that excess extracellular
glutamate is sufficient to induce hippocampal hyperme- 
tabolism and volume loss ( Lieberman et al., 2018; Schobel
et al., 2013 ) comparable to that observed as the CHR-P
state progresses to psychosis ( Allen et al., 2016; Ho et al.,
2017; Schobel et al., 2013 ). Novel pharmacotherapies
that can modulate the glutamate system—or associated
neural circuits—have therefore become a target for drug
development ( Lieberman et al., 2018; Millan et al., 2016 ).
In humans, metabolite levels can be quantified in vivo 
using proton magnetic resonance spectroscopy ( 1 H-MRS) 
( Provencher, 1993 ). Using this technique, numerous (but not 
all ( Merritt et al., 2016 )) studies have reported alterations 
in glutamate (and/or glutamate plus glutamine; Glx) levels 
in people at high risk of psychosis vs. controls, particularly 
in the hippocampus ( Bloemen et al., 2011; Shakory et al., 
2018 ), frontal ( Merritt et al., 2016 ) or anterior cingulate 
cortex (ACC)( Stone et al., 2009; Tibbo et al., 2004 ) and tha- 
lamus ( Stone et al., 2009 ). Moreover, within CHR-P samples, 
altered metabolite levels at baseline appear related to clin- 
ical outcomes; thalamic glutamate is lower at baseline in 
those who do not remit by follow up ( Egerton et al., 2014 ), 
and baseline hippocampal glutamate is elevated in those 
who transition (vs. those who do not), and in those with 
poor (vs. good) functional outcomes ( Bossong et al., 2018 ). 
There is also evidence that neurochemical alterations in 
CHR-P are not restricted to glutamate or Glx; higher levels 
of hippocampal myo-inositol at first presentation have been 
reported in CHR-P patients with poor functional and clinical 
outcomes (with effect sizes surpassing that of glutamate), 
which suggests that hippocampal integrity may be compro- 
mised more generally ( Bossong et al., 2018 ). Metabolite al- 
terations have also been observed in other brain regions in 
CHR-P and other (i.e., familial) high-risk groups, such as 
reduced N-acetylaspartate in the thalamus ( Stone et al., 
2009; Tandon et al., 2013; Yoo et al., 2009 ), ACC ( Capizzano 
et al., 2011; Jessen et al., 2006 ), and caudate ( Keshavan 
et al., 2009 )—although increases are also observed in the 
caudate ( de la Fuente-Sandoval et al., 2011 ). Increased Glx 
has been reported in the thalamus and caudate, as well as 
increased ( de la Fuente-Sandoval et al., 2016 ) or decreased 
( Menschikov et al., 2016 ) medial prefrontal GABA—although 
differences are not always found ( Modinos et al., 2018b; 
Wang et al., 2016 ). Finally, other studies have reported in- 
creased choline in the ACC ( Tandon et al., 2013 ), prefrontal 
cortex ( Wood et al., 2003 ) and hippocampus ( Capizzano 
et al., 2011 ) in populations at risk for psychosis. 
Prevention of psychosis in patients at CHR-P and amelio- 
ration of symptoms are clinical priorities. However, there 
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Fig. 1 Simplified schematic of proposed neural circuit mechanisms of glutamatergic dysfunction and CHR-P pathophysiology . In 
(1), low glutamate signal/input from hypofunctioning NMDARs (akin to ‘faulty homeostatic sensors’) leads GABAergic interneurons to 
homeostatically increase excitation by reducing inhibition (disinhibition) of glutamatergic pyramidal cells. However, by disinhibiting 
pyramidal cells (and thus increasing glutamate signalling) in this dysfunctional neural environment, the potential homeostatic adap- 
tation becomes allostatic (2). In (3), enhanced excitation leads to an overdrive in the responsivity of midbrain dopamine neurons 
which project to the associative striatum (note that the connection between hippocampal pyramidal cells and midbrain dopamine 
neurons is presented as monosynaptic but is actually polysynaptic via the ventral striatum and ventral pallidum). Completing the 
(simplified) circuit, local glutamatergic tone is increased in (4) but is not detected as such by hypofunctioning NMDARs on GABAergic 
interneurons. Figure reproduced and adapted with permission (CCBY 4.0) 1 from ( Davies et al., 2019 ). For original diagrams and dis- 
cussion of evidence for this proposed circuit, see ( Krystal et al., 2017; Krystal and Anticevic, 2015; Lieberman et al., 2018; Lisman 
et al., 2008; Modinos et al., 2015 ). Abbreviations: Glu, glutamate; NMDAR, N-methyl-D-aspartate receptor; CA1, Cornu Ammonis 1. 
are currently no licensed pharmacological treatments for 
this patient group, which remains an unmet clinical need 
( Davies et al., 2018a, b ). One potential novel treatment 
is the neuropeptide oxytocin, which is currently under 
investigation in relation to a number of neuropsychiatric 
disorders characterised by social dysfunction, such as 
autism spectrum disorder and schizophrenia. Oxytocin is 
a key modulator of social and emotional processes and 
possesses anxiolytic, prosocial, and potential anticonvul- 
sant properties ( Domes et al., 2007; Guastella et al., 2008; 
Kanat et al., 2015; Kirsch, 2005; Meyer-Lindenberg et al., 
2011 ). Intranasal oxytocin is also safe and has a benign side 
1 https://creativecommons.org/licenses/by/4.0/legalcode 
effect profile ( MacDonald et al., 2011 ), which is particularly 
important in CHR-P groups because many will not go on 
to develop psychosis. The effects of oxytocin on brain 
metabolites are not completely clear, but available evi- 
dence implicates some of the metabolites that have been 
found to be abnormal in CHR-P individuals: glutamate, Glx, 
N-acetylaspartate, choline and GABA. Specifically, in a pre- 
vious double-blind, placebo-controlled crossover trial of a
single acute dose of 24IU intranasal oxytocin in people with
autism spectrum disorder, oxytocin’s normalisation of brain
activation during a social cognition task and improvement
in social-communication symptoms was found to be related
to its effects on N-acetylaspartate levels ( Aoki et al., 2015 ).
Choline levels in the ACC also appeared to be decreased by
oxytocin, albeit at a relaxed significance threshold ( p = .02,
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uncorrected for multiple comparisons; see supplementary 
material in ( Aoki et al., 2015 )). In a separate double-blind, 
placebo-controlled, crossover trial of 48IU/day oxytocin, 
which was administered repeatedly over 6 weeks in peo- 
ple with autism spectrum disorder, oxytocin significantly 
reduced levels of Glx and N-acetylaspartate in the medial 
prefrontal cortex/ACC relative to placebo ( Benner et al., 
2018 ). This prior work demonstrates that exogenously 
administered oxytocin can alter levels of metabolites as 
measured by 1 H-MRS. Evidence for effects of oxytocin on 
glutamate and GABA comes from preclinical studies. For 
instance, oxytocin dose-dependently restores social and 
sensorimotor gating deficits in NMDAR antagonist-treated 
rats ( Feifel and Reza, 1999; Lee et al., 2005 ). Mice lacking 
the oxytocin receptor (through gene knock-out) are more 
vulnerable to NMDAR antagonist-induced sensorimotor 
gating deficits (but not those induced by amphetamine or 
apomorphine), which suggests that it is the glutamatergic 
(rather than dopaminergic) component of sensorimotor 
gating that is protected by oxytocin ( Caldwell et al., 2009 ). 
In mice, oxytocin attenuates methamphetamine-induced 
changes in glutamatergic neurotransmission in prefrontal 
cortex and hippocampus via regulation of NMDAR subunit 
(NR1) and glutamate transporter (GLT1) expression ( Qi 
et al., 2012 ). Furthermore, in animals, oxytocin enhances 
the signal-to-noise ratio of pyramidal cell firing by tar- 
geting fast-spiking GABAergic interneuron function ( Owen 
et al., 2013; Zaninetti and Raggenbass, 2000 )—part of the 
neural circuit implicated in psychosis onset ( Lieberman 
et al., 2018; Lisman et al., 2008; Modinos et al., 2015 ). 
When this circuit is acutely manipulated in humans, for 
example, by inducing NMDAR hypofunction using NMDAR 
antagonists, or by reducing glutamate release (e.g., using 
n-acetyl-cysteine), increases and decreases (respectively)
in the concentrations of regional glutamate/Glx levels as
measured by 1 H-MRS can be observed ( Kegeles et al., 2014;
Kraguljac et al., 2017; McQueen et al., 2018; Schmaal et al.,
2012 ). This demonstrates that the acute modulation of mi- 
crocircuit function can alter metabolite concentrations,
and that this can be observed experimentally using 1 H-MRS.
Despite these initial findings, no studies have yet exam- 
ined the effects of intranasal oxytocin on neurochemical 
metabolites in CHR-P individuals, which would further 
our understanding of its neurophysiological mechanism of 
action and potential disease-engaging effects. To fill this 
gap in knowledge, we investigated the effects of intranasal 
oxytocin on several neurochemical metabolites that are 
thought to be altered in CHR-P individuals in a double-blind, 
oxytocin vs. placebo single-dose challenge crossover 1 H-MRS 
study. In line with previous findings in CHR-P individuals, 
our primary aim was to assess the effects of oxytocin on 
levels of glutamate, and glutamate plus glutamine (Glx), 
in the left hippocampus, ACC and left thalamus ( Bloemen 
et al., 2011; Shakory et al., 2018; Stone et al., 2009; 
Tibbo et al., 2004 ). In view of recent literature suggesting 
that N-acetylaspartate, myo-inositol and choline may be 
altered in populations at risk of psychosis ( Bossong et al., 
2018; Tandon et al., 2013 ), and that oxytocin’s effects 
may involve several neurochemical pathways ( Aoki et al., 
2015; Benner et al., 2018; Ninan, 2011; Qi et al., 2012 ), our 
secondary aim was to examine the effects of oxytocin on 
these metabolite levels. 
2. Experimental procedures
2.1. Participants 
The study received National Research Ethics Service approval 
(14/LO/1692) and all subjects gave written informed consent. 
Using data from a previous 1 H-MRS study ( Stone et al., 2009 ) we 
conducted a power calculation using G ∗Power 3, which indicated 
that a sample size of 30 was sufficient to detect a medium within- 
subject effect size ( d z = 0.53), when alpha = 0.05 and power = 80%. 
Accordingly, 30 male, help-seeking CHR-P individuals aged 18–35 
were recruited from two specialist early detection services—the 
Outreach and Support in South London (OASIS) ( Fusar-Poli et al., 
2013b ) and Tower Hamlets Early Detection Service (THEDS). A 
CHR-P status was determined using the Comprehensive Assessment 
of At-Risk Mental States (CAARMS) 12/2006 criteria ( Yung et al., 
2005 ). The CHR-P state is heterogeneous ( Fusar-Poli et al., 2016a ) 
because subjects can meet one or more of the following subgroup 
criteria: (a) attenuated psychotic symptoms, (b) brief limited 
intermittent psychotic symptoms (BLIPS, psychotic episode lasting 
< 1 week, remitting without treatment), or (c) either schizotypal 
personality disorder or first-degree relative with psychosis ( Yung 
et al., 2005 ), all coupled with functional decline. Individuals were 
excluded if there was a history of previous psychotic disorder (with 
the exception of BLIPS ( Fusar-Poli et al., 2016 ), some of whom may 
meet Acute and Transient Psychotic Disorder criteria ( Fusar-Poli 
et al., 2017 ; Fusar-Poli et al., 2018 )) or manic episode, exposure 
to antipsychotics, neurological disorder or current substance-use 
disorder, estimated IQ < 70, acute intoxication on the day of 
scanning, and any contraindications to magnetic resonance imaging 
(MRI) or intranasal oxytocin or placebo. 
2.2. Procedure 
We used a double-blind, 40IU intranasal oxytocin vs. placebo single- 
dose challenge in a crossover design (one-week wash out). During 
each challenge, subjects underwent an MRI scan which started at 
11:30 AM to minimise potential effects of diurnal variation in oxy- 
tocin or vasopressin ( Paloyelis et al., 2016 ). Prior to the first scan, 
subjects completed a computerised Reading the Mind in the Eyes 
(RMET) task ( Baron-Cohen et al., 2001 ), which indexes mentalising 
(theory of mind) ability, for use in correlation analyses. The RMET 
requires participants to match the mental state of a person (as 
shown in a photograph of the eye region only) with one of four 
possible mental state words. Higher scores (out of a maximum of 
36) index better mentalising ability. For descriptive purposes, we
also collected information on baseline anxiety (State-Trait Anxiety
Inventory [STAI]), medication history, use of alcohol (Alcohol Use
Disorders Identification Test [AUDIT]), tobacco and cannabis, and
functioning using the Global Functioning (GF) Role and Social
scales ( Cornblatt et al., 2007 ). Intranasal administration followed
recommended guidelines and a protocol adopted by a previous
study conducted at our institute ( Paloyelis et al., 2016 ). Briefly,
participants self-administered one puff (4IU) of intranasal oxytocin
or matched placebo every 30 s, alternating between nostrils, until
40IU had been administered (Supplementary Material). Although
not presented here, the MRI scan included arterial spin labelling,
a functional MRI (fMRI) task, various structural scans and resting
state fMRI, followed by the three 1 H-MRS sequences (detailed
below).
2.3. Magnetic resonance imaging 
All scans were conducted on a General Electric Discovery MR750 
3 Tesla system (General Electric, Chicago, USA) using a 32- 
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channel head coil. A three-dimensional sagittal high-spatial- 
resolution Inversion Recovery Spoiled Gradient Echo (IR-SPGR) 
T1-weighted scan (TE = 3.016 ms; TR = 7.31 ms; TI = 400 ms; voxel 
size = 1.1 × 1.1 × 1.2 mm 3 ) was acquired for voxel planning and 
calculation of 1 H-MRS voxel tissue content. 1 H-MRS spectra were 
acquired in the left hippocampus, ACC, and left thalamus ( Fig. 2 ) 
using conventional Point-Resolved Spectroscopy acquisition (PRESS; 
TR = 3000 ms; TE = 30 ms; 96 averages) in three separate 6-min 
scans. We employed the standard GE PROBE (Proton Brain Exami- 
nation) sequence, which uses a standardised chemically selective 
suppression (CHESS) water suppression routine. Unsuppressed 
water reference spectra (16 averages) were also acquired as part 
of the standard acquisition for subsequent eddy current correction 
and water scaling. Shimming was optimised, with auto-prescan per- 
formed twice before each scan. The structural T1-weighted scan 
was used to plan the voxel placement as per standardised protocols, 
with voxel sizes of (right-left, anterior-posterior, superior-inferior) 
20 × 20 × 15 mm 3 in the hippocampus, 20 × 20 × 20 mm 3 in the 
ACC, and 15 × 20 × 20 mm 3 in the thalamus. The mean ± SD of 
the time from dosing offset (end of intranasal administration) 
for each region was: thalamus (75 ± 4 min), ACC (84 ± 5 min), 
and hippocampus (93 ± 6 min). These equate to approximate 
(mean) post-dosing sampling periods of: thalamus (75–81 min), ACC 
(84–90 min), and hippocampus (93–99 min). 
2.4. Data processing 
Spectra were analysed using LCModel ( Provencher, 1993 ) ver- 
sion 6.3-1L using the standard basis set of 16 metabolites 
(L-alanine, aspartate, creatine, phosphocreatine, GABA, glucose, 
glutamine, glutamate, glycerophosphocholine, glycine, myo- 
inositol, L-lactate, N-acetylaspartate, N-acetylaspartylglutamate, 
phosphocholine, and taurine) acquired at the same field strength 
(3 T), localisation sequence (PRESS), and echo time (30 ms). Model 
metabolites and concentrations used in the basis set are fully 
detailed in the LCModel manual ( http://s-provencher.com/pub/ 
LCModel/manual/manual.pdf ). Poorly fitted metabolite peaks 
(Cramer–Rao minimum variance bounds [CRLB] of > 20% as reported 
by LCModel) were excluded from further analysis. Spectral quality 
was further assessed using signal-to-noise ratio (SNR) and spectral 
linewidths (full width at half-maximum; FWHM). 
Our primary analysis used metabolite levels scaled to creatine. 
However, because creatine may be influenced by the experimental 
condition (oxytocin vs. placebo), we also report water-scaled 
metabolite levels corrected for voxel tissue content. To calculate 
and correct for 1 H-MRS voxel tissue content, an in-house script 
was used to (a) segment the T1-weighted structural images into 
grey matter, white matter, and cerebrospinal fluid (CSF) using 
Statistical Parametric Mapping 12 (SPM12; Wellcome Trust Centre 
for Neuroimaging, London, UK) running in Matlab R2017a, (b) 
locate and map the coordinates of each voxel to the segmented T1 
images, and (c) provide the tissue content proportions. Metabolite 
values were corrected for voxel tissue content using the formula: 
M corr = M × ([GM × 1.21] + WM + [CSF × 1.55]) / (WM + GM), where 
M is the uncorrected metabolite value and GM/WM/CSF are pro- 
portions of grey matter, white matter and CSF, respectively. The 
formula assumes a CSF water concentration of 55,556 mol/m 3 and 
the LCModel default brain water concentration of 35,880 mol/m 3 
( Gasparovic et al., 2006; Kreis et al., 1993 ). Apart from assum- 
ing T 2 = 80 ms for tissue water, no corrections were applied for 
metabolite and water relaxation times. 
2.5. Statistical analysis 
Statistical analyses were performed in SPSS version 24 (IBM Corp., 
Armonk, NY). Paired t-tests were used to examine differences 
in data quality (i.e., in linewidths, signal-to-noise ratio, CRLB, 
and voxel tissue proportions) between conditions. The effects of 
oxytocin vs. placebo on regional brain 1 H-MRS metabolite levels 
were assessed using paired t-tests. Our primary hypothesis tested 
for effects on glutamate and Glx scaled to creatine, and our 
secondary hypothesis tested for effects on other metabolites 
(myo-inositol, N-acetylaspartate and choline) scaled to creatine. 
Choline (or “total choline”) was the sum of glycerophosphocholine 
and phosphocholine. The alpha level was Bonferroni corrected 
(thresholded p < .05/5 metabolites = p < .01, two-tailed) for mul- 
tiple comparisons per region. For both primary and secondary 
analyses, boxplots were used to identify potential outliers and 
paired t-tests were repeated after their exclusion in sensitivity 
analyses. We also repeated the primary and secondary analyses 
after excluding those participants taking antidepressants ( N = 8) 
or benzodiazepines ( N = 1). The same procedures as detailed 
above were used in the analysis of water-scaled metabolite levels 
corrected for voxel tissue content (which also included analysis 
of creatine itself), which we conducted to ensure that our results 
were not driven by the scaling to creatine. Exploratory Spearman’s 
correlations were then used to examine whether the effects of 
oxytocin on the primary outcome (change in glutamate and Glx 
levels—scaled to creatine—in the hippocampus, ACC and thalamus 
in the oxytocin vs. placebo condition) were predicted by the 
baseline level of behavioural measures that characterise CHR-P 
patients. These included attenuated positive psychotic symptoms 
(sum of severity scores for items P1-P4 of the CAARMS) and social 
cognition, measured through the Reading the Mind in the Eyes task 
(RMET) scores. Since these correlations were exploratory in nature 
they were not corrected for multiple comparisons. Finally, given 
some attrition in study participation, we updated our power cal- 
culation for the primary hypotheses (glutamate and Glx) to assess 
the actual power of our analyses (see Supplementary Material). 
3. Results
3.1. Sample characteristics
Demographic and clinical characteristics of the sample are 
presented in Table 1 . One subject was removed due to pro- 
tocol violations, and one further subject did not complete 
the scanning session due to experiencing attenuated psy- 
chotic symptoms (at ∼75min during the placebo condition), 
leaving a sample of N = 28 for the ACC and thalamus. Two 
further subjects did not complete the hippocampal 1 H-MRS 
scan, leaving N = 26 for this region. No adverse side effects 
of oxytocin were clinically observed. 
3.2. 1 H-MRS data quality
Representative spectra for all regions (left hippocampus, 
ACC, and left thalamus) are provided in Fig. 2 . Spectra 
were of good quality in all regions—no data were excluded 
due to Cramer-Rao minimum variance bounds > 20% and 
no significant differences in spectral quality or voxel tissue 
content were observed between oxytocin and placebo 
conditions ( Table 2 ). 
3.3. Effects of oxytocin on glutamate and Glx
levels
The analysis of the primary outcome revealed no significant 
effects of oxytocin vs. placebo on glutamate or Glx scaled 
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Fig. 2 Example 1 H-MRS voxel positioning and spectra in (A) left hippocampus, (B) anterior cingulate cortex, and (C) left thalamus. 
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Table 1 Participant demographic and clinical characteristics. 
Variable Total sample ( N = 30) 
Demographic Age, years; mean (SD) 23.2 (4.7) 
Age range, years 18–35 
Sex, male/female 30/0 
Ethnicity (White/Black/Asian/Mixed) 16/6/4/4 
Handedness, right/left 26/4 
Education, years; mean (SD) 13.2 (1.9) 
Clinical CHR-P Subtype a (BLIPS/APS/GRD) 6/23/1 
CAARMS attenuated positive symptoms; b mean (SD) 11.7 (3.3) 
Baseline anxiety score; c mean (SD) 35.6 (8.7) 
GF social score; mean (SD) 6.8 (1.5) 
GF role score; mean (SD) 7.0 (1.7) 
RMET score; d mean (SD) 24.7 (5.6) 
Current antidepressant medication (yes/no) 8/22 
Current antipsychotic medication (yes/no) 0/30 
Current benzodiazepine medication (yes/no) 1/29 
Substance use Current smoker (yes/no) 17/13 
Cigarettes/day; mean (SD) 9.8 (6.0) 
Cannabis use; e median (range) 2 (0–4) 
Alcohol, AUDIT total; mean (SD) 7.2 (7.7) 
a Comprehensive Assessment of At-Risk Mental States (CAARMS) subgroup, BLIPS – Brief Limited Intermittent Psychotic Symptoms; APS –
Attenuated Psychotic Symptoms; GRD – Genetic Risk and Deterioration. 
b Sum of the global (severity) ratings for positive subscale items (P1-P4) of the CAARMS. 
c Mean of pre-scan anxiety scores across conditions as measured by the State Trait Anxiety Inventory (STAI), with 4 subjects missing 1/20 
items that constitute the total score, these were thus imputed using next-observation-carried-backwards. 
d Reading the Mind in the Eyes (RMET) social cognition task – two subjects did not complete the RMET, leaving N = 28. 
e Cannabis use: 0 = never, 1 = experimental use (tried occasionally), 2 = occasional use (small quantities from time to time), 3 = moderate 
use (moderate quantities regularly / large amounts occasionally), 4 = severe use (frequently used large quantities, often to intoxica- 
tion/debilitation). AUDIT – Alcohol Use Disorders Identification Test. CHR-P – Clinical High Risk for Psychosis. GF – Global Functioning (role 
and social) scale. 
to creatine (nor in voxel tissue-corrected glutamate or Glx 
levels) in the hippocampus, ACC or thalamus ( Table 3 ). 
3.4. Effects of oxytocin on other metabolite
levels
Analysis of the secondary outcomes revealed no significant 
effects on any other metabolites quantifiable from the 1 H- 
MRS spectra (myo-inositol, choline and N-acetylaspartate) 
in any region, with the exception of choline scaled to cre- 
atine in the ACC, which was significantly increased in the 
oxytocin (mean ± SD; 0.25 ± 0.02) relative to the placebo 
(mean ± SD; 0.24 ± 0.02) condition ( t (27) = 2.88, p = .008; 
Cohen’s d = 0.54; Fig. 3 ) ( Table 3 ). When using ACC choline 
levels corrected for voxel tissue content, we observed a nu- 
merical increase in the oxytocin (mean ± SD; 2.93 ± 0.36) 
relative to the placebo (mean ± SD; 2.77 ± 0.41) condition 
( t (27) = 2.57, p = .02; Table 3 ), but this effect was not signif- 
icant at the Bonferroni-corrected significance threshold of 
p < .01 ( Table 3 ). 
3.5. Sensitivity analysis
Removal of outliers made no material change to the results 
of any statistical test ( Table 3 ). Removal of subjects tak- 
ing antidepressants and benzodiazepines meant that choline 
scaled to creatine was now significantly increased in the 
thalamus in the oxytocin (mean ± SD; 0.30 ± 0.03) rel- 
ative to the placebo (mean ± SD; 0.28 ± 0.03) condition 
( t (20) = 3.11, p = .006). 
3.6. Exploratory correlations
3.6.1. Social cognition 
One subject did not complete the Reading the Mind in the 
Eyes task (RMET), leaving N = 25 for the hippocampus, and 
N = 27 for the ACC and thalamus. RMET (theory of mind) 
scores were negatively associated with absolute change in 
glutamate scaled to creatine (rho = −0.546, p = .005) and 
Glx scaled to creatine (rho = −0.509, p = .009) in the hip- 
pocampus (Supplementary Table S1). That is, those with 
better theory of mind scores tended to have the biggest 
decreases in hippocampal glutamate after oxytocin, while 
those with lower scores (where oxytocin is presumed to 
have the greatest effect ( Feeser et al., 2015; Spengler 
et al., 2017 )) tended to have an increase in hippocampal 
glutamate after oxytocin (Supplementary Figure S1). There 
were no significant correlations between RMET scores and 
glutamate or Glx levels in the ACC or thalamus (all p > .05; 
Table S1). It should be noted that exploratory correlations 
were not corrected for multiple comparisons. 
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Fig. 3 Choline levels (scaled to creatine) in the anterior cingu- 
late cortex in oxytocin and placebo conditions. Individual data 
points are presented (overlaid) on standard boxplots, with grey 
lines connecting paired values. 
3.6.2. Attenuated psychotic symptoms 
One subject had one item missing out of the four items 
that constitute the positive subscale of the CAARMS, leaving 
N = 25 for the hippocampus, N = 27 for the ACC and N = 27 
for the thalamus. There were no significant correlations be- 
tween CAARMS attenuated psychotic symptom scores and 
change in glutamate or Glx scaled to creatine in the hip- 
pocampus, ACC or thalamus (Supplementary Table S2). 
4. Discussion
This is the first study to investigate the neurochemical ef- 
fects of a single dose of oxytocin in CHR-P individuals. The 
key finding was that oxytocin did not modulate glutamate 
(or glutamate plus glutamine; Glx) levels in the hippocam- 
pus, ACC or thalamus in the time interval examined (approx- 
imately 75–99 min post-dosing). There were also no effects 
on other metabolites, with the exception of choline in the 
ACC, concentrations of which were significantly increased 
after oxytocin. 
Our primary hypothesis, that an acute dose of oxytocin 
would modulate glutamate or Glx levels in CHR-P individu- 
als, was not verified. One implication of these findings re- 
lates to the potential mechanism of oxytocin’s effects. A 
previous study found that an acute dose of intranasal oxy- 
tocin had marked effects on cerebral perfusion ( Paloyelis 
et al., 2016 ) across regions that show neurochemical alter- 
ations in CHR-P groups ( Merritt et al., 2016; Poels et al., 
2014; Tandon et al., 2013 ). Our own work has also revealed 
that acute oxytocin modulates hippocampal perfusion in 
those at CHR-P ( Davies et al., 2019 ). Given these demon- 
strable neural effects, in this study we sought to test the 
hypothesis that oxytocin also modulates metabolite concen- 
trations (especially glutamate and Glx) in CHR-P individuals. 
Negative findings are underreported in the scientific litera- 
ture and can be difficult to interpret, but three different 
possibilities are presented below. First, while we did not 
find any effect on glutamate or Glx levels in the hippocam- 
pus, ACC or thalamus, it is still possible that oxytocin medi- 
ates its effects via modulation of glutamatergic neurotrans- 
mission either (a) directly, but we are not able to detect 
it using 1 H-MRS (e.g., due to its lack of specificity for neu- 
ronal glutamate/Glx and large voxel size), or (b) indirectly 
via modulation of GABA and associated neural microcircuits, 
which was not directly quantifiable in the current study. In- 
deed, some preclinical studies have shown that exogenous 
oxytocin administration does not alter basal glutamate lev- 
els per se, but blocks or attenuates changes in glutamate 
induced by deleterious manipulations such as drug-induced 
deficits and restraint stress ( Qi et al., 2009 , 2012)—while 
it can directly alter basal GABA levels ( Qi et al., 2012 ). It 
may also be the case that the heterogeneity inherent in 
CHR-P samples, both clinically and in relation to regional 
metabolite concentrations at the specific time of scanning 
(which may differ between those who will and will not later 
transition, and those with good vs. poor functional out- 
comes ( Bossong et al., 2018 )), may dilute and obscure ob- 
servable oxytocin effects on glutamate when measured at 
group level. Stratification of CHR-P samples in future stud- 
ies would—in theory—allow exploration of this possibility. 
A second possible explanation for these negative findings 
may be that the time interval between intranasal adminis- 
tration of oxytocin and the onset of the 1 H-MRS acquisition 
was too long and potential effects on glutamate/Glx were 
missed. The mean ± SD of the time since intranasal ad- 
ministration for each region in the current study was: 
thalamus (75 ± 4 min), ACC (84 ± 5 min), and hippocampus 
(93 ± 6 min). Early—albeit indirect—evidence suggested 
that the neural effects of intranasal oxytocin would last at 
least as long as our data sampling intervals. For example, 
notwithstanding the extremely small sample, previous 
work reported that following intranasal administration, 
the oxytocin signal in cerebrospinal fluid only begins to 
significantly increase at 75 min post-dosing ( Striepens 
et al., 2013 ). Another study found that while the effects of 
oxytocin on human cerebral blood flow peak at 39–51 min 
post-administration (with a gradual diminution thereafter), 
they observed sustained perfusion effects over the entire 
post-treatment interval (up to 78 min) ( Paloyelis et al., 
2016 ). However, more recent work suggests that the effects 
of oxytocin vary as a function of method of administration, 
brain region, dosage and time since dosing ( Martins et al., 
2019 ). For example, in one study of healthy males, oxy- 
tocin’s effects on amygdala inhibition were observed only 
between 45–70 min post-administration, and not before or 
after ( Spengler et al., 2017 ). A forthcoming study ( Martins 
et al., 2019 ) using a double-blind, placebo-controlled, 
crossover procedure and comparing various methods of 
oxytocin administration, indicates that oxytocin-induced 
decreases in amygdala perfusion are present only within 
the first ∼15–30 min post-dosing. Furthermore, we recently 
showed that in the same CHR-P sample used in the current 
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study, the effects of oxytocin on hippocampal perfusion 
were more robust in the earlier (22–28 min) vs the later 
(30–36 min) post-dosing interval ( Davies et al., 2019 ). It 
may therefore be that in the hippocampus, thalamus and 
ACC, changes in glutamate and Glx are occurring closer to 
the time of administration. 
Third, the observed lack of effects (especially on gluta- 
mate and Glx) may be related to the acute vs. repeated 
(longer-term) oxytocin dosing regimen. A recent study 
found that repeated administration of 48IU/day intranasal 
oxytocin over 6 weeks in people with autism spectrum 
disorder significantly decreased N-acetylaspartate and 
Glx levels in the medial prefrontal cortex ( Benner et al., 
2018 ), effects that were not observed after 24IU acute 
challenge ( Aoki et al., 2015 ). Akin to the current work, 
both of the aforementioned studies were double-blind, 
placebo-controlled, crossover designs ( Aoki et al., 2015; 
Benner et al., 2018 ). In addition, their mouse model showed 
that repeated—but not acute—oxytocin administration sig- 
nificantly downregulated Nr2b (a subunit of the glutamate 
NMDA receptor) transcript expression, while acute admin- 
istration reduced levels of molecules associated with the 
oxytocinergic system (oxytocin mRNA) and with neural 
activity (immediate early genes; cFos and Arc), but not 
Nr2b ( Benner et al., 2018 ). In light of these findings, it is 
possible that longer-term treatment with oxytocin would 
have had significant effects on the glutamate system, with 
altered metabolite levels detectable using 1 H-MRS. 
A final potential contributing factor for our lack of 
observed effects on glutamate and Glx relates to statistical 
power. The current study had a relatively large sample size 
for a neuroimaging-based, within-subject drug challenge 
study. However, we cannot rule out the possibility that 
oxytocin had effects of smaller magnitude (e.g., Cohen’s D 
less than ∼0.56), which corresponds to a maximum percent 
change in metabolite (glutamate or Glx) levels of between 
∼13–20% (depending on the brain region).
Our secondary hypothesis was that oxytocin would mod- 
ulate metabolites that have been found to be altered in 
CHR-P and other high-risk groups ( Bossong et al., 2018; 
Stone et al., 2009; Tandon et al., 2013 ). We found that, at 
∼75–99 min post-dosing, oxytocin had no effects on concen- 
trations of N-acetylaspartate, myo-inositol or creatine in
the hippocampus, ACC or thalamus. The poor availability of
previous literature hinders interpretation of these results
and as discussed above, we may have had insufficient power
to test for effects on these metabolites. We also found that
oxytocin had no effects on choline in the hippocampus and
thalamus, but did have an effect on choline in the ACC,
which was significantly increased after oxytocin. Choline
has a two-fold greater concentration in glial cells com- 
pared to neurons ( Urenjak et al., 1993 ), is a precursor and
metabolite of acetylcholine, and as an essential component
of membrane phospholipids is considered a marker of mem- 
brane turnover and integrity ( Bertolino and Weinberger,
1999 ). Previous evidence has implicated altered choline in
the early phases of psychosis. Increased regional choline
levels have been found in patients with first-episode psy- 
chosis ( Plitman et al., 2016 ) and schizophrenia ( Bustillo
et al., 2014 ) and is associated with a longer duration of
untreated illness ( Théberge et al., 2004 )—potentially due
to glutamatergic excitotoxicity causing cell damage ( Gasull
et al., 2000 ), resulting in elevated choline from increased 
cell membrane turnover ( Bertolino and Weinberger, 1999; 
Théberge et al., 2004 ), or potentially due to increased 
astrocytic turnover of glutamatergic compounds ( Bustillo 
et al., 2014; Plitman et al., 2016 ). There is also specific ev- 
idence suggesting that abnormal choline levels characterise 
populations at risk of psychosis. Earlier work showed that 
choline levels are altered in familial high risk individuals 
vs. low risk controls in the hippocampus ( Capizzano et al., 
2011 ) and in the ACC ( Tandon et al., 2013 ), with ACC 
increases correlating with attenuated psychotic symptom 
severity and schizotypy ( Tandon et al., 2013 ). Within CHR-P 
individuals, ACC choline levels are increased in those who 
go on to transition vs. those who do not ( Jessen et al., 
2006 )—although CHR-P differences are not always found 
( Stone et al., 2009; Uhl et al., 2011 ). There is also evidence 
demonstrating an effect of oxytocin on choline in the ACC. 
A previous study conducted in males with autism spectrum 
disorder found that acute administration of oxytocin mod- 
ulated levels of choline—but not any other metabolite—in 
the medial prefrontal cortex/ACC, albeit at a relaxed 
statistical theshold ( Aoki et al., 2015 ). However, it is im- 
portant to note that effects on choline were not within our 
primary hypothesis and these findings should, therefore, be 
interpreted with caution. Despite similar results in other 
neurodevelopmental disorders ( Aoki et al., 2015 ), further 
independent replication studies are needed to validate this 
finding. The stringent correction for multiple comparisons 
(implemented because our primary hypothesis was for glu- 
tamate and Glx only) may also account for the (statistically) 
discordant choline results from the creatine-scaled vs. the 
voxel tissue content-corrected methods. 
This study has some limitations. First, 1 H-MRS is not able 
to distinguish between intracellular vs. extracellular (or 
neuronal vs. non-neuronal) metabolites, and rather rep- 
resents a whole tissue measure within the specified voxel 
( Jelen et al., 2018 ). This leaves the possibility that oxy- 
tocin modulated glutamate/Glx specifically in the neuronal 
component (i.e. related to neurotransmission/pyramidal 
neurons—which represents a very small proportion of the 
total glutamate in brain tissue—in the region of uM con- 
centrations) vs. the non-neuronal component (i.e., within 
glia), which cannot be discriminated. Nevertheless, 1 H-MRS 
at 3 Tesla is widely used to quantify glutamate and Glx and 
the data acquired in the current study were of high quality. 
We therefore think it unlikely that acute oxytocin has 
effects on neurochemical metabolite concentrations other 
than choline in CHR-P individuals (at least at ∼75–99 min 
post-dosing) and propose that this absence of effects is not 
attributable to methodological shortcomings. Scanning at 
higher field strengths (e.g., 7 Tesla) and advanced tech- 
niques (such as GluCEST or 1 H-fMRS) are now becoming 
available, and will enable future research to reliably sepa- 
rate spectral components and investigate dynamic changes 
in metabolite levels ( Jelen et al., 2018; Roalf et al., 2017; 
Thakkar et al., 2017 ). Our use of metabolite values scaled 
to creatine could also have meant that the results were 
caused by changes in voxel creatine levels. We overcame 
this limitation by also presenting water-scaled metabolite 
levels corrected for voxel tissue content. Furthermore, 
while we recruited a representative sample of CHR-P males 
as typically found in specialist CHR-P services ( Fusar-Poli 
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et al., 2013b ), none of which were taking antipsychotics, 
a number of participants were taking antidepressants and 
benzodiazepines. However, we found no material change 
in the results after exclusion of these cases, aside from 
an increase in thalamic choline after oxytocin. Future 
oxytocin studies should also investigate effects in females 
(which we excluded due to the known sexual dimorphism 
in oxytocinergic function ( Rilling et al., 2014 )) and may 
want to explore variation in the oxytocin receptor gene, 
which is likely to modulate response to intranasal oxytocin 
( Tost et al., 2010 ). Finally, an interesting caveat is that 
while previous studies in autism spectrum disorder found 
no absolute differences in metabolite levels after acute 
oxytocin beyond choline in the ACC, oxytocin’s effects on 
medial prefrontal N-acetylaspartate levels were related to 
the oxytocin-induced recovery in functional MRI signal in 
the same region during a social cognition fMRI task, and 
improvement in social-communication related symptoms 
( Aoki et al., 2015 ). Examining whether changes in brain 
activation or functional connectivity after oxytocin are 
associated with oxytocin’s effects on metabolites in CHR-P 
patients remains an avenue for future research. 
5. Conclusions
This study suggests that at ∼75–99 min post-dosing, acute 
administration of oxytocin does not alter levels of glu- 
tamate, glutamate + glutamine, N-acetylaspartate, myo- 
inositol or choline in the hippocampus, ACC, or thalamus 
in those at CHR-P, aside from potential effects on choline in 
the ACC. 
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Supplementary Experimental Procedures 
Subjects were asked to abstain from using recreational drugs for at least one week 
prior to each MRI scan, and alcohol for at least 24 hours prior to each MRI scan. Urine 
screening was conducted before the scan for each participant. 
 
The blinded spray bottles used for each session (containing oxytocin or matched 
placebo; see section below for formulation details) were visually identical and 
dispensed by the Maudsley Hospital Pharmacy. Intranasal administration followed 
recommended guidelines (Guastella et al, 2013) and a protocol adopted by a previous 
study conducted at our institute (Paloyelis et al, 2016). After a demonstration of the 
intranasal administration from a researcher using a spray bottle containing water, 
participants self-administered (in the presence of and with feedback from a researcher) 
one puff (4IU) of intranasal oxytocin or placebo every 30 seconds, alternating between 
nostrils, until 40IU (10 puffs) had been administered. The administration phase lasted 
approximately 4.5 minutes.  
 
Both the participants and researchers were blind to the (crossover) treatment sequence 
(AB or BA) allocation. A randomisation list was generated by the Maudsley Hospital 
Pharmacy, which determined whether a participant received oxytocin or placebo in their 
first study visit and vice versa for the second study visit. On recruitment of a study 
participant, an unblinded clinical trial pharmacist, who was not involved with the rest of 
the study, allocated the participant to one of the two sequences (AB, BA) based on the 
randomisation list. Allocation information was kept concealed in the Maudsley Hospital 
Pharmacy. 
 
Oxytocin and Placebo Formulation 
The finished intranasal product was manufactured by the Pharmacy Manufacturing 
Unit, Guy’s and St Thomas’ NHS Foundation Trust. Active (Oxytocin): Syntocinon was 
obtained as Syntocinon Spray, marketed by Hersteller, 68330 Huningue, France. This 
was decanted into a 10ml amber dropper bottle and capped with a 10IU white nasal 
atomiser with 69mm dip and overcap. Placebo was placed in the same containers as 










Table S1. Spearman’s correlation coefficients for change in metabolites (oxytocin 
– placebo) in the hippocampus, ACC and thalamus vs RMET scores 
 




Sig. (2-tailed) N 
Hippocampus 
Change in Glu/Cre -.546** .005 25 
Change in Glx/Cre -.509** .009 25 
ACC 
Change in Glu/Cre .288 .145 27 
Change in Glx/Cre -.035 .861 27 
Thalamus 
Change in Glu/Cre .120 .551 27 
Change in Glx/Cre .232 .245 27 
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Figure S1. Scatterplots depicting relationship between change in glutamate and 
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Attenuated Psychotic Symptoms 
 
Table S2. Spearman’s correlation coefficients for change in metabolites 
(oxytocin – placebo) in the hippocampus, ACC and thalamus vs CAARMS 
positive subscale severity scores 
 
There were no significant correlations between CAARMS positive scores and 
change in glutamate or Glx scaled to creatine in the hippocampus, ACC or 
thalamus (Table S2). However, after removing those subjects taking 
antidepressants and benzodiazepines in sensitivity analyses, there was a 
significant positive association between CAARMS positive scores and change 
in thalamic glutamate scaled to creatine (rho= .523, p=.018; N=20) and change 
in thalamic Glx scaled to creatine (rho= .606, p=.005; N=20)(Figure S2). That 
is, higher levels of positive symptoms were associated with increased glutamate 
(and Glx) after oxytocin, while lower levels of positive symptoms were 
associated with a reduction of thalamic glutamate (and Glx) after oxytocin vs 
placebo (Figure S2). 
Metabolite Spearman’s Rho for CAARMS Sig. (2-tailed) N 
Hippocampus 
Change in Glu/Cre -.326 .111 25 
Change in Glx/Cre -.211 .311 25 
ACC 
Change in Glu/Cre .043 .831 27 
Change in Glx/Cre .175 .383 27 
Thalamus 
Change in Glu/Cre .344 .079 27 
Change in Glx/Cre .336 .087 27 
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Figure S2. Scatterplots depicting relationship between change in glutamate 
and Glx scaled to creatine (oxytocin – placebo) in the thalamus vs CAARMS 
positive subscale severity scores [after excluding those subjects taking 
antidepressants or benzodiazepines in sensitivity analyses] 
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Updated Power Calculations 
Updated power calculations were computed using the mean and SD of control 
metabolite values from a previous study (Stone et al, 2009). All calculations are 
for paired t-tests (two-tailed; 80% power; a=.05), where the assumed SD is the 
same for both sessions: SDdiff = √2 x SD. The final sample sizes in the current 
study were hippocampus=26, ACC=28, thalamus=28.  
 
Overall, the updated power calculations indicated that the minimum effect size 
(Cohen’s D) for within-subject change in glutamate (detectable at 80% power 
when a=.05), was d=0.57 (~18% change in glutamate levels) in the hippocampus, 
d=0.55 (~13% change) in the ACC, and d=0.55 (~13% change) in the thalamus. 
The same values for Glx were: d=0.57 (~20% change in Glx) in the hippocampus, 
d=0.55 (~14.5% change) in the ACC, and d=0.55 (~19% change) in the thalamus. 
Therefore, it is possible that oxytocin induced changes of smaller magnitude but 
we were unable to detect them with our final sample sizes due to low statistical 
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Table S3. For each Cohen’s D effect size (small, medium, large), showing 
the associated % change in metabolite, the power we had in the current 
study to detect this % change (or D) [given the sample size for each region], 


























Hippocampus (this study N=26) 
Small (d=0.2) 7 18% 176 7 16% 210 
Medium (d=0.5) 16 66% 36 18 69% 34 
Large (d=0.8) 26 97% 15 29 98% 15 
ACC (this study N=28) 
Small (d=0.2) 5 19% 180 5 16% 223 
Medium (d=0.5) 12 73% 33 13 71% 35 
Large (d=0.8) 19 98% 15 21 98% 15 
Thalamus (this study N=28) 
Small (d=0.2) 5 18% 186 7 18% 195 
Medium (d=0.5) 12 72% 34 17 71% 35 
Large (d=0.8) 19 98% 15 28 98% 15 
 
From Table S3 it becomes clear that effects of oxytocin would have to be of 
medium to large magnitude (as defined by Cohen’s D) for us to detect them with 
our final sample sizes. 
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7. DISCUSSION 
7.1. SUMMARY OF FINDINGS 
Using two distinct but complementary research approaches, the studies within this thesis 
set out to advance our understanding of current (and previously tested) interventions [Part 
1] and a potentially novel treatment strategy [Part 2] for patients at CHR-P. The objective 
of Part 1 was to apply more sophisticated (network) meta-analytical methods than have 
been previously used to synthesise and summarise the evidence regarding the efficacy 
and acceptability of treatments for (a) preventing transition to psychosis from a CHR-P 
state, and (b) reducing attenuated positive psychotic symptoms. The objective of Part 2 
was to use a placebo-controlled pharmacological challenge and MRI to examine whether 
a potential novel treatment strategy, the neuropeptide oxytocin, engaged two 
pathophysiological targets linked to psychosis onset, primarily (a) hippocampal 
perfusion, and (b) glutamate (and Glx) concentrations in the hippocampus, ACC and 
thalamus. Without repeating the discussions of the individual papers, in the sections that 
follow I will discuss these findings in context with the wider literature, consider the 
implications for research and clinical practice, review methodological strengths and 
limitations and suggest areas for future investigation.  
 
The key finding from Part 1 is that at present, there is no evidence that any specific 
treatment is superior to any other treatment—including the lowest level needs-based 
intervention—in preventing transition to psychosis (Paper 1), reducing attenuated 
positive psychotic symptoms (Paper 2) or in acceptability. These findings have 
contributed to knowledge because they were the first to challenge the prevailing view that 
CBT is somehow superior to all other treatments and should be offered to CHR-P patients 
as an evidence-based intervention (NICE, 2014). As will be discussed in the following 
sections, the studies within Part 1 have also allowed identification of numerous potential 
sources of bias and issues with how current clinical trials are conducted, while also 
proposing ways of overcoming them in the next generation of research. 
 
The main findings from Part 2 are that oxytocin modulates resting hippocampal perfusion 
in CHR-P patients (Paper 3) but does not appear to alter concentrations of glutamate (or 
Glx) in the hippocampus, ACC or thalamus when measured using 1H-MRS (Paper 4). 
More specifically, in the study of cerebral blood flow, oxytocin was found to increase 
perfusion in the left hippocampus in a region-of-interest analyses of data collected at 22–
28 (run 1) and at 30–36 (run 2) mins post-administration. The effect in run 1 (but not run 
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2) remained significant after controlling for effects on global blood flow. In exploratory 
analyses, we found that oxytocin increased perfusion in each of the tested hippocampal 
subregions: CA1, CA2, CA3, dentate gyrus and subiculum. In addition to the 
hippocampus, in a whole-brain analysis we also discovered that oxytocin modulated 
perfusion in further brain regions associated with social and emotional processing (as well 
as CHR-P pathophysiology), such as the thalamus, fusiform gyrus, parietal cortex and 
cerebellum. As will be discussed below (section 7.5.1), these findings advance knowledge 
by demonstrating that acutely administered oxytocin can engage one of the key 
pathophysiological targets associated with the onset of psychosis in patients at CHR-P, 
and therefore merits further investigation as a candidate novel treatment.  
 
Conversely, results from the 1H-MRS study (Paper 4) suggested that oxytocin does not 
modulate the concentrations of glutamate or Glx in the left hippocampus, ACC or left 
thalamus in CHR-P patients, at least not in the time intervals sampled in the current study 
(starting 75 to 93 mins post-dosing). The only significant finding from analyses of the 
remaining metabolites (NAA, choline and myo-inositol) was of increased choline in the 
ACC after oxytocin. As will be discussed in section 7.5.1 below, these—mostly 
negative—findings may help us understand the best way of evaluating the effects of 
oxytocin in these patients in future trials. 
7.2. EVIDENCE SYNTHESIS – FINDINGS IN CONTEXT & IMPLICATIONS 
7.2.1. THE HYPE CYCLE – THE JOURNEY SO FAR 
One way of conceptualising and situating our findings within the historical development 
and progression of the CHR-P field (and its search for preventive treatments) is using the 
“Gartner Hype Cycle” (Gartner, 2018) model (adapted to the CHR-P paradigm in (Fusar-
Poli, 2018)). The Gartner Hype Cycle describes the course of new technological 
discoveries, assuming that humans tend to overestimate the impact of a new discovery in 
the short term, while largely underestimating the same in the long term. The Hype 
Cycle—illustrated in Figure 7–1 on page 147—includes 5 different stages: (1) innovation 
trigger, (2) peak of inflated expectations, (3) trough of disillusionment, (4) slope of 
enlightenment, and (5) plateau of productivity or knowledge.  
 
Innovation trigger – the beginning 
With reference to the CHR-P paradigm, the innovation trigger for the development of 
preventive treatments for psychosis was the set-up of the first CHR-P clinic in 1995, 
followed in 2002 by the publication of the first randomised controlled trial in CHR-P 
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individuals. This trial employed antipsychotic (risperidone) plus psychological treatment 
(CBT) and demonstrated that they were effective in reducing the risk of developing first-
episode psychosis in CHR-P samples (McGorry et al, 2002). Over the ensuing years, the 
innovation trigger led to an explosion of enthusiasm with the development of additional 
treatments that—it was hoped—could prevent the onset of psychosis from a CHR-P state. 
As reviewed in full in Part 1 Introduction (section 1.2 starting on page 18), randomised 
controlled trials involving antipsychotics (olanzapine (McGlashan et al, 2006)), 
psychological therapies (CBT (Morrison et al, 2004) and Integrated Psychological 
Interventions (Bechdolf et al, 2012)) and dietary interventions (omega-3 (Amminger et 
al, 2010)) all confirmed some degree of efficacy for reducing the onset of psychosis in 
CHR-P individuals. 
 
Inflated expectations  
The peak of inflated expectations and optimism was likely reached through the 
publication of the NICE Clinical Guideline 178 (NICE, 2014) and the European 
Psychiatric Association (EPA) guidelines (Schmidt et al, 2015). These guidelines set the 
gold standard for the prevention of psychosis in CHR-P individuals in clinical routine. At 
the same time, these guidelines also represented the starting point of the trough of 
disillusionment, because they were grounded on “non-conclusive” and “moderate 
quality” evidence of small magnitude (risk difference -0.07, 95% CIs -0.14 to -0.01) 
(Stafford et al, 2013a, 2013b). Upon closer inspection, the two guidelines were already 
reflecting a lack of robust evidence at the time of their release because they were partially 
discordant—while prophylactic treatment with antipsychotics was altogether prohibited 
by NICE guidelines (NICE, 2014), the EPA allowed their use in the case of severe and 
progressive symptomatology (Schmidt et al, 2015). 
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McGorry et al 2002
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Morrison et al 2012
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Symptoms/functioning (Devoe 2018)
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Innovative trial designs
New experimental treatments
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NICE CG178 guidelines, 2014
EPA guidelines, 2015 
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Trough of disillusionment – where we are now 
Over the following years, the trough of disillusionment for effective preventative 
treatments received additional corroborating support. Two large randomised controlled 
trials showed that neither CBT (Morrison et al, 2012) nor omega-3 interventions 
(McGorry et al, 2017; Nelson et al, 2018a) were effective in reducing the progression to 
psychosis from a CHR-P state. Overall, seven new RCTs involving 992 new CHR-P 
participants (an increase of more than 50%) have been published since the last meta-
analysis (Stafford et al, 2013a) that informed the NICE guidelines (Davies et al, 2018a). 
All of these new trials were negative (Davies et al, 2018a; Fusar-Poli, 2017a). The 
updated network meta-analysis (Paper 1) incorporating these new RCTs (and using the 
most sophisticated meta-analytic methods to date) confirmed the lack of evidence to 
support specific treatments over each—and every—other for the prevention of psychosis 
in CHR-P individuals (Davies et al, 2018a). Paper 2 of this thesis (Davies et al, 2018b), 
and an independent study using the same methods and outcomes (Devoe et al, 2019) also 
confirmed no superiority of any treatment for reducing attenuated psychotic symptoms.  
 
Our finding that no specific interventions were superior to any others—including the 
lowest-level ‘nonspecific’ needs-based intervention—may have been the first evidence 
synthesis to present such sobering conclusions, but when evaluating the wider literature, 
these results are perhaps not entirely surprising. This includes the fact that the seven most 
recent (Bechdolf et al, 2016; Cadenhead et al, 2017; Kantrowitz et al, 2015; McGorry et 
al, 2017; Miklowitz et al, 2014; Stain et al, 2016; Woods et al, 2017) and three largest 
(Bechdolf et al, 2016; McGorry et al, 2017; Morrison et al, 2012) RCTs all produced 
non-significant results for preventing transition, and independent meta-analyses 
conducted outside of our research team have since published concordant findings for 
additional outcomes (Devoe et al, 2018c, 2018a, 2018b, 2019).  
 
7.2.2. COMPARISON WITH RECENT META-ANALYSES – VARIOUS 
OUTCOMES 
To further demonstrate that the findings of Paper 1 and Paper 2 are concordant with the 
wider literature and across various clinical outcomes, a systematic search of meta-
analyses (adapted from Paper 5 of this thesis, which is under review as noted in the 
Preface) was conducted and details of the most recent meta-analyses were extracted and 
reported in Table 7–1 on page 150.  
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The most updated meta-analytical evidence, summarised in Table 7–1, shows no 
evidence to favour any preventive treatments over each (and any) other for improving 
any of the following clinical outcomes relevant for CHR-P individuals: risk of developing 
a first episode of psychosis (Paper 1) (Davies et al, 2018a), acceptability of treatments 
(Paper 1) (Davies et al, 2018a), severity of attenuated positive (Paper 2) (Davies et al, 
2018b; Devoe et al, 2019) or negative psychotic symptoms (Devoe et al, 2018c, 2018b), 
depression (Stafford et al, 2013a), symptom-related distress (Hutton and Taylor, 2014), 
level of social functioning (Devoe et al, 2018a), level of general functioning (Hutton and 
Taylor, 2014) or quality of life (Hutton and Taylor, 2014).  
 
Although CHR-P patients may have symptomatic improvement pre-post treatment (and 
longitudinally in naturalistic settings (Fusar-Poli et al, 2015b)), there are no substantial 
differences across interventions or between intervention and control conditions. 
Importantly, although the meta-analyses presented in Table 7–1 were conducted by 
independent research teams, their results converge. For example, two independent meta-
analyses (including Paper 2) both concluded that there is no evidence to favour specific 
treatments over each (and every) other for improving attenuated psychotic symptoms in 
CHR-P individuals (Davies et al, 2018b; Devoe et al, 2019). Unfortunately, there is also 
no robust evidence that current treatments can improve functioning in these patients. The 
most recent meta-analysis to have explored this outcome concluded that CBT did not 
significantly improve social functioning at 6 months, 12 months or 18 months; omega-3 
did not significantly improve social functioning at 6 months or 12 months and cognitive 
remediation did not significantly improve social functioning at 2–3 month follow up 
(Devoe et al, 2018a). 
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Table 7–1. Efficacy of treatments for CHR-P individuals. Overview of the most recent meta-analyses per outcome (up to January 2019). 
Outcome Author Year Type of evidence 
N of studies 




Transition to psychosis Davies et al (Paper 1) 2018 
Aggregate Network 
Meta-Analysis (RCTs) 16 (2035) 
Lack of evidence to favour specific 
treatments 
Acceptability Davies et al (Paper 1) 2018 
Aggregate Network 
Meta-Analysis (RCTs) 14 (1848) 
Lack of evidence to favour specific 
treatments 
Severity of attenuated 
positive symptoms 
Davies et al 
(Paper 2) 2018 
Aggregate Network 
Meta-Analysis (RCTs) 14 (1707) 
Lack of evidence to favour specific 
treatments 
Devoe et al 2018 Aggregate Network Meta-Analysis (RCTs) 12 (1457)
b  Lack of evidence to favour specific treatments 
Severity of attenuated 
negative symptoms Devoe et al 2018 
Aggregate Network 
Meta-Analysis (RCTs) 14 (1467)
c Lack of evidence to favour specific 
treatments 
Depression Stafford et al 2013 Aggregate Pairwise Meta-Analysis (RCTs) 5 (714) 
No significant treatment effects at any 
time point 
Symptom-related 
distress Hutton et al 2014 
Aggregate Pairwise 
Meta-Analysis (RCTs) Unclear  No significant treatment effects 
Social functioning Devoe et al 2018 Aggregate Pairwise Meta-Analysis (RCTs) 9 (1040) 
No treatment significantly improved 
social functioning 
Functioning Hutton et al 2014 Aggregate Pairwise Meta-Analysis (RCTs) 6 (800) No significant treatment effects 
Quality of life Hutton et al 2014 Aggregate Pairwise Meta-Analysis (RCTs) Unclear No significant treatment effects 
a sample sizes based on the total sample sizes reported in the meta-analysis minus the sample size of any studies that were not included in their meta-analytic 
computations; b sample size of Ising et al (2016) and the non-randomised arm of McGorry et al 2013 (N=78) not included; c sample size computed by summing 
study sample sizes from Table 1 in the paper. The non-randomised arm of McGorry et al 2013 (N=78) was not included. 
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7.2.3. THE HYPE CYCLE – THE CHALLENGES TO OVERCOME 
Slope of enlightenment 
Publication of the negative (non-significant findings) in Papers 1 and 2, along with the 
accumulating number of failed clinical trials, has prompted critique and discussion about 
the CHR-P field (van Os and Guloksuz, 2017) as a whole, including whether transition is 
even a primary outcome of interest and whether treatments are effective for other 
outcomes. As I will argue in the following sections, rather than taking these findings as 
evidence to abandon the search for preventative treatments and the CHR-P field, 
‘negative’ findings (such as Papers 1 and 2), and a systematic identification of the 
limitations of current knowledge, may actually help us to advance the field. This is 
precisely the approach taken by other medical specialties; the uncertain stage of 
knowledge typically associated with the “trough of disillusionment” is not specific to the 
CHR-P state; rather, it has also been observed in other branches of medicine, such as 
cancer prevention (Cuzick, 2017).  
 
As I will discuss below, implementing the “slope of enlightenment” will also likely 
require the coordinated efforts of researchers to improve trial designs and pay increased 
attention to factors such as: (a) ensuring sufficient risk enrichment in study samples, (b) 
estimation of specific treatment effect estimates rather than clinically uninterpretable 
pooled effect sizes, and (c) consensus on what constitutes the primary outcome(s) for the 
field. 
 
7.2.4. THE NEED FOR SPECIFIC TREATMENT EFFECT ESTIMATES 
Why were treatments not ‘pooled’ altogether?  
Since preventative treatments for CHR-P individuals are highly heterogeneous, pooled 
effect sizes (of all different treatments combined) are clinically meaningless and cannot 
be used to inform treatment guidelines. How would a clinician, who needs to decide on 
the best treatment to offer to a CHR-P patient, fare when interpreting a pooled effect size 
which has been estimated across pharmacological, psychological and dietary 
interventions combined vs heterogeneous control conditions? Such an effect size would, 
at best, suggest that “any type of experimental treatment” is better, worse, or similar to 
“any type of control condition”. This is clearly uninformative from a clinical standpoint. 
Treatment guidelines—and therefore the underlying evidence—needs to be as specific as 
possible because clinicians, healthcare providers and patients rely on them for clear 
direction and education on the best ways of adhering to them.  
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Accordingly, the rationale for conducting the first randomised controlled trial in the CHR-
P population was based on the need to examine more “specific interventions” (page 922 
in (McGorry et al, 2002)). It therefore follows that in meta-analyses of CHR-P treatments, 
it is the examination of specific—as opposed to general—treatment efficacy that is 
important. Independent research teams have now used network meta-analytical 
approaches to investigate the specific efficacy of interventions for CHR-P individuals 
and, importantly, none of them have produced pooled effect sizes across treatment 
modalities (Davies et al, 2018a, 2018b, Devoe et al, 2018c, 2019). 
 
Treatment heterogeneity 
Interventions for CHR-P patients are intrinsically heterogeneous because they include 
different therapeutic components. This is due to the fact that when interventions were 
originally introduced in the first RCT, the strategy adopted was to “include the best-bet 
specific therapies in a single enhanced intervention package to determine whether it was 
possible to delay the onset of psychosis” (McGorry et al, 2002). The subsequent trials 
followed this approach by testing different packages of care, each of which was 
characterised by specific—but differing—therapeutic components. This issue is evident, 
for example, in the case of different types (and differing protocols) of psychological 
therapies, which have been defined as “black boxes” (Hartmann et al, 2017). The 
additional and substantial problem with using pooled effect sizes in the CHR-P field is 
that the control group, traditionally termed “treatment as usual” or “needs-based 
intervention” (van der Gaag et al, 2012), is per se poorly standardised and largely 
dependent on local service configurations and the availability of specific resources or 
competences (Davies et al, 2018a). For example, treatment as usual may encompass 
supportive psychotherapy (primarily focusing on pertinent issues such as social 
relationships and vocational or family problems), case management, providing 
psychosocial assistance with accommodation, education or employment, brief family 
psychoeducation and support, medications other than antipsychotics or clinical 
monitoring and crisis management (McGorry et al, 2002; Yung et al, 2007).  
 
One way to overcome these issues is to employ network meta-analyses—as in Papers 1 
and 2—which are considered the highest level of evidence as recommended by the World 
Health Organisation (Kanters et al, 2016; Leucht et al, 2016). 
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7.2.5. PREVENTING TRANSITION – THE PRIMARY OUTCOME? 
Until now, there has been a converging consensus in the CHR-P field that prevention of 
psychosis was the foremost outcome and the ultimate aim of the entire paradigm. Authors 
of RCTs in CHR-P individuals have declared that the goals of early detection are: (1) 
postponement or prevention of the transition to frank psychosis, (2) reduction of the 
duration of untreated psychosis to a minimum in patients who develop florid psychosis, 
and (3) prevention of delayed access to mental health services (van der Gaag et al, 2012). 
The importance of preventing the onset of psychosis in CHR-P individuals has been 
further endorsed worldwide and supported by consensus papers (Fusar-Poli et al, 2013a). 
Notably, the first RCT in these patients aimed at determining whether it was possible to 
delay the onset of psychosis (McGorry et al, 2002), with the rationale that this would be 
the most important way of altering the course of the disorder and thereby improving the 
lives of many patients. Outcomes other than the onset of psychosis have also been poorly 
operationalised in the CHR-P field. For example, there is no clear definition for 
symptomatic remission or good outcomes in these patients. Such accumulating evidence 
clearly indicates that the prevention of psychosis has been “the” first-order issue in the 
CHR-P field. 
 
It also does not seem justified to downgrade the relevance of preventing psychosis in 
CHR-P individuals just because recent meta-analyses (including Papers 1 and 2) have not 
found robust evidence to favour specific preventive interventions. Evidence synthesis is 
conducted to test the robustness of findings on a determinate topic and the reporting of 
negative findings is equally as important as positive findings. By systematically 
identifying and addressing gaps in knowledge, “negative” evidence syntheses (such as in 
Papers 1 and 2) may, in fact, help to advance the field. For example, on closer inspection, 
the results of Paper 1 concluded that owing to wide confidence intervals, the actual 
efficacy of treatments for preventing psychosis is mostly undetermined (Davies et al, 
2018a). Some signal of treatment efficacy may have been missed because of the large 
clinical heterogeneity of the population being investigated (Radua et al, 2018). On a more 
conceptual level, there is some consensus that psychosis onset as defined categorically is 
an arbitrary concept (Fusar-Poli et al, 2016a, 2017a; Fusar-Poli and Van Os, 2013; 
McGorry et al, 2018) and that it should be refined or complemented by other relevant 
outcomes, such as severity of attenuated psychotic symptoms, disability and functioning. 
However, the prevention of psychosis should remain the cornerstone and the most 
important outcome for the CHR-P field, complemented by other outcomes.  
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Downgrading—or at worst, dropping—such a primary outcome would be an indirect 
demonstration that current CHR-P research has approached the lowest depths of the 
trough of disillusionment, with complete failure in its ability to prevent psychosis. It 
would also prove that preventive psychiatry is different from other branches of medicine. 
For example, lack of effective treatments to prevent dementia (van Charante et al, 2016) 
from a mild cognitive impairment stage has not triggered neurologists to claim that 
prevention of dementia should be downgraded to a second-order issue (rather, it has 
become a public health priority (Frankish and Horton, 2017)). 
 
7.2.6. UNDERPOWERED TRIALS – THE ESSENTIAL ROLE OF RISK 
ENRICHMENT 
Another factor that will need to be addressed on the slope of enlightenment relates to risk 
enrichment, i.e., the actual level of risk for psychosis in the study samples being recruited. 
The psychometric instruments traditionally used to ascertain the presence of a CHR-P 
state have been validated worldwide and, overall, have demonstrated excellent prognostic 
accuracy (area under the curve [AUC] at 3 years: 0.9), which is comparable to that of 
other prognostic instruments employed in medicine (Fusar-Poli et al, 2015a). However, 
this excellent prognostic accuracy is mostly due to the excellent sensitivity (96%) of 
CHR-P instruments to detect a state of risk for psychosis; they are able to detect nearly 
all individuals who will develop psychosis, and consequently, nearly all individuals 
testing negative should be individuals who will not develop psychosis. In other words, a 
negative CHR-P assessment is associated with a very small probability of developing 
psychosis (1.56% at 3 years, negative likelihood ratio of 0.09) (Fusar-Poli et al, 2015a; 
Fusar-Poli and Schultze-Lutter, 2016). Conversely, CHR-P instruments have a poor 
specificity (47%)—among individuals testing positive, most will not develop psychosis, 
or in other words, a positive CHR-P assessment is still associated with a relatively small 
probability of developing psychosis (26% at 3 years, positive likelihood ratio of 1.82) 
(Fusar-Poli et al, 2015a; Fusar-Poli and Schultze-Lutter, 2016). Therefore, there is only 
a limited predictive gain in testing positive on a CHR-P assessment. As a result, CHR-P 
instruments should be used in samples that have already been enriched in their initial risk 
for psychosis (i.e. referrals based on suspicion of psychosis risk) and not as screening 
methods in the general population (see below) (Fusar-Poli, 2017b; Fusar-Poli et al, 
2015a). Otherwise, the global number of false positives would be so high that most 
individuals testing positive would be false positives (Fusar-Poli, 2017b). 
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When individuals undergoing a CHR-P assessment are recruited from mental health 
services, they have already accumulated several risk factors for the disorder (Fusar-Poli 
et al, 2017b) which increase their level of risk to 15% at 3 years, compared to the 0.43% 
3-year risk in the local age-matched general population (Fusar-Poli et al, 2018a). This 
level of risk is also termed “pretest risk” because it is ascertained in the whole group of 
people undergoing a CHR-P assessment before the results of the assessment itself are 
known. The pretest risk in individuals recruited through mental health services (i.e. 
measured in naturalistic studies, excluding randomised controlled trials) is 15% at 3 years, 
worldwide (Fusar-Poli et al, 2016e). When these individuals are assessed, those meeting 
CHR-P criteria will have a 26% (post-test) risk of developing psychosis at 3 years (1.7-
fold increase from the pretest of 15%) and those not meeting CHR-P criteria will have a 
1.56% (post-test) risk of developing psychosis at 3 years (10-fold decrease from the 
pretest risk of 15%) (Fusar-Poli et al, 2015a). However, such an estimate is highly 
variable, with 95% CIs for the pretest risk ranging from 9% to 24% because it is based 
on unstandardised and idiosyncratic recruitment strategies (Fusar-Poli et al, 2016e). 
 
As indicated in Table 7–2 (on page 157), assuming an alpha of 0.05, power of 80% and 
two-tailed test, it is possible to estimate the sample size required to test a new 
experimental treatment for preventing psychosis against treatment as usual (e.g. needs-
based intervention). If the experimental treatment is able to halve the risk of psychosis 
(risk ratio, RR=0.5), 538 CHR-P individuals (conservatively using the 9% lower bound 
of the 95% CIs to avoid additional underpowered trials (Fusar-Poli, 2017a)) are required 
to complete the trial. After considering some attrition due to loss to follow-up (e.g. 20%), 
the final sample size required would be approximately 646 CHR-P individuals. However, 
this sample size is based on the pretest risk estimate from naturalistic studies that 
represent the whole population seeking help at specialised CHR-P clinics. When CHR-P 
individuals detected by these specialised clinics are recruited into randomised controlled 
trials, it is likely that additional sampling biases would apply, further reducing the risk 
enrichment. For example, the push towards recruiting sufficient numbers of trial 
participants within a fixed period of time may lead to more intensive outreach campaigns 
in the local community, which are well known to dilute the pretest risk of the resulting 
sample (Fusar-Poli et al, 2016d). In other words, when using unstructured recruitment 
strategies in new trials, 646 CHR-P patients may not provide sufficient power to test 
preventive effects of magnitude RR= 0.5. If the efficacy of the preventative treatment is 
lower, for example, if the experimental treatment is able to reduce the risk of psychosis 
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onset by only 40% (RR=0.6) or 30% (RR=0.7), 894 and 1,680 CHR-P patients are needed 
(ignoring attrition), respectively.  
If individuals undergoing a CHR-P assessment are mostly recruited from the community, 
they will have accumulated fewer (or no) risk factors for psychosis and their pretest risk 
would be 0.43% at 3 years. Following the estimates reported in Table 7–2, the sample 
size required for a similar RCT would exceed 13,000 CHR-P individuals (ignoring 
attrition) and again, CHR-P instruments themselves do not work well when they are 
applied outside of clinical samples that have already undergone some pretest risk 
enrichment (Fusar-Poli, 2017b). Thus, as noted above, it is clear that the way individuals 
are recruited (for undergoing a CHR-P assessment) drives the level of risk enrichment 
(Fusar-Poli et al, 2016e) and ultimately, impacts the statistical power of the trial. For 
example, the NEURAPRO trial observed a risk of psychosis onset of 
approximately 14% at 3.4 years in CHR-P individuals who received the control 
condition, which suggests a pretest risk of 8.2% (assuming that the control condition 
had little effect on the risk for psychosis) (McGorry et al, 2017; Nelson et al, 
2018a). Under those circumstances, 596 CHR-P individuals were needed to detect a 
50% decrease in risk in the experimental condition, which exceeds the sample size 
employed by the trial. In the case of some effect of the control condition on the risk of 
transitioning to psychosis (as speculated by the authors (McGorry et al, 2017)), the 
estimated sample size would then be lower. 
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Table 7–2. Risk enrichment impacts statistical power and sample size for experimental therapeutic trials in CHR-P samples. 
Sampling Recruitment (pretest) 
Psychometric assessment 
(post-test) 
Total sample size (ignoring 
attrition) (c) 
Type of sample Risk of psychosis at 3 yrs (%) 
Risk of psychosis at 
3 yrs (%) 
Risk Ratio (risk experimental 
treatment / risk needs-based 
intervention) 
CHR+ (a) CHR- (b) 0.5 0.6 0.7 
0.43 0.7 <0.1 13,378 22,292 42,100 
 14 0.8 596  988 1,860 
13.7 0.8 610 1,014 1,906 
General population 
NEURAPRO control arm 
Pretest risk stratification 
Average pretest risk in 
people undergoing CHR-P 




(95% CI 9–24) 15.3 0.9 538 894 1,680 
(a) LR+ = 1.82; (b) LR- = 0.09; (c) alpha=0.05; power 80%; 2-sided; allocation ratio = 1. Post-test probability (in %) ={LR*pretest probability/[(1-pretest 
probability)+(pretest probability*LR)]}*100. The sample sizes reported in the table indicate the individuals who should complete the trial (to estimate the 
baseline sample, attrition should be considered); (d) the average is 15% but because it depends on unstandardised idiosyncratic recruitment strategies (Fusar-
Poli et al, 2016e), it is highly variable. It tends to be on the lower side when the recruitment focuses on children and adolescent populations, intermediate when 
the recruitment focuses on primary care settings, and higher when the recruitment focuses on secondary care (Fusar-Poli et al, 2016c). To allow a conservative 
estimate of the sample size required, in this table only the lower bound of 9% is used.
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It is therefore possible that the low level of risk for psychosis decreased the statistical 
power of the NEURAPRO trial for detecting small signal effects associated with the 
experimental treatment. Lack of statistical power due to poor level of psychosis risk 
may actually be one of the causes of the negative RCTs in this population (Fusar-Poli, 
2017a) and of the associated wide 95% confidence intervals observed in the latest 
network meta-analyses (including Papers 1 and 2) (Davies et al, 2018a, 2018b).  
 
The main problem is that recruitment strategies in this field are idiosyncratic and poorly 
standardised and as such, it is not possible to control the level of pretest risk enrichment. 
This is particularly concerning in the case of recruitment into trials which, as noted 
above, introduces additional selection biases that may further dilute the risk enrichment. 
For example, likely because of more intense outreach campaigns in the community (e.g. 
from increasing pressure to recruit participants among many simultaneous competing 
studies), the actual risk of psychosis in CHR-P samples has been declining from 29% 
in 2012 (Fusar-Poli et al, 2012a) to 20% in 2016 (Fusar-Poli et al, 2016b) worldwide. 
Interestingly, there are exceptions to this phenomenon, such as the Outreach and 
Support in South London (OASIS) CHR-P service (Fusar-Poli et al, 2013b), where 
transition risk has not declined over time (Fusar-Poli et al, 2018c). This is again due to 
the fact that recruitment strategies have, overall, maintained a stable pretest risk 
enrichment. Ultimately, innovative strategies are needed to ensure that a sufficient level 
of risk enrichment is obtained to allow adequate statistical power in future trials.  
 
Risk enrichment - solutions for future research 
A possible solution for future research could be to apply risk stratification algorithms 
that have been developed and validated for this population. For example, pretest risk 
estimation algorithms based on the source of referral to CHR-P clinics and ethnicity 
can be used to stratify individuals into four classes of risk enrichment: low risk (1% 
risk at 2 years, »22% of the CHR-P population), moderately-low risk (8% at 2 years, 
»53% of the CHR-P population), moderately-high (18% at 2 years, »21% of the CHR-
P population), and high (35% at 2 years, »4% of the CHR-P population) (Fusar-Poli et 
al, 2016c). If this simple tool is applied to individuals recruited for a CHR-P 
assessment, and those at low risk are screened out from trial eligibility, a pretest risk 
enrichment of at least 8% would be ensured. Under those circumstances, a total sample 
of 610 CHR-P individuals (ignoring attrition) would guarantee sufficient statistical 
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power (80%) to test treatment effects that can halve the risk of developing psychosis 
(Table 7–2 on page 157).  
 
Importantly, however, these estimates still relate to relatively large effect sizes 
(RR=0.5). Interventional CHR-P studies to date have not been powered to detect 
smaller effects, and it therefore remains possible that treatments have a preventative 
effect but of smaller magnitude. This problem arises because the outcome (transition) 
is infrequent and therefore conducting research (in the hope of finding significant 
preventative effects) is complex. Nevertheless, controlling pretest risk enrichment 
through recruitment is a promising method that would help mitigate the existing 
challenges and facilitate the slope of enlightenment phase (Figure 7–1 on page 147). 
 
7.2.7. CLINICAL HETEROGENEITY – STRATIFICATION AND PRECISION 
MEDICINE 
As noted above, the lack of evidence to favour any specific preventive treatment over 
any others should be the basis to promote further research in this field, rather than to 
abandon it. For example, it is likely that a ‘one-size-fits-all’ treatment approach in 
CHR-P populations is not effective and that some treatments may work (only) for 
specific subgroups of patients. The implication here is that if testing treatments at group 
level (without stratification) produces negative results, we may potentially conclude 
that a treatment is broadly ineffective when it may, in fact, have efficacy for specific 
subgroups.  
 
The failure of some studies, such as the NEURAPRO (omega-3) trial when tested in an 
unstratified CHR-P sample (McGorry et al, 2017), has naturally led to the suggestion 
that omega-3 might be more efficacious in those individuals who specifically have low 
levels of membrane fatty acids at baseline (Kane and Correll, 2017). This makes sense 
from a pathophysiological perspective—psychosis is a heterogeneous disorder with 
likely many different neurobiological ‘paths’ and risk factors (Radua et al, 2018), which 
may perturb an individual’s neural circuitry in various (innumerable) ways and which 
ultimately presents as psychosis (Millan et al, 2016). Therefore, different individuals, 
despite all meeting CHR-P criteria, may respond differently to treatments depending 
on which neurobiological aberrations are contributing to the pathophysiological 
processes underlying their psychosis or CHR-P state. In the future, it may be possible 
to assess patients at first presentation for the presence of specific biomarkers which 
would indicate their likely response to specific treatments (or other future outcomes, 
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such as transition vs non-transition). This same method (depicted in Figure 7–2 on page 
171) could also be used to stratify individuals into research studies (e.g. low membrane 
fatty acids could indicate suitability for omega-3 trials) and may ultimately reveal that 
some of the previously tested treatments are effective in specific subgroups.  
 
There are several lines of evidence to support the possibility that clinical heterogeneity 
may be affecting current (and previous) trials. First, some meta-analyses, including 
Papers 1 and 2 and a number of those in Table 7–1 (on page 150), reported wide 95% 
confidence intervals for different treatments, indicating high levels of heterogeneity. 
Second, there is converging evidence that the CHR-P population is clinically 
heterogeneous. For example, there is high heterogeneity in the level of risk for 
psychosis across the three CHR-P subgroups: attenuated psychotic symptoms, brief and 
limited intermittent psychotic symptoms, and genetic risk and deterioration syndrome 
(Fusar-Poli et al, 2016b, 2016a, 2017a). In particular, those meeting the brief and 
limited intermittent psychotic symptoms criteria have a very high risk of developing 
persistent psychotic disorders. Such a heterogeneity calls for a revision of the CHR-P 
paradigm which, even at this early stage (in the absence of biomarkers), should include 
clinical stratification across these three subgroups. Ongoing international consortia 
such as PSYSCAN, PRONIA and NAPLS have already started delivering precision 
medicine tools for stratifying CHR-P individuals which may permit an individualised 
prediction of their outcomes and subgroup allocation for future clinical trials (NAPLS, 
2018; PRONIA, 2018; PSYSCAN, 2018). 
 
7.2.8. HOW SHOULD WE TREAT THE CHR-P STATE NOW? 
Early intervention, prior to the onset of first-episode psychosis, is supported by more 
than 20 years of research in the CHR-P field (Yung et al, 2007). From a neurobiological 
perspective (Millan et al, 2016), it also makes sense to arrest pathophysiological 
processes as early as possible (Krystal and Anticevic, 2015; Lieberman et al, 2018) 
before more severe or enduring neural changes take place (that may be less amenable 
to later treatment). Keeping the critical developmental windows across the lifespan in 
mind (Marín, 2016), and given that we are currently not able to intervene in the so-
called “pre-drome” (prior to overt symptoms) (Krystal and Anticevic, 2015), the CHR-
P state—particularly in adolescence—would seem an apt time for intervention (Marín, 
2016; Millan et al, 2016). The need for treatment during this stage is therefore well 
established. While we may not have biomarkers and definitive evidence for specific 
effective treatments for a number of years to come, it remains imperative to provide the 
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best evidence-based clinical care possible for CHR-P patients in the here and now. 
How, therefore, should we select interventions at the present time, given the state of the 
current evidence for (lack of) superiority of the different available treatments? 
 
Overall, no reliable recommendations can be made regarding whether specific 
interventions (e.g. psychological interventions, medications, dietary interventions, 
needs-based interventions) are more or less effective compared to each other for the 
prevention of psychosis and reducing attenuated psychotic symptoms (Davies et al, 
2018a, 2018b). Consequently, the safest approach is recommended, which would entail 
needs-based interventions and psychological interventions over antipsychotics, because 
the latter are not more efficacious than other options and have known side effects (Liu 
and Demjaha, 2013). In the absence of unequivocal evidence, the selection of 
interventions should also take into account the characteristics and needs of each 
individual. These may include patients’ preferences (e.g. some patients may prefer 
talking therapies to any form of pharmacotherapy), social circumstances (e.g. needs-
based interventions, which include housing/vocational support, may be suited to 
patients for whom these issues represent current stressors), nature of symptoms (e.g. 
CBT may be indicated for those presenting with cognitive biases), predicted risk (e.g. 
those presenting with brief and limited intermittent psychotic symptoms may need 
psychological treatments beyond needs-based interventions), or local service factors, 
such as the availability of each intervention (e.g. whether a waiting list is required for 
some treatments but not others) and staff training/competencies for delivering specific 
treatments. 
 
Going forward, it will be essential to consult the results of forthcoming studies as they 
emerge. In this regard, a “living” network meta-analyses (discussed in section 7.4 
below), defined as the updating of a (network) meta-analysis whenever a new eligible 
RCT becomes available, could provide new and specific evidence earlier than would 
be available through the updating of conventional meta-analysis (Nikolakopoulou et al, 
2018). 
7.3. EVIDENCE SYNTHESIS – STRENGTHS & LIMITATIONS 
Strengths and limitations have been discussed in Papers 1 and 2. In addition, strengths 
of the two network meta-analyses presented here include the fact that the studies were 
pre-registered with detailed and specific analysis plans which included the node 
clustering definitions (Davies et al, 2017). However, even if network meta-analyses do 
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not require the “shoehorning” of treatments into inappropriate pairwise categories, 
there is still an element of clustering the specific interventions into nodes. We therefore 
tested the robustness of our findings to different clustering options in sensitivity 
analyses and found no material change to the results or conclusions. A major limitation 
of the field as a whole is that the evidence base is limited with still too few studies. 
However, our analyses are the most highly powered to date (by including the most 
comprehensive dataset available) and therefore provide the best treatment effect 
estimates currently available. Evaluating treatments on a binary outcome (transition to 
psychosis) as well as a continuous outcome (reduction of attenuated psychotic 
symptoms) also enabled us to show that our non-significant conclusions were not just 
secondary to low statistical power for testing the transition outcome (Davies et al, 
2018a, 2018b). However, our measure of acceptability was crude and nonspecific (but 
pragmatic). One potential limitation in this field is that because allocating CHR-P 
patients to a pure “no treatment” condition is not considered ethical, relatively more 
“active” control conditions are used (such as needs-based interventions). It has been 
argued that these control conditions may be “too active” and therefore obscure 
significant treatment effects (Kane and Correll, 2017). However, ethical requirements 
mean that this is unlikely to change in future. 
7.4. EVIDENCE SYNTHESIS – FUTURE DIRECTIONS 
Individual participant data living meta-analyses 
In addition to improved trial designs, including controlling sample risk enrichment 
(section 7.2.6), screening out of low-risk patients and clinical stratification (section 
7.2.7), another precision medicine approach that could advance knowledge is the use 
of individual participant data network meta-analyses. The use of individual data as 
opposed to aggregate (study)-level data would allow (a) stratification of the efficacy of 
treatments across different confounders (including the three CHR-P subgroups), and 
(b) development of evidence-based prognostic algorithms to forecast the likelihood of 
treatment response at the individual subject level. It is expected that these individual 
participant data meta-analyses will identify specific subgroups of CHR-P individuals 
for whom current treatments (e.g. integrated psychological interventions, which had the 
largest—albeit nonsignificant—effect size OR=0.04) may already be effective. A 
relevant issue is that the future publication of a single study with robust evidence of 
efficacy may significantly change the level of evidence and conclusions regarding 
preventative treatments for psychosis. As discussed in the Introduction to Part 2, novel 
compounds for this patient population are under intense investigation and it is thus 
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expected that new results will be released over the next few years. Unfortunately, meta-
analyses—even if based on individual participant data—are outdated as soon as new 
studies on the same topic emerge. Once published, only a minority of meta-analyses 
are then updated within two years of publication (Jadad et al, 1998). Such an inability 
to maintain recency may lead to significant inaccuracy and clinical practice which is 
not updated with evidence-based medicine. For example, by two years post-publication, 
23% of non-updated meta-analyses will have failed to incorporate new evidence that 
would substantively change its conclusions (Shojania et al, 2007).  
 
Cumulative meta-analysis, defined as updating a meta-analysis whenever a new eligible 
RCT becomes available, can be used to address this (Nikolakopoulou et al, 2018). 
However, the problem is that the median time taken for a primary study to be 
incorporated into a meta-analysis ranges from 2.5 to 6.5 years (Elliott et al, 2014). Thus, 
in 2014, “living” systematic reviews were proposed as a framework for continuously 
updating meta-analyses (Elliott et al, 2014). Living meta-analyses are particularly 
indicated when (a) the question to be addressed is essential to decision-making, (b) 
when there is uncertainty of the evidence, (c) when new information is likely to change 
the findings, and (d) when there is likely to be new evidence (Elliott et al, 2017). All of 
these conditions apply to the CHR-P field. A potential promising method for the CHR-
P field would, then, be to combine the network meta-analyses presented in Papers 1 and 
2 with living meta-analytical approaches over the coming years. A recent empirical 
study has demonstrated that prospectively planned living network meta-analyses 
produced strong evidence against the null hypothesis more often—and earlier—than 
conventional pairwise meta-analyses (Nikolakopoulou et al, 2018). 
 
Finally, in addition to more sophisticated meta-analytic procedures, continued research 
into novel therapeutics is needed. This endeavour will be supported by increased 
understanding of the neurobiological mechanisms underlying psychosis risk and onset, 
which will allow us to develop treatments specifically targeted to precise neural 
processes rather than the current empirical attempts which are not (generally speaking) 
based on validated pathophysiological mechanisms (Millan et al, 2016). This would 
allow resources to be directed to the best-bet approaches and may expedite the search 
for effective preventive interventions. The growing use of experimental medicine 
approaches (as used in Part 2 of this thesis) are one way of assessing the potential 
therapeutic or mechanistic effects of potential novel treatments in vivo and can allow 
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the fast (and relatively low cost) assessment of a treatment’s potential before embarking 
on later-phase clinical trials that may ultimately fail. 
7.5. OXYTOCIN – FINDINGS IN CONTEXT & FUTURE RESEARCH 
The purpose of experimental medicine studies is to (a) test a drug against a specific 
target to assess its likely therapeutic potential, and (b) provide support for go/no-go 
decisions regarding later (more resource-intensive) clinical trials. This is particularly 
advantageous for assessing the effects of oxytocin because despite the abundance of 
preclinical work (which shows promising physiological effects on blood volumes and 
glutamate), very few studies have tested these effects in humans (Aoki et al, 2015; 
Benner et al, 2018; Paloyelis et al, 2016) and none have tested this in CHR-P 
individuals. The two experiments presented in Papers 3 and 4 therefore allowed the first 
evaluation of oxytocin’s effects in CHR-P individuals and have provided 
neurophysiological evidence of therapeutic potential. Without repeating the discussions 
from Papers 3 and 4 (Davies et al, 2019a, 2019b), the following section reviews the 
findings in light of key CHR-P mechanisms, factors impacting potential future 
translation of oxytocin into a therapy, and methodological strengths and limitations. 
 
7.5.1. FINDINGS & PATHOPHYSIOLOGICAL MECHANISMS 
One implication of our findings relates to mechanisms, and what the direction of our 
effects means in relation to established models of CHR-P pathophysiology. The model 
of CHR-P pathophysiology presented in Figure 1 in Papers 3 and 4 was used as the 
basis for our experimental hypotheses. The model posits that hypofunctioning NMDA 
receptors on GABAergic interneurons leads to disinhibition of pyramidal neurons, 
excess glutamate neurotransmission and increased perfusion, which together with 
downstream processes leads to attenuated psychotic symptoms and psychosis onset 
(Lieberman et al, 2018; Lisman et al, 2008; Modinos et al, 2015a; Schobel et al, 2013). 
Mechanistically, increased excitatory drive is mediated by increased extracellular 
glutamate, which increases metabolic demand and which therefore drives increased 
blood flow (Lecrux et al, 2019). Evidence suggests that dysfunction in these processes 
initially occurs in the hippocampal CA1 subregion, which spreads to the subiculum and 
extra-hippocampal regions (such as the frontal cortex) as frank psychosis develops 
(Schobel et al, 2009, 2013). The spreading functional pathology appears to be followed 
by structural changes—such as reduced hippocampal/cortical volumes (Ho et al, 2017a, 
2017b)—which are likely less amenable to treatment, suggesting that targeting CA1 
hyperperfusion or glutamate neurotransmission may have optimum therapeutic 
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potential. The neural circuitry involved in the above also provides numerous points (or 
processes) which could potentially become targets for therapeutic intervention, with the 
most likely targets being altered glutamate neurotransmission and hippocampal 
hyperperfusion (blood flow). For instance, one line of research may seek to directly 
normalise extracellular glutamate levels/neurotransmission (e.g. with n-acetylcysteine, 
lamotrigine or gabapentin), while another strategy may be to specifically target cerebral 
perfusion.  
 
One issue is that because we cannot specifically measure extracellular glutamate levels 
in living humans, it can be difficult to interpret 1H-MRS results for novel 
pharmacotherapies, particularly when the findings are negative (such as in Paper 4). 
However, examining cerebral perfusion (which is measurable in vivo) offers a viable 
method for evaluating novel treatments in patients; glutamate/excitatory drive and 
perfusion are also closely linked, are both implicated in the same model of CHR-P 
pathophysiology and normalising perfusion is a goal in itself. The ultimate aim of drug 
(oxytocin) challenge in this scenario would, then, be to normalise hippocampal 
perfusion in CHR-P patients.  
 
In line with this, in Papers 3 and 4 we used oxytocin with the aim of modulating the 
functioning of this neural circuitry. However, under our experimental conditions, 
oxytocin increased rather than decreased hippocampal perfusion. This would not seem 
to be the desired direction of effects, given that increased hippocampal perfusion has 
been associated with adverse outcomes in CHR-P individuals (such as non-remission 
or transition to psychosis) (Allen et al, 2016, 2018; Schobel et al, 2013). However, 
there are two reasons why the direction of effects does not immediately discount 
oxytocin as a candidate compound with potentially relevant neurophysiological effects. 
First, in the absence of a parallel group of healthy controls, we cannot infer which 
direction (an increase or decrease) would represent ‘normalised’ perfusion. We also do 
not know if the effects of oxytocin on hippocampal perfusion are specific to CHR-P 
patient groups—where we may expect altered perfusion at baseline—or whether this 
would also be found in healthy controls. Relatedly, this study was not powered (nor 
designed to assess) the effects of oxytocin on symptoms, and so we cannot infer 
whether increased perfusion is associated with improved or worsening 
symptomatology. Second, as discussed in Papers 3 and 4, the physiological effects of 
oxytocin are known to be highly dependent on the dose, route of administration and the 
duration of the sampling period (time between dosing and data collection) (Martins et 
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al, 2019; Quintana et al, 2016, 2017, 2019b; Spengler et al, 2017). Due to the cross-
reactivity of oxytocin with vasopressin receptors—which is likely to occur with 
medium-to-high range doses (as used in the current study)—and given that vasopressin 
can produce diametrically opposite effects to oxytocin, e.g. vasopressin can be 
anxiogenic while oxytocin can be anxiolytic (Neumann and Landgraf, 2012), it is 
possible that lower doses of oxytocin will still engage the hippocampus but would 
decrease rather than increase perfusion. However, such an understanding can only come 
from future studies with the required design and sample size. While it would have been 
elegant to show that oxytocin modulates perfusion and glutamate/Glx concentrations in 
the same region, as reviewed in the Discussion in Paper 4 (and in section 7.6.2 on page 
169 below), 1H-MRS may not be a sensitive enough gauge for evaluating 
neurotransmission within the neural circuits of interest, or oxytocin may simply not 
alter the concentrations of these neurochemicals. 
 
7.5.2. COULD OXYTOCIN HAVE THERAPEUTIC EFFECTS? 
As discussed in the Part 2 Introduction (section 4.3), no studies have yet assessed the 
effects of oxytocin on symptoms, functioning, preventing transition to psychosis, or 
social-emotion processing in CHR-P individuals. Therefore, in trying to understand the 
possible symptomatic effects, we are limited to previous studies in people with 
established psychotic disorders. However, there are numerous reasons why testing 
compounds in people with established psychotic disorders is not the same as in those 
at CHR-P. In line with the pathophysiological models and supporting evidence 
discussed above (section 7.5.1), CHR-P individuals may respond differently—and 
perhaps better—to certain medications because early neurobiological perturbations are 
perhaps (a) qualitatively different, and (b) more amenable to intervention (Lieberman 
et al, 2018; Millan et al, 2016; Schobel et al, 2013). Indeed, authors have described a 
need for illness stage-specific pharmacological intervention in psychosis and the CHR-
P state (Krystal and Anticevic, 2015). CHR-P individuals are also (generally) 
antipsychotic naïve and lack illness chronicity. In addition, the ethical requirement for 
add-on studies in patients with established psychosis is avoided in CHR-P samples—a 
‘cleaner’ estimate of efficacy can therefore be derived and smaller sample sizes can be 
used. 
 
Evidence from established psychotic disorders 
The early studies in patients with psychosis were promising in showing significant 
reductions across positive, negative, general and total symptoms (Feifel et al, 2010, 
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2015; Modabbernia et al, 2013; Pedersen et al, 2011). However, a series of negative 
trials have since followed (Dagani et al, 2016; Feifel et al, 2015; Jarskog et al, 2017) 
and recent meta-analyses have concluded that (a) oxytocin does not improve any aspect 
of schizophrenia psychopathology (positive, negative, general or total symptoms) 
(Williams and Bürkner, 2017), and (b) in terms of social cognition, benefits are likely 
to be found only for paradigms testing higher-order social cognition (Bürkner et al, 
2017). However, there is some evidence that these recent negative results may be due 
to other factors rather than treatment failure per se. For example, an equivalence-testing 
study of intranasal oxytocin research found that of the 34 non-significant effects 
reported, 74% were due to data insensitivity rather than absence of an effect (Quintana, 
2018). In fact, low study power has been an enduring issue in the oxytocin field and 
likely originated from the small, initial studies which showed large effect sizes for 
behavioural or questionnaire-style outcomes (Quintana, 2018; Walum et al, 2015). 
Such large effect sizes were likely false-positives but they set the tone for future studies, 
which did not account for the “winner’s curse” phenomenon, and which were then 
subsequently underpowered (Button et al, 2013). In summary, the evidence we have 
from RCTs in psychosis have not shown robust or replicated benefits of oxytocin on 
any given outcomes. However, as per the reasons outlined above, this does not 
necessarily mean that oxytocin would be ineffective for people at CHR-P. 
 
Acute vs long-term effects 
Another factor to address is the effects of acute vs repeated administration and whether 
there are differing associated physiological and clinical outcomes. If, as has been 
indicated in forthcoming research (Martins et al, 2019), different devices for 
administering intranasal oxytocin also produce different neural effects, then future 
studies should ensure use of the optimal delivery method. This study also indicated that 
oxytocin’s effects on subcortical perfusion—which is the primary target of interest for 
psychosis/CHR-P research—are present only ~15-35 mins post-administration 
(Martins et al, 2019). In future, if oxytocin’s therapeutic effects are found to be related 
to modulation of subcortical function, then this time course may affect its viability as a 
treatment (because even twice/day dosing may not be sufficient). While in previous 
years alternative oxytocin receptor agonists—with longer half-lives—were being 
developed by multiple pharmaceutical companies (for childbirth), these have since all 
but ceased. However, a forthcoming study suggests that, when using the effects of 
oxytocin on amygdala reactivity to fearful faces and amygdala–prefrontal functional 
connectivity as an outcome, every-other day dosing was superior to daily dosing due to 
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the rapid decline in effects with daily treatment (preprint (Kou et al, 2018)). These 
factors will need to be investigated in future studies. 
 
Going forward, larger RCTs that can assess clinical outcomes are required. Ideally, 
these would be preceded by—or in addition to—dose-finding studies, as well as studies 
testing different dosing regimens and methods of administration. Study outcomes could 
include reduction of attenuated psychotic symptoms, negative symptoms, higher-order 
social cognition and emotional processing. However, examination of these outcomes 
(especially attenuated psychotic symptoms) would require repeated dosing over longer 
durations so that symptom change can be reliably measured with validated CHR-P 
assessments (such as the CAARMS). Further longer-term trials (e.g. with a 12-month 
follow up) could also investigate potential preventative effects on transition. 
7.6. OXYTOCIN – STRENGTHS & LIMITATIONS 
7.6.1. ASL 
Strengths of our ASL approach include the double-blind, placebo-controlled crossover 
design and the relatively large sample size for a within-subject neuroimaging study. 
Collecting data over two runs also allowed us to perform a combined analysis (i.e. with 
double the amount of data) in an attempt to increase the signal-to-noise ratio. However, 
there a number of important limitations. One is that the direction of the effect we 
observed in this study (increased perfusion) seems to be in the opposite direction to 
what one would predict would be therapeutic in these patients (i.e. a decrease) (Allen 
et al, 2016, 2018). This makes interpretation more difficult, but the key goal of our 
study was to show disease-target engagement—that oxytocin can alter perfusion in this 
target region. In addition, the dose effects of oxytocin are well known—the effect 
direction (increase vs decrease; or presence vs absence of effects) across indices of 
neural function (Spengler et al, 2017) and behavioural or symptomatic response 
(Kosaka et al, 2016; Quintana et al, 2017) is modulated by the given dose, likely due 
to cross-reactivity with vasopressin receptors (Galbusera et al, 2017; Heinrichs et al, 
2009). Observing an increase in the current study does not, therefore, discount the 
possibility that different doses may engage the hippocampus but have effects in the 
opposite direction. A parallel healthy control group would enable better delineation of 
the direction of the effects and this remains an avenue for future research. One potential 
limitation is that we focused only on the hippocampus and omitted analyses into other 
regions strongly linked to oxytocinergic and social-emotional functioning, such as the 
amygdala (Zink and Meyer-Lindenberg, 2012). However, we opted for the 
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hippocampus because the a priori evidence for altered hippocampal perfusion in CHR-
P individuals is strong and has been independently replicated (Allen et al, 2016, 2018), 
which is not the case for amygdala perfusion in CHR-P. Nevertheless, amygdala 
perfusion is altered in psychotic patients (Pinkham et al, 2015) and given the known 
effects of oxytocin on amygdala activation and functional connectivity (as discussed in 
section 4.3.3), such investigations remain avenues for future research. Another 
limitation (common to the both the ASL and 1H-MRS studies) was that we did not 
collect pre-post questionnaire data on key clinical outcomes, such as levels of 
attenuated psychotic symptoms. However, our study was designed and powered to 
detect neurophysiological effects and assessing efficacy for symptoms would require 
significantly larger sample sizes (and likely repeated dosing over time so that symptom 
change can be measured). Whether our neurophysiological findings translate into 
clinical efficacy therefore remains unknown and will need to be evaluated by future 
trials. Another limitation is that the regions-of-interest used in the current study were 
small (especially the hippocampal subregions), which is why we opted for a traditional 
region-of-interest approach (where one value is extracted for each patient in each 
condition, representing the mean perfusion across the total region-of-interest), rather 
than a voxel-wise region-of-interest analysis which can be affected by the cluster-level 
significance thresholds in SPM (when the clusters are small). 
 
7.6.2. 1H-MRS 
Strengths of our 1H-MRS approach included the double-blind, placebo-controlled 
crossover design and the relatively large sample size (although see the point about final 
sample size and power below), and the fact that none of our data were excluded due to 
poor quality spectra. 1H-MRS is also a relatively quick, non-invasive way to examine 
aspects of glutamatergic function in vivo. By conducting both creatine-scaled and voxel 
tissue content-corrected analyses, we reduced the possibility that our (ultimately 
negative) findings were due to methodological issues (e.g. changes in creatine itself, 
differing voxel placements leading to differing proportions of CSF/WM/GM). 
However, there are a number of important limitations. 1H-MRS cannot discriminate 
between intra- and extra-cellular metabolites and so provides total-voxel 
concentrations. As a result, while we have preclinical evidence for the 
pathophysiological model based on NMDAR hypofunction on GABAergic 
interneurons (leading to disinhibition of pyramidal cells; Figure 1 in Papers 3 and 4), 
and can measure ‘overall’ glutamatergic/Glx function using 1H-MRS as a proxy, we 
are not actually able to measure the microscale functioning of these neural circuits (i.e. 
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glutamatergic neurotransmission) in living human brain. This means that, in theory, 
oxytocin may have had an effect on the aforementioned neural circuits, restoring 
inhibition of pyramidal neurons and therefore decreasing glutamate signalling, but we 
are unable to detect such changes (which occur on the scale of micromolar (uM) 
concentrations) with 1H-MRS. However, previous studies using NMDAR antagonists 
(such as ketamine) (Kegeles et al, 2014; Kraguljac et al, 2017) or other compounds that 
alter glutamate release (such as n-acetylcysteine) (McQueen et al, 2018; Schmaal et al, 
2012) have demonstrated changes in total-voxel 1H-MRS glutamate/Glx 
concentrations, which provides (indirect) evidence that modulation of neural circuit 
function can alter total-voxel metabolite concentrations. Therefore, it is conceivable 
that if oxytocin had acutely modulated glutamatergic neurotransmission, we may have 
expected to observe the effects using 1H-MRS. Nevertheless, this indirectness is a 
limitation and resolution of this issue would require the development of glutamatergic 
radiotracers. In addition to the limitations inherent in 1H-MRS, our updated power 
calculations suggested that our study was only powered to detect medium-to-large 
changes (Cohen’s d ~0.55) in glutamate/Glx, which means we would have been unable 
to detect smaller—but potentially significant—effects. Increased power could be 
achieved in future by increasing the sample size. Another factor is that of the duration 
between dosing and 1H-MRS collection—it remains possible that we simply ‘missed’ 
neurochemical effects of oxytocin because our data sampling period was too delayed. 
Our acute dosing regimen also did not allow us to examine whether longer-term 
repeated dosing would have effects on metabolite concentrations. 
7.7. INTEGRATING EVIDENCE SYNTHESIS & EXPERIMENTAL 
MEDICINE – TOWARDS THE PLATEAU OF KNOWLEDGE
As discussed throughout this thesis, it is hoped that ongoing research into the clinical 
and neurobiological stratification of CHR-P individuals will facilitate more successful 
clinical trials (as well as all other study types) across the field. For example, taking a 
precision medicine approach, stratifying individuals based on the presence vs absence 
of specific biomarkers is arguably the most promising way to reduce the heterogeneity 
within research samples. This will likely impact clinical trials (because specific drugs 
can be tested in those for whom it is indicated) and case-control studies of neural 
structure and function (because signal-to-noise will be increased in the group-level data 
due to reduced neurobiological heterogeneity).  
  [171] 
Within the framework presented in Figure 7–2 (below), evidence synthesis (as in Part 
1) and experimental medicine (as in Part 2) are two important components—among a 
number of others—that together would help bring about a precision medicine approach 
to the CHR-P field (as well as improved research methodologies and hopefully, 
commensurate results). First of all, the knowledge from meta-analyses, such as those 
presented in Papers 1 and 2, provide critical insight into the current state of evidence, 
the most likely beneficial treatments for future investigation and can highlight issues 
that may undermine the success of RCTs—e.g. unstructured recruitment strategies 
leading to poor risk enrichment and low statistical power. This evidence can then be 
used to improve trial methodologies and increase the robustness of experimental 
findings. For example, treatments are more likely to show a signal if they are effective 
(e.g. because they are sufficiently powered), and if they show no signal of effectiveness, 
we can be more certain that this result is due to treatment failure rather than suboptimal 
study design. 
 
Figure 7–2. How different research approaches complement each other towards 
precision psychiatry and improved treatments in the CHR-P field. 
  
Second, prior to the types of studies examined in Part 1 of this thesis (RCTs for 
efficacy), a growing methodologic approach for use in drug development is 
experimental medicine. Given that ~75% and ~45% of novel compounds (with 
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2014; Hwang et al, 2016; Thomas et al, 2016), the screening out of the most likely 
failures (prior to phase II) is beneficial in terms of resources and time and can increase 
the chances of success for drugs that make it to later-phase trials. Experimental 
medicine also bridges preclinical work with human in vivo studies and allows 
exploration of possible mechanisms and novel therapeutic targets. In the CHR-P field, 
experimental medicine methods can be of particular value—in the absence of any 
validated pathophysiological mechanisms and biomarkers, we are currently in a time 
of desperate need for effective treatments, but we do not have a clear-cut ‘assay’ in 
humans that reliably identifies a drug as effective or ineffective. We are therefore 
proceeding with RCTs of pharmacological compounds that have a very high chance of 
failure. Experimental medicine studies can therefore provide critical evidence to 
support early go/no-go decisions for specific treatments. However, for the full potential 
of experimental medicine studies to be harnessed, reliable (even ‘intermediate’) 
biomarkers for each desired outcome in CHR-P samples is required. For example, if a 
novel therapeutic that effectively normalises hippocampal perfusion is also shown to 
decrease transition risk (or symptoms) over time, then reducing hippocampal perfusion 
becomes a target against which many novel (or repurposed) compounds can be tested 
against. Together then, it will likely be the combined contributions of evidence 
synthesis, experimental medicine and improved large-scale clinical trial methodologies 
that will ultimately pave the way to more effective treatments and improved outcomes 
for those at CHR-P.  
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7.8. CONCLUSIONS 
In Part 1 of this thesis, I established that there is currently no evidence that any specific 
treatment is superior to any other treatment—including the lowest level needs-based 
intervention—in preventing transition, reducing attenuated psychotic symptoms or in 
acceptability in patients at CHR-P. These findings have contributed to knowledge because 
they were the first to challenge the prevailing view (NICE, 2014) that CBT is superior to 
all other treatments and should be offered to CHR-P patients as an evidence-based 
intervention. In Part 2 of this thesis, I established that oxytocin modulates resting 
hippocampal perfusion in CHR-P patients but does not appear to alter concentrations of 
glutamate (or Glx) in the hippocampus, ACC or thalamus when measured using 1H-MRS. 
These findings advance knowledge by demonstrating that oxytocin can engage one of the 
key pathophysiological targets associated with the onset of psychosis in patients at CHR-
P, and therefore merits further investigation as a candidate novel treatment. Within this 
thesis, I have also argued that the prevention of psychosis from a CHR-P state has been, 
and should remain, the primary goal for interventional trials, refined and complemented 
by other clinically meaningful outcomes. However, as transition to psychosis is a 
relatively infrequent outcome, previous clinical trials in CHR-P populations have only 
been powered to detect large effect sizes for preventive treatments. It therefore remains 
possible that current treatments have preventative effects but of smaller magnitude. 
Controlling risk enrichment through recruitment and increasing sample sizes could help 
to mitigate this issue in future trials. Rather than give us cause to abandon the CHR-P 
field, the negative meta-analytic findings within this thesis (reflecting the ‘stagnation of 
knowledge’) should also promote innovative and collaborative research efforts, in line 
with the progressive and incremental nature of medical knowledge. Advancements will 
most likely be associated with the development of experimental therapeutics along with 
the ability to deconstruct the large heterogeneity within CHR-P populations. This would 
require the estimation of treatment-specific effect sizes through living individual-
participant data meta-analyses, development of biomarkers or validated 
pathophysiological mechanisms underlying psychosis onset, and the use of experimental 
medicine approaches. The evidence-based challenges and proposed solutions addressed 
by this thesis can also inform the next generation of therapeutics research in the CHR-P 
field. It is hoped that these innovations will ultimately pave the way towards a future 
‘plateau of knowledge’, effective preventative treatments and, most importantly, 
improved psychiatric, social and functional outcomes for patients and their families.
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